<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 39.96?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?covid-19-tdm?>
<?subarticle pone.0287179.r001?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
    <journal-id journal-id-type="iso-abbrev">PLoS One</journal-id>
    <journal-id journal-id-type="publisher-id">plos</journal-id>
    <journal-title-group>
      <journal-title>PLOS ONE</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1932-6203</issn>
    <publisher>
      <publisher-name>Public Library of Science</publisher-name>
      <publisher-loc>San Francisco, CA USA</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10289339</article-id>
    <article-id pub-id-type="doi">10.1371/journal.pone.0287179</article-id>
    <article-id pub-id-type="publisher-id">PONE-D-22-21799</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Research Article</subject>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and life sciences</subject>
        <subj-group>
          <subject>Organisms</subject>
          <subj-group>
            <subject>Viruses</subject>
            <subj-group>
              <subject>RNA viruses</subject>
              <subj-group>
                <subject>Coronaviruses</subject>
                <subj-group>
                  <subject>SARS coronavirus</subject>
                  <subj-group>
                    <subject>SARS CoV 2</subject>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and life sciences</subject>
        <subj-group>
          <subject>Microbiology</subject>
          <subj-group>
            <subject>Medical microbiology</subject>
            <subj-group>
              <subject>Microbial pathogens</subject>
              <subj-group>
                <subject>Viral pathogens</subject>
                <subj-group>
                  <subject>Coronaviruses</subject>
                  <subj-group>
                    <subject>SARS coronavirus</subject>
                    <subj-group>
                      <subject>SARS CoV 2</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Medicine and health sciences</subject>
        <subj-group>
          <subject>Pathology and laboratory medicine</subject>
          <subj-group>
            <subject>Pathogens</subject>
            <subj-group>
              <subject>Microbial pathogens</subject>
              <subj-group>
                <subject>Viral pathogens</subject>
                <subj-group>
                  <subject>Coronaviruses</subject>
                  <subj-group>
                    <subject>SARS coronavirus</subject>
                    <subj-group>
                      <subject>SARS CoV 2</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and life sciences</subject>
        <subj-group>
          <subject>Organisms</subject>
          <subj-group>
            <subject>Viruses</subject>
            <subj-group>
              <subject>Viral pathogens</subject>
              <subj-group>
                <subject>Coronaviruses</subject>
                <subj-group>
                  <subject>SARS coronavirus</subject>
                  <subj-group>
                    <subject>SARS CoV 2</subject>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Physical Sciences</subject>
        <subj-group>
          <subject>Physics</subject>
          <subj-group>
            <subject>Thermodynamics</subject>
            <subj-group>
              <subject>Free Energy</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Research and Analysis Methods</subject>
        <subj-group>
          <subject>Mathematical and Statistical Techniques</subject>
          <subj-group>
            <subject>Statistical Methods</subject>
            <subj-group>
              <subject>Forecasting</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Physical Sciences</subject>
        <subj-group>
          <subject>Mathematics</subject>
          <subj-group>
            <subject>Statistics</subject>
            <subj-group>
              <subject>Statistical Methods</subject>
              <subj-group>
                <subject>Forecasting</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Physical Sciences</subject>
        <subj-group>
          <subject>Chemistry</subject>
          <subj-group>
            <subject>Physical Chemistry</subject>
            <subj-group>
              <subject>Chemical Bonding</subject>
              <subj-group>
                <subject>Hydrogen Bonding</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Biochemistry</subject>
          <subj-group>
            <subject>Biochemical Simulations</subject>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Computational Biology</subject>
          <subj-group>
            <subject>Biochemical Simulations</subject>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Biochemistry</subject>
          <subj-group>
            <subject>Enzymology</subject>
            <subj-group>
              <subject>Enzymes</subject>
              <subj-group>
                <subject>Proteases</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Biochemistry</subject>
          <subj-group>
            <subject>Proteins</subject>
            <subj-group>
              <subject>Enzymes</subject>
              <subj-group>
                <subject>Proteases</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Physical Sciences</subject>
        <subj-group>
          <subject>Chemistry</subject>
          <subj-group>
            <subject>Computational Chemistry</subject>
            <subj-group>
              <subject>Molecular Dynamics</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Physical Sciences</subject>
        <subj-group>
          <subject>Chemistry</subject>
          <subj-group>
            <subject>Computational Chemistry</subject>
            <subj-group>
              <subject>Molecular Docking</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>M<sup>pro</sup>pred: A machine learning (ML) driven Web-App for bioactivity prediction of SARS-CoV-2 main protease (M<sup>pro</sup>) antagonists</article-title>
      <alt-title alt-title-type="running-head">A Web-App for bioactivity prediction of SARS-CoV-2 main protease (M<sub>pro</sub>) antagonists</alt-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" equal-contrib="yes">
        <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4240-6829</contrib-id>
        <name>
          <surname>Ferdous</surname>
          <given-names>Nadim</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
        <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
        <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Reza</surname>
          <given-names>Mahjerin Nasrin</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
        <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
        <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
        <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Hossain</surname>
          <given-names>Mohammad Uzzal</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff002" ref-type="aff">
          <sup>2</sup>
        </xref>
        <xref rid="aff003" ref-type="aff">
          <sup>3</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Mahmud</surname>
          <given-names>Shahin</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
        <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Napis</surname>
          <given-names>Suhami</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <xref rid="aff004" ref-type="aff">
          <sup>4</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chowdhury</surname>
          <given-names>Kamal</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff005" ref-type="aff">
          <sup>5</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4188-6592</contrib-id>
        <name>
          <surname>Mohiuddin</surname>
          <given-names>A. K. M.</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="cor001" ref-type="corresp">*</xref>
      </contrib>
    </contrib-group>
    <aff id="aff001">
      <label>1</label>
      <addr-line>Department of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Santosh, Tangail, Bangladesh</addr-line>
    </aff>
    <aff id="aff002">
      <label>2</label>
      <addr-line>Department of Pharmacology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom</addr-line>
    </aff>
    <aff id="aff003">
      <label>3</label>
      <addr-line>Bioinformatics Division, National Institute of Biotechnology, Ashulia, Ganakbari, Savar, Dhaka, Bangladesh</addr-line>
    </aff>
    <aff id="aff004">
      <label>4</label>
      <addr-line>Department of Molecular Biology, Universiti Putra Malaysia, Serdang, Selangor D.E., Malaysia</addr-line>
    </aff>
    <aff id="aff005">
      <label>5</label>
      <addr-line>Biology Department, Claflin University, Orangeburg, SC, United States of America</addr-line>
    </aff>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Gallicchio</surname>
          <given-names>Emilio</given-names>
        </name>
        <role>Editor</role>
        <xref rid="edit1" ref-type="aff"/>
      </contrib>
    </contrib-group>
    <aff id="edit1">
      <addr-line>Brooklyn College of the City University of New York, UNITED STATES</addr-line>
    </aff>
    <author-notes>
      <fn fn-type="COI-statement" id="coi001">
        <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
      </fn>
      <corresp id="cor001">* E-mail: <email>akmmohiu@yahoo.com</email></corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>23</day>
      <month>6</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>23</day>
      <month>6</month>
      <year>2023</year>
    </pub-date>
    <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
    <volume>18</volume>
    <issue>6</issue>
    <elocation-id>e0287179</elocation-id>
    <history>
      <date date-type="received">
        <day>29</day>
        <month>8</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>31</day>
        <month>5</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2023 Ferdous et al</copyright-statement>
      <copyright-year>2023</copyright-year>
      <copyright-holder>Ferdous et al</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <self-uri content-type="pdf" xlink:href="pone.0287179.pdf"/>
    <abstract>
      <p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic emerged in 2019 and still requiring treatments with fast clinical translatability. Frequent occurrence of mutations in spike glycoprotein of SARS-CoV-2 led the consideration of an alternative therapeutic target to combat the ongoing pandemic. The main protease (M<sup>pro</sup>) is such an attractive drug target due to its importance in maturating several polyproteins during the replication process. In the present study, we used a classification structure–activity relationship (CSAR) model to find substructures that leads to to anti-M<sup>pro</sup> activities among 758 non-redundant compounds. A set of 12 fingerprints were used to describe M<sup>pro</sup> inhibitors, and the random forest approach was used to build prediction models from 100 distinct data splits. The data set’s modelability (MODI index) was found to be robust, with a value of 0.79 above the 0.65 threshold. The accuracy (89%), sensitivity (89%), specificity (73%), and Matthews correlation coefficient (79%) used to calculate the prediction performance, was also found to be statistically robust. An extensive analysis of the top significant descriptors unveiled the significance of methyl side chains, aromatic ring and halogen groups for M<sup>pro</sup> inhibition. Finally, the predictive model is made publicly accessible as a web-app named M<sup>pro</sup>pred in order to allow users to predict the bioactivity of compounds against SARS-CoV-2 M<sup>pro</sup>. Later, CMNPD, a marine compound database was screened by our app to predict bioactivity of all the compounds and results revealed significant correlation with their binding affinity to M<sup>pro</sup>. Molecular dynamics (MD) simulation and molecular mechanics/Poisson Boltzmann surface area (MM/PBSA) analysis showed improved properties of the complexes. Thus, the knowledge and web-app shown herein can be used to develop more effective and specific inhibitors against the SARS-CoV-2 M<sup>pro</sup>. The web-app can be accessed from <ext-link xlink:href="https://share.streamlit.io/nadimfrds/mpropred/Mpropred_app.py" ext-link-type="uri">https://share.streamlit.io/nadimfrds/mpropred/Mpropred_app.py</ext-link>.</p>
    </abstract>
    <funding-group>
      <funding-statement>The author(s) received no specific funding for this work.</funding-statement>
    </funding-group>
    <counts>
      <fig-count count="7"/>
      <table-count count="6"/>
      <page-count count="21"/>
    </counts>
    <custom-meta-group>
      <custom-meta id="data-availability">
        <meta-name>Data Availability</meta-name>
        <meta-value>All relevant data are within the paper and its <xref rid="sec021" ref-type="sec">Supporting Information</xref> files.</meta-value>
      </custom-meta>
      <custom-meta id="outbreaks">
        <meta-name>Outbreaks</meta-name>
        <meta-value>COVID-19</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
  <notes>
    <title>Data Availability</title>
    <p>All relevant data are within the paper and its <xref rid="sec021" ref-type="sec">Supporting Information</xref> files.</p>
  </notes>
</front>
<body>
  <sec sec-type="intro" id="sec001">
    <title>Introduction</title>
    <p>The COVID-19 pandemic, which was triggered by SARS-CoV-2, is still having a disastrous impact on public health and the worldwide economy [<xref rid="pone.0287179.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0287179.ref002" ref-type="bibr">2</xref>]. On earlier march of 2020, the outbreak was declared as a pandemic after initially discovering the virus in end of 2019 in Wuhan, China [<xref rid="pone.0287179.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0287179.ref004" ref-type="bibr">4</xref>]. SARS-CoV-2 is a single-stranded RNA virus with an increased mutation rate, a short period of replication, and a high production of virion [<xref rid="pone.0287179.ref005" ref-type="bibr">5</xref>–<xref rid="pone.0287179.ref008" ref-type="bibr">8</xref>]. The virus acquires a significant amount of genetic variation as it spreads, enabling it to adapt quickly to stresses brought on by natural selection, particularly those imposed by the immune system of the host. Mutations build up over time, resulting in alterations to the amino acids that make immune-targeted proteins less antigenic. This process is known as “antigenic drift”, that is the gradual alteration in viral protein antigenicity caused by selective immunological pressure [<xref rid="pone.0287179.ref009" ref-type="bibr">9</xref>]. Antigenic drift permits viruses to avoid host immunity continuously, allowing for recurring viral outbreaks. In cases of acute infectious disease, antibody responses are mostly responsible, resulting in the selection of escape mutants [<xref rid="pone.0287179.ref009" ref-type="bibr">9</xref>]. The spike protein contains several variations in amino acids identified in SARS-CoV-2 variants, is the main target that antibodies neutralize [<xref rid="pone.0287179.ref010" ref-type="bibr">10</xref>]. These antibodies are the sole immune system component capable of providing sterilizing immunity, preventing infection of host cells by the virus. The SARS-CoV-2 spike protein has evolved at a considerably faster rate than similar proteins in additional known viruses that cause severe infectious diseases in humans [<xref rid="pone.0287179.ref011" ref-type="bibr">11</xref>]. In addition, SARS-CoV-2 proteins have accumulated a substantial number of amino acid modifications that are not recognized antibody targets. In acute viral infections, antibody responses are predominantly responsible for antigenic drift; therefore, these amino acid alterations may have given the virus a fitness benefit independent to antibody immunity [<xref rid="pone.0287179.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0287179.ref013" ref-type="bibr">13</xref>].</p>
    <p>As a result, structural and functional research of SARS-CoV-2 infection processes have primarily shifted to the main protease (M<sup>pro</sup>), which cleaves native polypeptides and forms active fragments that are crucial for viral replication, transcription, and translation process [<xref rid="pone.0287179.ref014" ref-type="bibr">14</xref>]. The protease is consists of three domains [<xref rid="pone.0287179.ref015" ref-type="bibr">15</xref>]. A loop (residues 185–200) connects domain II with domain III. The ligand binding site is found in the loop between the first two domains, where the catalytic dyad consisting of Cys 145 and His 41 is crucial for ligand management [<xref rid="pone.0287179.ref015" ref-type="bibr">15</xref>]. SARS-CoV-2 replication is significantly facilitated by M<sup>pro</sup> [<xref rid="pone.0287179.ref015" ref-type="bibr">15</xref>]. Moreover, it is not functionally associated with human homologue proteases, implying that M<sup>pro</sup> is a promising target for therapeutic development [<xref rid="pone.0287179.ref015" ref-type="bibr">15</xref>].</p>
    <p>The functions of compounds both at structural and chemical level, are crucial in understanding the impact of physicochemical qualities on bioactivity. Computer-aided drug design (CADD) portrays a set of computational techniques that has proven useful in chemical biology and computational approaches to understanding the structure–activity relationship [<xref rid="pone.0287179.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0287179.ref017" ref-type="bibr">17</xref>]. Computational tools are used to decipher bioactivity using ligands, which are known as chemical descriptors [<xref rid="pone.0287179.ref018" ref-type="bibr">18</xref>]. Molecular descriptors computation softwares can also be used to calculate the physicochemical properties of different compounds. The QSAR (quantitative structure activity relationship) is considered a widely used computational technique to construct prediction models which can distinguish the impact of important molecular fingerprints regulating their bioactivities and properties [<xref rid="pone.0287179.ref019" ref-type="bibr">19</xref>]. A variety of targets, including antioxidant [<xref rid="pone.0287179.ref020" ref-type="bibr">20</xref>], antibacterial [<xref rid="pone.0287179.ref021" ref-type="bibr">21</xref>,<xref rid="pone.0287179.ref022" ref-type="bibr">22</xref>], anticancer [<xref rid="pone.0287179.ref023" ref-type="bibr">23</xref>,<xref rid="pone.0287179.ref024" ref-type="bibr">24</xref>], and antiviral [<xref rid="pone.0287179.ref025" ref-type="bibr">25</xref>,<xref rid="pone.0287179.ref026" ref-type="bibr">26</xref>] activities, have been successfully modeled using QSAR models.</p>
    <p>In silico strategies such as QSAR, pharmacophore modeling, docking and molecular dynamics (MD) simulation have extensively studied for identifying new inhibitors of M<sup>pro</sup>. Isabela et al. used an in-house designed machine learning technique, molecular docking, MM-PBSA calculations, and meta dynamics to find FDA-approved compounds that could potentially suppress the enzyme activity of the M<sup>pro</sup> [<xref rid="pone.0287179.ref027" ref-type="bibr">27</xref>]. Nedra et al. developed a machine learning approach by employing the support vector machine (SVM) classification model to categorize two hundred novel chemo-types as potentially active against the viral protease using a dataset of two million commercially accessible drugs [<xref rid="pone.0287179.ref028" ref-type="bibr">28</xref>]. Mahesha et al. used an integrative strategy to screen 1528 anti-HIV1 compounds, using a machine learning predictive model, molecular docking, and a deep learning model that considered the IC50 values of known inhibitors [<xref rid="pone.0287179.ref029" ref-type="bibr">29</xref>]. But the models developed in these works are not accessible as readily available web-apps for the scientific community to further apply on different sets of compounds in order to identify more potent anti-M<sup>pro</sup> inhibitors.</p>
    <p>In the present study, we collected a set of compounds (non-redundant) with known IC50 values against the SARS-CoV-2 M<sup>pro</sup>. Several fingerprint descriptors were used to describe the examined compounds binning the IC50 values to qualitative labels such as active and inactive. Following that, the RF algorithm was used to build prediction models. The sensitivity, specificity, accuracy and Matthews correlation coefficient of the built QSAR model were tested in classifying active or inactive compounds against SARS-CoV-2 M<sup>pro</sup>. In addition, the underlying key substructures that are critical for bioactivity were identified and defined. A web-app was built based on the model and made publicly accessible. We also utilized our app to view into the correlation of predicted bioactivity of compounds with their binding affinity to M<sup>pro</sup>. As a result, this knowledge can be exploited to develop more potent and specialized drugs against SARS-CoV-2 M<sup>pro</sup>.</p>
  </sec>
  <sec sec-type="materials|methods" id="sec002">
    <title>Materials and methods</title>
    <p>A step-wise protocol was followed to build a web-app in order to predict bioactivities of compounds against the M<sup>pro</sup> of SARS-CoV-2. The work flow is shown in <xref rid="pone.0287179.g001" ref-type="fig">Fig 1</xref>.</p>
    <fig position="float" id="pone.0287179.g001">
      <object-id pub-id-type="doi">10.1371/journal.pone.0287179.g001</object-id>
      <label>Fig 1</label>
      <caption>
        <title>Schematic workflow of building a web-app to predict bioactivities of compounds against the M<sup>pro</sup> of SARS-CoV-2.</title>
        <p>The upper side of the flowchart depicts the methodology of building the web-app while the lower side shows the molecular modeling protocol that was used to view into the correlation of predicted bioactivity of compounds with their corresponding binding affinity.</p>
      </caption>
      <graphic xlink:href="pone.0287179.g001" position="float"/>
    </fig>
    <sec id="sec003">
      <title>Dataset preparation and curation</title>
      <p>A data set consisting of antagonists against SARS-CoV-2 main protease (M<sup>pro</sup>) was compiled from an extensive literature review that was initially comprised of 758 compounds [<xref rid="pone.0287179.ref030" ref-type="bibr">30</xref>]. The mean value was calculated in the event that multiple IC50 values were found for the same compound. As our study aims to developing a classification model of M<sup>pro</sup> antagonists, we defined the thresholds as &lt;0.5 and &gt;10 μM to distinguish active compounds from inactive ones, respectively. Also, intermediate bioactivities with IC50 values that ranged between 1 and 10 were excluded from the study, consisting of 284 inhibitors. Finally, the curated set of compounds consisting of 478 inhibitors was obtained and analyzed.</p>
    </sec>
    <sec id="sec004">
      <title>Calculation of molecular descriptors</title>
      <p>The PaDEL-Descriptor software was utilized briefly to compute the fingerprints of the data set [<xref rid="pone.0287179.ref031" ref-type="bibr">31</xref>]. Generally, molecular descriptors are very crucial for QSAR studies because they are used to characterize the various properties of compounds and aid in the structural information analyses. In the present study, 12 molecular fingerprints that belong to 9 classes were used to describe the structures, and these consisted of 2D AtomPairs, CDK (including extended and graph only version), E-state, PubChem, Klekota–Roth, Substructure and MACCS.</p>
    </sec>
    <sec id="sec005">
      <title>Data filtering and balancing</title>
      <p>To choose the fingerprint descriptor sets, variables that were constant or nearly constant were used with a view to removing the bias and complexity in building the model. Using 0.1 as the SD cut-off value, all the constants of each fingerprint descriptor were calculated. For further investigation, fingerprints having SD values of &gt;0.1 were chosen. The undersampling technique was employed by random selection of subset of the active compounds from the starting set to avoid the propensity for overfitting of imbalanced data. Additionally, the data was divided into two sets, with the internal set being 80% of the total data set and the external set comprising the remaining 20% to avoid any possibility of getting a predicted model that is biased.</p>
    </sec>
    <sec id="sec006">
      <title>Multivariate analysis of model</title>
      <p>A CSAR model’s prediction performance is influenced by both the predictor and the compound descriptors. Considering the success in various models and the interpretability in many applications, we employed RF in this study.</p>
      <p>Random forest is an ensemble classifier that uses a randomly selected subset of training samples and variables to generate a number of decision trees. The classification of RF begins at the root node, where the value of particular descriptors is used to divide the data set at every node, with the descriptors of various activities being primarily transported to distinct branches [<xref rid="pone.0287179.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0287179.ref033" ref-type="bibr">33</xref>]. The classification is then obtained by averaging the outcomes of all trees using a majority vote from each tree [<xref rid="pone.0287179.ref034" ref-type="bibr">34</xref>,<xref rid="pone.0287179.ref035" ref-type="bibr">35</xref>]. The <italic toggle="yes">randomForest</italic> package of the R language was used to create the RF classifier. To effectively predict M<sup>pro</sup> inhibitor activity, two RF model parameters must be tuned: the number of trees used to form the RF classifier (ntree) and the number of random candidate features (<italic toggle="yes">mtry</italic>). The parameter “<italic toggle="yes">mtry”</italic> was created using the <italic toggle="yes">randomForest</italic> package’s tuneRF function, while the ntree parameter was tuned using a 10-fold CV technique from the range of ntree € {100,200,…,1,000} [<xref rid="pone.0287179.ref036" ref-type="bibr">36</xref>]. The importance estimator, an efficient built-in component of the RF model, was also utilized to find informative descriptors to better explain the bioactivity of M<sup>pro</sup> inhibitors.</p>
    </sec>
    <sec id="sec007">
      <title>Modelability of data set</title>
      <p>The underlying relatedness of chemical structures and their bioactivities is required for modelability. Activity cliffs, also known as two compounds with remarkably different bioactivities (i.e., one pair of compounds has favorable biological activity while the other in the pair has low bioactivity), are detrimental to machine learning algorithms that try to correlate structures with related biological activity. Similar compounds having comparable bioactivities would, on the other hand, contribute favorably to the data set’s modelability. Golbraikh et al. developed this modelability index (MODI) [<xref rid="pone.0287179.ref037" ref-type="bibr">37</xref>]. The following formula can be used to calculate the statistical metric:</p>
      <p>Step 1: The normalized Euclidean distance (Dnormalized) for each pair of the compounds, Ci and Cj described by m-dimensional vector is calculated as follows:
<disp-formula id="pone.0287179.e001"><alternatives><graphic xlink:href="pone.0287179.e001.jpg" id="pone.0287179.e001g" position="anchor"/><mml:math id="M1" display="block" overflow="scroll"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mo>=</mml:mo><mml:msqrt><mml:mrow><mml:msubsup><mml:mo stretchy="true">∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:msqrt></mml:math></alternatives><label>(1)</label></disp-formula>
<disp-formula id="pone.0287179.e002"><alternatives><graphic xlink:href="pone.0287179.e002.jpg" id="pone.0287179.e002g" position="anchor"/><mml:math id="M2" display="block" overflow="scroll"><mml:mover accent="true"><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>¯</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:msubsup><mml:mo stretchy="true">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfrac></mml:math></alternatives><label>(2)</label></disp-formula>
<disp-formula id="pone.0287179.e003"><alternatives><graphic xlink:href="pone.0287179.e003.jpg" id="pone.0287179.e003g" position="anchor"/><mml:math id="M3" display="block" overflow="scroll"><mml:msub><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>z</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>¯</mml:mo></mml:mover><mml:mo>−</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mo>(</mml:mo><mml:mover accent="true"><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>¯</mml:mo></mml:mover><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">max</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>−</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mo>(</mml:mo><mml:mover accent="true"><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>¯</mml:mo></mml:mover><mml:mo>)</mml:mo></mml:mrow></mml:mfrac></mml:math></alternatives><label>(3)</label></disp-formula>
where d<sub>ij</sub>, <inline-formula id="pone.0287179.e004"><alternatives><graphic xlink:href="pone.0287179.e004.jpg" id="pone.0287179.e004g" position="anchor"/><mml:math id="M4" display="inline" overflow="scroll"><mml:mover accent="true"><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>¯</mml:mo></mml:mover></mml:math></alternatives></inline-formula> shows distance scores between two compounds and the n represent mean Euclidean distance.</p>
      <p>Step 2: The MODI can be calculated for each compound in a data set by determining whether its first nearest neighbor belongs to the same class as the compound or a different class:
<disp-formula id="pone.0287179.e005"><alternatives><graphic xlink:href="pone.0287179.e005.jpg" id="pone.0287179.e005g" position="anchor"/><mml:math id="M5" display="block" overflow="scroll"><mml:mi>M</mml:mi><mml:mi>O</mml:mi><mml:mi>D</mml:mi><mml:mi>I</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mrow><mml:msubsup><mml:mo stretchy="false">∑</mml:mo><mml:mrow><mml:mi>I</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msubsup><mml:mrow><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math></alternatives><label>(4)</label></disp-formula></p>
      <p>Where the <italic toggle="yes">N</italic><sub><italic toggle="yes">C</italic></sub> denotes the number of classes, <italic toggle="yes">N</italic><sub><italic toggle="yes">i</italic></sub><sup>same</sup> denotes the number of total compounds in the <italic toggle="yes">i</italic>th class having the same <italic toggle="yes">i</italic>th class as their first nearest neighbors, and <italic toggle="yes">Ni</italic><sup>total</sup> denotes number of total compounds in the <italic toggle="yes">i</italic>th class. Any data set is deemed modelable provided that MODI index falls beyond the cutoff value of 0.65. Here, the MODI index was calculated using a R code that was used for assessing modelibility of the HCVpred [<xref rid="pone.0287179.ref038" ref-type="bibr">38</xref>] server.</p>
    </sec>
    <sec id="sec008">
      <title>Model validation (Statistical approach)</title>
      <p>Several statistical measures, such as overall prediction sensitivity (Sn), specificity (Sp), accuracy (Ac) and Matthew’s correlation coefficient (MCC), were used to evaluate the model’s fitness.
<disp-formula id="pone.0287179.e006"><alternatives><graphic xlink:href="pone.0287179.e006.jpg" id="pone.0287179.e006g" position="anchor"/><mml:math id="M6" display="block" overflow="scroll"><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>N</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mfrac><mml:mo>×</mml:mo><mml:mn>100</mml:mn></mml:math></alternatives><label>(5)</label></disp-formula>
<disp-formula id="pone.0287179.e007"><alternatives><graphic xlink:href="pone.0287179.e007.jpg" id="pone.0287179.e007g" position="anchor"/><mml:math id="M7" display="block" overflow="scroll"><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mfrac><mml:mo>×</mml:mo><mml:mn>100</mml:mn></mml:math></alternatives><label>(6)</label></disp-formula>
<disp-formula id="pone.0287179.e008"><alternatives><graphic xlink:href="pone.0287179.e008.jpg" id="pone.0287179.e008g" position="anchor"/><mml:math id="M8" display="block" overflow="scroll"><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>T</mml:mi><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>N</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mfrac><mml:mo>×</mml:mo><mml:mn>100</mml:mn></mml:math></alternatives><label>(7)</label></disp-formula>
<disp-formula id="pone.0287179.e009"><alternatives><graphic xlink:href="pone.0287179.e009.jpg" id="pone.0287179.e009g" position="anchor"/><mml:math id="M9" display="block" overflow="scroll"><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mo>×</mml:mo><mml:mi>T</mml:mi><mml:mi>N</mml:mi><mml:mo>−</mml:mo><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mo>×</mml:mo><mml:mi mathvariant="normal">F</mml:mi><mml:mi mathvariant="normal">N</mml:mi></mml:mrow><mml:mrow><mml:msqrt><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mo>)</mml:mo><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>N</mml:mi><mml:mo>)</mml:mo><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mo>)</mml:mo><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>N</mml:mi><mml:mo>)</mml:mo></mml:msqrt></mml:mrow></mml:mfrac></mml:math></alternatives><label>(8)</label></disp-formula>
where True positives, false positives, true negatives, and false negatives are denoted by the abbreviations TP, FP, TN and FN, respectively.</p>
    </sec>
    <sec id="sec009">
      <title>Applicability domain analysis</title>
      <p>The boundaries within which the model may produce precise predictions for compounds based on similarity towards the compounds on which the model was built are established by the applicability domain (AD). Only those compounds are found inside the AD that match the model’s parameters. In this study, the AD of the compounds from both the training and testing sets were analyzed using the PCA bounding box.</p>
    </sec>
    <sec id="sec010">
      <title>Deployment of model as web-app</title>
      <p>Finally, we deployed the developed RF model as a web-app with a view to enabling easy access for the research community. The web-app named “M<sup>pro</sup>pred” was built in the Streamlit python package (<ext-link xlink:href="https://www.streamlit.io/" ext-link-type="uri">https://www.streamlit.io/</ext-link>) and deployed on the “Streamlit Share” cloud application platform while the source-code is maintained in a GitHub repository. The web-app can accept SMILES IDs and compound names in the form of a text (.txt) file and return the predicted pIC50 values of the compounds.</p>
    </sec>
    <sec id="sec011">
      <title>Correlation of predicted bioactivity with binding affinity (Molecular modeling and simulation)</title>
      <p>We further tested the correlation of predicted bioactivity of compounds with their corresponding binding affinity to M<sup>pro</sup> via an integrated molecular modeling and simulation approach with the utilization of our developed web-app. A new comprehensive marine natural products database named CMNPD was used for this purpose [<xref rid="pone.0287179.ref039" ref-type="bibr">39</xref>]. As no previous research was published on testing the efficacy of the compounds from this database against M<sup>pro</sup>, we downloaded all the available 31,492 compounds from the database, collected their SMILES IDs, and submitted them to the M<sup>pro</sup>pred web-app for bioactivity (pIC50) prediction. Later, the 3D structures of the top compounds with high pIC50 values were generated using Open Babel and prepared for molecular docking upon energy minimization using the MMFF94 forcefield. The 3D-structure of SARS-CoV-2 M<sup>pro</sup> in complexed with an inhibitor N3 (PDB ID: 6LU7) was used as receptor. Molecular docking was run using Autodock Vina with the same grid box parameters covering the ligand binding residues that were used in our previous work [<xref rid="pone.0287179.ref040" ref-type="bibr">40</xref>,<xref rid="pone.0287179.ref041" ref-type="bibr">41</xref>]. The exhaustiveness value was set to 100. The aim of this approach was to assess whether the compounds with predicted high pIC50 bind to the protease with high affinity.</p>
      <p>The top 5 complexes with high binding interaction with M<sup>pro</sup> were subjected to MD simulation to view their conformational changes. The GROningen MAchine for Chemical Simulations (GROMACS) version 5.1.2 was utilized to perform the MD simulations with the parameters that we previously used [<xref rid="pone.0287179.ref042" ref-type="bibr">42</xref>,<xref rid="pone.0287179.ref043" ref-type="bibr">43</xref>]. The topologies of proteins and the ligands were generated using the ‘pdb2gmx’ script and the PRODRG server, respectively [<xref rid="pone.0287179.ref044" ref-type="bibr">44</xref>]. The GROMOS96 54a7 force field was used to get the energy minimized conformations of complexes and, further, they were solvated in a square box with 1.0 nm of padding using a single point charge (SPC) water model [<xref rid="pone.0287179.ref045" ref-type="bibr">45</xref>]. The net charges in the systems were neutralized using the ‘gmx genion’ script of GROMACS. The steepest descent algorithm was employed to minimize energy of the complexes with &lt; 10.0 kJ/mol force and a maximum of 50,000 steps. Later, NVT and NPT ensembles were performed to equilibrate the systems, both at 300 K temperature and 1 atm for 100 picoseconds (ps). In the simulation, the thermostat and barostat were chosen as the V-rescale and Parrinello-Rahman, respectively. The final production run was performed for 100 nanoseconds (ns) in the HPC cluster of National Institute of Biotechnology, Savar, Bangladesh at 300 K with a 2-fs time step. The simulations were accelerated using a “NVIDIA GTX 3070” graphics processing unit (GPU). The root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (Rg), solvent accessible surface area (SASA) and number of hydrogen bonds were analyzed to evaluate the stability of the complexes after completion of the simulation. The GRACE software was used to plot the graphs.</p>
      <p>We also calculated the binding free energies (MM/PBSA) using the ‘g_mmpbsa’ package of GROMACS followed after the final production run [<xref rid="pone.0287179.ref046" ref-type="bibr">46</xref>]. The following equation is used to calculate the binding energies in this method:
<disp-formula id="pone.0287179.e010"><alternatives><graphic xlink:href="pone.0287179.e010.jpg" id="pone.0287179.e010g" position="anchor"/><mml:math id="M10" display="block" overflow="scroll"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:msub><mml:mi mathvariant="normal">G</mml:mi><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">G</mml:mi><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="normal">G</mml:mi><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">G</mml:mi><mml:mrow><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives><label>(9)</label></disp-formula>
where ΔG<sub>binding</sub> is the overall binding energy of the complex, G<sub>protein</sub> is the free protein binding energy, and G<sub>ligand</sub> is the unbounded ligand binding energy.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="sec012">
    <title>Results</title>
    <sec id="sec013">
      <title>Chemical space analysis</title>
      <p>The dataset that we used in this study is contained in <xref rid="pone.0287179.s001" ref-type="supplementary-material">S1 File</xref> including the SMILES ID of the 758 compounds with references. Exploration of the typical distinctions between active and inactive compounds is one of the major motives for undertaking chemical space analysis. We visualized the actives and inactives distribution as the function of molecular weight (MW) vs. the Ghose–Crippen–Viswanadhan octanol–water partition coefficient to investigate the general chemical space (ALogP). Then, using Lipinski’s rule-of-five (Ro5), we compared the actives and inactives. <xref rid="pone.0287179.g002" ref-type="fig">Fig 2(A)</xref> depicts the MW as the function of ALogP. As can be seen, the majority of the compounds are located in the MW range of 250–600 Da and have an ALogP of 0–6. (<xref rid="pone.0287179.g002" ref-type="fig">Fig 2B–2E</xref>) includes visualization of data and the statistical analysis of the Ro5. The majority of the compounds meet the Ro5 criteria, having a MW of 500 Da, nHBDon and nHBAcc and ALogP values of &lt;10. Furthermore, the findings of statistical analysis show a noteworthy difference among the active and inactive compounds from employment of the Mann–Whitney U test (<xref rid="pone.0287179.t001" ref-type="table">Table 1</xref>). The ALogP values of inactive compounds were found to be higher than the active ones. The nHBDon values of both the active and inactive compounds were similar, however the nHBAcc values of the active compounds were found to be lower than the values of inactive ones.</p>
      <fig position="float" id="pone.0287179.g002">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.g002</object-id>
        <label>Fig 2</label>
        <caption>
          <p>Chemical space analysis (A), box plot of Lipinski’s rule-of five descriptors (B-E) and applicability domain analysis (F) for analyzed M<sup>pro</sup> inhibitors.</p>
        </caption>
        <graphic xlink:href="pone.0287179.g002" position="float"/>
      </fig>
      <table-wrap position="float" id="pone.0287179.t001">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.t001</object-id>
        <label>Table 1</label>
        <caption>
          <title>Mann–Whitney U test results of various properties of the compounds.</title>
        </caption>
        <alternatives>
          <graphic xlink:href="pone.0287179.t001" id="pone.0287179.t001g" position="float"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="center" rowspan="1" colspan="1">Properties</th>
                <th align="center" rowspan="1" colspan="1">Mann–Whitney U test result</th>
                <th align="center" rowspan="1" colspan="1">P value</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="center" rowspan="1" colspan="1">Molecular weight (MW)</td>
                <td align="center" rowspan="1" colspan="1">Different distribution</td>
                <td align="center" rowspan="1" colspan="1">0.016141739</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Octanol–water partition coefficient (AlogP)</td>
                <td align="center" rowspan="1" colspan="1">Different distribution</td>
                <td align="center" rowspan="1" colspan="1">4.12E-10</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Number of Hydrogen bond donors (nHBDon)</td>
                <td align="center" rowspan="1" colspan="1">Different distribution</td>
                <td align="center" rowspan="1" colspan="1">0.033026915</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Number of Hydrogen bond acceptors (nHBAcc)</td>
                <td align="center" rowspan="1" colspan="1">Same distribution</td>
                <td align="center" rowspan="1" colspan="1">0.095506873</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
      </table-wrap>
      <p>Furthermore, the AD of the built model was determined using the MACCS fingerprints as the starting input for PCA analysis, as shown in <xref rid="pone.0287179.g002" ref-type="fig">Fig 2(F)</xref>. After balancing, the data set of 478 compounds was randomly divided into internal and external (80% and 20% respectively) subsets. It’s important to note that the internal set (80%) is used as the training set for building predictive models to predict on the external set. The external set’s chemical space distribution was revealed to be well inside the internal set’s boundaries. As a result, the AD for the CSAR model described herein appears to be well defined.</p>
    </sec>
    <sec id="sec014">
      <title>QSAR modeling</title>
      <p>To develop an interpretable QSAR model, we used fingerprints computed through the PaDEL-Descriptor software. <xref rid="pone.0287179.s002" ref-type="supplementary-material">S2</xref>–<xref rid="pone.0287179.s013" ref-type="supplementary-material">S13 Files</xref> contains the computed 12 molecular fingerprints of our dataset. The data set’s modelability score or MODI index sorts active compounds from inactive compounds to determine the likelihood of obtaining the CSAR model. It was found that all the fingerprint descriptors have a MODI value greater than 0.65, proving that the data set is reliable for developing a classification model. <xref rid="pone.0287179.t002" ref-type="table">Table 2</xref> lists all of these fingerprints, as well as their descriptions and MODI indices.</p>
      <table-wrap position="float" id="pone.0287179.t002">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.t002</object-id>
        <label>Table 2</label>
        <caption>
          <title>List of molecular fingerprints employed in the current study for representing chemical structures of the M<sup>pro</sup> inhibitor dataset along with their MODI indices.</title>
        </caption>
        <alternatives>
          <graphic xlink:href="pone.0287179.t002" id="pone.0287179.t002g" position="float"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="center" rowspan="1" colspan="1">Fingerprint</th>
                <th align="center" rowspan="1" colspan="1">Number<break/>of features</th>
                <th align="center" rowspan="1" colspan="1">Description</th>
                <th align="center" rowspan="1" colspan="1">MODI Index</th>
                <th align="center" rowspan="1" colspan="1">References</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="center" rowspan="1" colspan="1">CDK</td>
                <td align="center" rowspan="1" colspan="1">1,024</td>
                <td align="center" rowspan="1" colspan="1">Fingerprint having length of 1,024, with a search depth of 8</td>
                <td align="center" rowspan="1" colspan="1">0.77</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref047" ref-type="bibr">47</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CDK extended</td>
                <td align="center" rowspan="1" colspan="1">1,024</td>
                <td align="center" rowspan="1" colspan="1">Extends the CDK fingerprint with additional bits that describes ring features</td>
                <td align="center" rowspan="1" colspan="1">0.78</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref047" ref-type="bibr">47</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CDK graph only</td>
                <td align="center" rowspan="1" colspan="1">1,024</td>
                <td align="center" rowspan="1" colspan="1">A special CDK version considering only the connectivity, not bond order</td>
                <td align="center" rowspan="1" colspan="1">0.77</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref047" ref-type="bibr">47</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">E-state</td>
                <td align="center" rowspan="1" colspan="1">79</td>
                <td align="center" rowspan="1" colspan="1">Atom types of electrotopological state</td>
                <td align="center" rowspan="1" colspan="1">0.73</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref048" ref-type="bibr">48</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCS</td>
                <td align="center" rowspan="1" colspan="1">166</td>
                <td align="center" rowspan="1" colspan="1">MACCS keys defined binary representation of chemical features</td>
                <td align="center" rowspan="1" colspan="1">0.79</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref049" ref-type="bibr">49</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">PubChem</td>
                <td align="center" rowspan="1" colspan="1">881</td>
                <td align="center" rowspan="1" colspan="1">PubChem defined binary representation of substructures</td>
                <td align="center" rowspan="1" colspan="1">0.75</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref050" ref-type="bibr">50</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Substructure</td>
                <td align="center" rowspan="1" colspan="1">307</td>
                <td align="center" rowspan="1" colspan="1">Presence of the SMARTS patterns for various functional groups</td>
                <td align="center" rowspan="1" colspan="1">0.76</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref051" ref-type="bibr">51</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Substructure count</td>
                <td align="center" rowspan="1" colspan="1">307</td>
                <td align="center" rowspan="1" colspan="1">Count of the SMARTS patterns for various functional groups</td>
                <td align="center" rowspan="1" colspan="1">0.79</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref051" ref-type="bibr">51</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Klekota–Roth</td>
                <td align="center" rowspan="1" colspan="1">4,860</td>
                <td align="center" rowspan="1" colspan="1">Presence of various chemical substructures</td>
                <td align="center" rowspan="1" colspan="1">0.79</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref052" ref-type="bibr">52</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Klekota–Roth count</td>
                <td align="center" rowspan="1" colspan="1">4,860</td>
                <td align="center" rowspan="1" colspan="1">Count of various chemical substructures</td>
                <td align="center" rowspan="1" colspan="1">0.75</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref052" ref-type="bibr">52</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">2D atom pairs</td>
                <td align="center" rowspan="1" colspan="1">780</td>
                <td align="center" rowspan="1" colspan="1">Presence of atom pairs at various topological distances</td>
                <td align="center" rowspan="1" colspan="1">0.79</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref053" ref-type="bibr">53</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">2D atom pairs count</td>
                <td align="center" rowspan="1" colspan="1">780</td>
                <td align="center" rowspan="1" colspan="1">Count of atom pairs at different topological distances</td>
                <td align="center" rowspan="1" colspan="1">0.73</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref053" ref-type="bibr">53</xref>]</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
      </table-wrap>
      <p>To distinguish between active and inactive M<sup>pro</sup> inhibitors, we created the CSAR model using the RF algorithm in this work. <xref rid="pone.0287179.t003" ref-type="table">Table 3</xref> displays the results of 100 independent runs with all the distinct categories of fingerprints, including internal validation test, 10-fold CV, and external validation test. Best averaged values for the MACCS fingerprints were Ac 84.69% and MCC 0.691, as determined by a 10-fold CV analysis. The external validation for the MACCS, Klekota–Roth, and 2D atom pairs fingerprint descriptors, as shown in <xref rid="pone.0287179.t003" ref-type="table">Table 3</xref>, was also better than the rest of the descriptors. Taking into account the results from 10-fold CV as well as the external validation tests, it is found that the MACCS fingerprint descriptors outperform the other fingerprint classes. <xref rid="pone.0287179.g003" ref-type="fig">Fig 3</xref> contains the plot of experimental vs predicted pIC50 values for model that was constructed with MACCS fingerprint descriptors.</p>
      <fig position="float" id="pone.0287179.g003">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.g003</object-id>
        <label>Fig 3</label>
        <caption>
          <title>Plot showing experimental versus predicted pIC50 values for model constructed with MACCS fingerprint descriptors.</title>
        </caption>
        <graphic xlink:href="pone.0287179.g003" position="float"/>
      </fig>
      <table-wrap position="float" id="pone.0287179.t003">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.t003</object-id>
        <label>Table 3</label>
        <caption>
          <title>Performance summary of CSAR models for predicting M<sup>pro</sup> inhibitors of SARS-CoV-2.</title>
        </caption>
        <alternatives>
          <graphic xlink:href="pone.0287179.t003" id="pone.0287179.t003g" position="float"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="center" rowspan="2" colspan="1">Descriptor class</th>
                <th align="center" colspan="5" rowspan="1">Training set</th>
                <th align="center" colspan="4" rowspan="1">10-fold CV set</th>
                <th align="center" colspan="4" rowspan="1">External set</th>
              </tr>
              <tr>
                <th align="center" rowspan="1" colspan="1">Ac<break/>(%)</th>
                <th align="center" rowspan="1" colspan="1">RMSE</th>
                <th align="center" rowspan="1" colspan="1">Sn</th>
                <th align="center" rowspan="1" colspan="1">Sc</th>
                <th align="center" rowspan="1" colspan="1">MCC</th>
                <th align="center" rowspan="1" colspan="1">Ac (%)</th>
                <th align="center" rowspan="1" colspan="1">Sn</th>
                <th align="center" rowspan="1" colspan="1">Sc</th>
                <th align="center" rowspan="1" colspan="1">MCC</th>
                <th align="center" rowspan="1" colspan="1">Ac (%)</th>
                <th align="center" rowspan="1" colspan="1">Sn</th>
                <th align="center" rowspan="1" colspan="1">Sc</th>
                <th align="center" rowspan="1" colspan="1">MCC</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="center" rowspan="1" colspan="1">CDK</td>
                <td align="center" rowspan="1" colspan="1">99.79</td>
                <td align="center" rowspan="1" colspan="1">0.1045</td>
                <td align="center" rowspan="1" colspan="1">0.998</td>
                <td align="center" rowspan="1" colspan="1">0.99</td>
                <td align="center" rowspan="1" colspan="1">0.996</td>
                <td align="center" rowspan="1" colspan="1">83.43</td>
                <td align="center" rowspan="1" colspan="1">0.834</td>
                <td align="center" rowspan="1" colspan="1">0.864</td>
                <td align="center" rowspan="1" colspan="1">0.670</td>
                <td align="center" rowspan="1" colspan="1">76.84</td>
                <td align="center" rowspan="1" colspan="1">0.768</td>
                <td align="center" rowspan="1" colspan="1">0.744</td>
                <td align="center" rowspan="1" colspan="1">0.537</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CDK extended</td>
                <td align="center" rowspan="1" colspan="1">99.58</td>
                <td align="center" rowspan="1" colspan="1">0.107</td>
                <td align="center" rowspan="1" colspan="1">0.996</td>
                <td align="center" rowspan="1" colspan="1">1</td>
                <td align="center" rowspan="1" colspan="1">0.991</td>
                <td align="center" rowspan="1" colspan="1">81.55</td>
                <td align="center" rowspan="1" colspan="1">0.816</td>
                <td align="center" rowspan="1" colspan="1">0.834</td>
                <td align="center" rowspan="1" colspan="1">0.630</td>
                <td align="center" rowspan="1" colspan="1">83.15</td>
                <td align="center" rowspan="1" colspan="1">0.832</td>
                <td align="center" rowspan="1" colspan="1">0.826</td>
                <td align="center" rowspan="1" colspan="1">0.663</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CDK graph only</td>
                <td align="center" rowspan="1" colspan="1">99.16</td>
                <td align="center" rowspan="1" colspan="1">0.1124</td>
                <td align="center" rowspan="1" colspan="1">0.992</td>
                <td align="center" rowspan="1" colspan="1">0.99</td>
                <td align="center" rowspan="1" colspan="1">0.983</td>
                <td align="center" rowspan="1" colspan="1">84.06</td>
                <td align="center" rowspan="1" colspan="1">0.841</td>
                <td align="center" rowspan="1" colspan="1">0.884</td>
                <td align="center" rowspan="1" colspan="1">0.686</td>
                <td align="center" rowspan="1" colspan="1">84.21</td>
                <td align="center" rowspan="1" colspan="1">0.842</td>
                <td align="center" rowspan="1" colspan="1">0.840</td>
                <td align="center" rowspan="1" colspan="1">0.684</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">E-state</td>
                <td align="center" rowspan="1" colspan="1">96.43</td>
                <td align="center" rowspan="1" colspan="1">0.1247</td>
                <td align="center" rowspan="1" colspan="1">0.964</td>
                <td align="center" rowspan="1" colspan="1">0.96</td>
                <td align="center" rowspan="1" colspan="1">0.927</td>
                <td align="center" rowspan="1" colspan="1">88.46</td>
                <td align="center" rowspan="1" colspan="1">0.885</td>
                <td align="center" rowspan="1" colspan="1">0.861</td>
                <td align="center" rowspan="1" colspan="1">0.766</td>
                <td align="center" rowspan="1" colspan="1">80.00</td>
                <td align="center" rowspan="1" colspan="1">0.800</td>
                <td align="center" rowspan="1" colspan="1">0.714</td>
                <td align="center" rowspan="1" colspan="1">0.613</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCS</td>
                <td align="center" rowspan="1" colspan="1">99.37</td>
                <td align="center" rowspan="1" colspan="1">0.1057</td>
                <td align="center" rowspan="1" colspan="1">0.994</td>
                <td align="center" rowspan="1" colspan="1">0.99</td>
                <td align="center" rowspan="1" colspan="1">0.987</td>
                <td align="center" rowspan="1" colspan="1">84.69</td>
                <td align="center" rowspan="1" colspan="1">0.847</td>
                <td align="center" rowspan="1" colspan="1">0.884</td>
                <td align="center" rowspan="1" colspan="1">0.691</td>
                <td align="center" rowspan="1" colspan="1">89.47</td>
                <td align="center" rowspan="1" colspan="1">0.895</td>
                <td align="center" rowspan="1" colspan="1">0.733</td>
                <td align="center" rowspan="1" colspan="1">0.790</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">PubChem</td>
                <td align="center" rowspan="1" colspan="1">99.79</td>
                <td align="center" rowspan="1" colspan="1">0.1449</td>
                <td align="center" rowspan="1" colspan="1">0.998</td>
                <td align="center" rowspan="1" colspan="1">0.995</td>
                <td align="center" rowspan="1" colspan="1">0.996</td>
                <td align="center" rowspan="1" colspan="1">80.08</td>
                <td align="center" rowspan="1" colspan="1">0.801</td>
                <td align="center" rowspan="1" colspan="1">0.810</td>
                <td align="center" rowspan="1" colspan="1">0.599</td>
                <td align="center" rowspan="1" colspan="1">75.78</td>
                <td align="center" rowspan="1" colspan="1">0.758</td>
                <td align="center" rowspan="1" colspan="1">0.717</td>
                <td align="center" rowspan="1" colspan="1">0.515</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Substructure</td>
                <td align="center" rowspan="1" colspan="1">97.68</td>
                <td align="center" rowspan="1" colspan="1">0.1702</td>
                <td align="center" rowspan="1" colspan="1">0.977</td>
                <td align="center" rowspan="1" colspan="1">0.97</td>
                <td align="center" rowspan="1" colspan="1">0.953</td>
                <td align="center" rowspan="1" colspan="1">78.57</td>
                <td align="center" rowspan="1" colspan="1">0.786</td>
                <td align="center" rowspan="1" colspan="1">0.745</td>
                <td align="center" rowspan="1" colspan="1">0.560</td>
                <td align="center" rowspan="1" colspan="1">78.94</td>
                <td align="center" rowspan="1" colspan="1">0.789</td>
                <td align="center" rowspan="1" colspan="1">0.711</td>
                <td align="center" rowspan="1" colspan="1">0.580</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Substructure count</td>
                <td align="center" rowspan="1" colspan="1">99.78</td>
                <td align="center" rowspan="1" colspan="1">0.144</td>
                <td align="center" rowspan="1" colspan="1">0.998</td>
                <td align="center" rowspan="1" colspan="1">0.995</td>
                <td align="center" rowspan="1" colspan="1">0.996</td>
                <td align="center" rowspan="1" colspan="1">79.41</td>
                <td align="center" rowspan="1" colspan="1">0.794</td>
                <td align="center" rowspan="1" colspan="1">0.750</td>
                <td align="center" rowspan="1" colspan="1">0.577</td>
                <td align="center" rowspan="1" colspan="1">82.1</td>
                <td align="center" rowspan="1" colspan="1">0.821</td>
                <td align="center" rowspan="1" colspan="1">0.777</td>
                <td align="center" rowspan="1" colspan="1">0.641</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Klekota-Roth</td>
                <td align="center" rowspan="1" colspan="1">99.58</td>
                <td align="center" rowspan="1" colspan="1">0.1349</td>
                <td align="center" rowspan="1" colspan="1">0.996</td>
                <td align="center" rowspan="1" colspan="1">0.99</td>
                <td align="center" rowspan="1" colspan="1">0.991</td>
                <td align="center" rowspan="1" colspan="1">83.64</td>
                <td align="center" rowspan="1" colspan="1">0.836</td>
                <td align="center" rowspan="1" colspan="1">0.796</td>
                <td align="center" rowspan="1" colspan="1">0.664</td>
                <td align="center" rowspan="1" colspan="1">83.15</td>
                <td align="center" rowspan="1" colspan="1">0.832</td>
                <td align="center" rowspan="1" colspan="1">0.782</td>
                <td align="center" rowspan="1" colspan="1">0.664</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Klekota-Roth count</td>
                <td align="center" rowspan="1" colspan="1">99.58</td>
                <td align="center" rowspan="1" colspan="1">0.137</td>
                <td align="center" rowspan="1" colspan="1">0.996</td>
                <td align="center" rowspan="1" colspan="1">0.99</td>
                <td align="center" rowspan="1" colspan="1">0.991</td>
                <td align="center" rowspan="1" colspan="1">81.97</td>
                <td align="center" rowspan="1" colspan="1">0.82</td>
                <td align="center" rowspan="1" colspan="1">0.796</td>
                <td align="center" rowspan="1" colspan="1">0.631</td>
                <td align="center" rowspan="1" colspan="1">87.36</td>
                <td align="center" rowspan="1" colspan="1">0.874</td>
                <td align="center" rowspan="1" colspan="1">0.869</td>
                <td align="center" rowspan="1" colspan="1">0.747</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">2D atom pairs</td>
                <td align="center" rowspan="1" colspan="1">96.64</td>
                <td align="center" rowspan="1" colspan="1">0.1955</td>
                <td align="center" rowspan="1" colspan="1">0.966</td>
                <td align="center" rowspan="1" colspan="1">0.965</td>
                <td align="center" rowspan="1" colspan="1">0.931</td>
                <td align="center" rowspan="1" colspan="1">85.74</td>
                <td align="center" rowspan="1" colspan="1">0.860</td>
                <td align="center" rowspan="1" colspan="1">0.854</td>
                <td align="center" rowspan="1" colspan="1">0.713</td>
                <td align="center" rowspan="1" colspan="1">84.21</td>
                <td align="center" rowspan="1" colspan="1">0.842</td>
                <td align="center" rowspan="1" colspan="1">0.822</td>
                <td align="center" rowspan="1" colspan="1">0.683</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">2D atom pairs count</td>
                <td align="center" rowspan="1" colspan="1">99.79</td>
                <td align="center" rowspan="1" colspan="1">0.1471</td>
                <td align="center" rowspan="1" colspan="1">0.998</td>
                <td align="center" rowspan="1" colspan="1">1</td>
                <td align="center" rowspan="1" colspan="1">0.996</td>
                <td align="center" rowspan="1" colspan="1">80.29</td>
                <td align="center" rowspan="1" colspan="1">0.803</td>
                <td align="center" rowspan="1" colspan="1">0.791</td>
                <td align="center" rowspan="1" colspan="1">0.602</td>
                <td align="center" rowspan="1" colspan="1">81.05</td>
                <td align="center" rowspan="1" colspan="1">0.811</td>
                <td align="center" rowspan="1" colspan="1">0.804</td>
                <td align="center" rowspan="1" colspan="1">0.621</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
      </table-wrap>
    </sec>
    <sec id="sec015">
      <title>Interpretation of feature importance</title>
      <p>The top-ranked MACCS fingerprints as obtained from the RF model are mentioned in <xref rid="pone.0287179.t004" ref-type="table">Table 4</xref>, comprised of fingerprints pertaining to different classes such as aromatic compounds, nitrogen-containing compounds, oxygen-containing compounds, halogens etc.</p>
      <table-wrap position="float" id="pone.0287179.t004">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.t004</object-id>
        <label>Table 4</label>
        <caption>
          <title>List of the top-ranking MACCS fingerprints and their corresponding description.</title>
        </caption>
        <alternatives>
          <graphic xlink:href="pone.0287179.t004" id="pone.0287179.t004g" position="float"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="center" rowspan="1" colspan="1">Fingerprint</th>
                <th align="center" rowspan="1" colspan="1">SMARTS pattern</th>
                <th align="center" rowspan="1" colspan="1">Substructure description</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCSFP16</td>
                <td align="center" rowspan="1" colspan="1">(’[!#6;!#1]1~*~*~1’,0)</td>
                <td align="center" rowspan="1" colspan="1">Heteroatom + any 2 heteroatoms + linkage to first atom</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCSFP23</td>
                <td align="center" rowspan="1" colspan="1">(’[#7]~[#6](~[#8])~[#8]’,0)</td>
                <td align="center" rowspan="1" colspan="1">NC(O)O</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCSFP82</td>
                <td align="center" rowspan="1" colspan="1">(’*~[CH<sub>2</sub>]~[!#6;!#1;!H0]’,0)</td>
                <td align="center" rowspan="1" colspan="1">Any heavy atom + CH<sub>2</sub>-heteroatom + H</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCSFP87</td>
                <td align="center" rowspan="1" colspan="1">(’[F,Cl,Br,I]!@*@*’,0)</td>
                <td align="center" rowspan="1" colspan="1">Halogen (part of chain) + any heteroatom connected to another heteroatom with an aromatic bond</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCSFP89</td>
                <td align="center" rowspan="1" colspan="1">(’[#8]~*~*~*~[#8]’,0)</td>
                <td align="center" rowspan="1" colspan="1">O + any 2 heteroatoms + O</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCSFP103</td>
                <td align="center" rowspan="1" colspan="1">(’Cl’,0)</td>
                <td align="center" rowspan="1" colspan="1">Cl</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCSFP107</td>
                <td align="center" rowspan="1" colspan="1">(’[F,Cl,Br,I]~*(~*)~*’,0)</td>
                <td align="center" rowspan="1" colspan="1">Halogen + heteroatom (heteroatom) heteroatom</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCSFP115</td>
                <td align="center" rowspan="1" colspan="1">(’[CH<sub>3</sub>]~*~[CH<sub>2</sub>]~*’,0)</td>
                <td align="center" rowspan="1" colspan="1">CH<sub>3</sub> + any heteroatom + CH<sub>2</sub> + any heteroatom</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCSFP125</td>
                <td align="center" rowspan="1" colspan="1">(’?’,0)</td>
                <td align="center" rowspan="1" colspan="1">Aromatic Ring &gt; 1</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCSFP134</td>
                <td align="center" rowspan="1" colspan="1">(’[F,Cl,Br,I]’,0)</td>
                <td align="center" rowspan="1" colspan="1">Halogen</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCSFP145</td>
                <td align="center" rowspan="1" colspan="1">(’*1~*~*~*~*~*~1’,1)</td>
                <td align="center" rowspan="1" colspan="1">6-member ring &gt; 1</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
      </table-wrap>
    </sec>
    <sec id="sec016">
      <title>Model deployment as the M<sup>pro</sup>pred web-app and assessment</title>
      <p>In order to allow biologists or chemists without a computer science background to apply the prediction model in their research, we deployed it as a public web-app known as the M<sup>pro</sup>pred and is available at <ext-link xlink:href="https://share.streamlit.io/nadimfrds/mpropred/Mpropred_app.py" ext-link-type="uri">https://share.streamlit.io/nadimfrds/mpropred/Mpropred_app.py</ext-link>. Briefly, a guide on using the M<sup>pro</sup>pred web-app (<xref rid="pone.0287179.g004" ref-type="fig">Fig 4</xref>) is given below:</p>
      <p><bold>Step 1</bold>. A text file (.txt) should be created containing the SMILES ID of the desired compounds space separated by a given name/ID (<xref rid="pone.0287179.g004" ref-type="fig">Fig 4A</xref>). SMILES IDs for any desired small compounds can be acquired from various databases e.g. Drugbank [<xref rid="pone.0287179.ref054" ref-type="bibr">54</xref>], PubChem [<xref rid="pone.0287179.ref055" ref-type="bibr">55</xref>] or ChemSpider [<xref rid="pone.0287179.ref056" ref-type="bibr">56</xref>] whereas custom compounds can be drawn on JSME structure editor [<xref rid="pone.0287179.ref057" ref-type="bibr">57</xref>] or ChemDraw [<xref rid="pone.0287179.ref058" ref-type="bibr">58</xref>] so as to create the SMILES notation of unknown compounds.</p>
      <p><bold>Step 2</bold>. The above-mentioned URL should be typed into any web browser to view homepage of the web-app (<xref rid="pone.0287179.g004" ref-type="fig">Fig 4B</xref>).</p>
      <p><bold>Step 3</bold>. The created text file should be uploaded to the web-app by clicking on the “Browse files” button (<xref rid="pone.0287179.g004" ref-type="fig">Fig 4C</xref>).</p>
      <p><bold>Step 4</bold>. The process of prediction can be started upon clicking on the “Predict!” button (<xref rid="pone.0287179.g004" ref-type="fig">Fig 4C</xref>).</p>
      <p><bold>Step 5</bold>. The results are showed in a box found below the “Prediction results” heading (<xref rid="pone.0287179.g004" ref-type="fig">Fig 4D</xref>). Typically, only a few seconds is required for the web-app to process the task. The users can also download the predicted results in the form of a CSV file by clicking the “Download Predictions” button.</p>
      <fig position="float" id="pone.0287179.g004">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.g004</object-id>
        <label>Fig 4</label>
        <graphic xlink:href="pone.0287179.g004" position="float"/>
      </fig>
    </sec>
    <sec id="sec017">
      <title>Binding affinity of CMNPD compounds with M<sup>pro</sup></title>
      <p>Out of the various possible binding positions of each compound predicted by Autodock Vina, the best one was picked considering the lowest binding energy. The molecular docking score of top 200 CMNPD compounds with M<sup>pro</sup> ranged from -4.3 Kcal/mol to -10 Kcal/mol shown in <xref rid="pone.0287179.s014" ref-type="supplementary-material">S14 File</xref> while the result of top 5 compounds is presented in <xref rid="pone.0287179.t005" ref-type="table">Table 5</xref>. The amino acid interactions of M<sup>pro</sup> with the top 5 compounds was also identified. The lowest binding energy was found for the compound CMNPD285. The CMNPD16005 is stabilized by a highest number of seven hydrogen bonds and four hydrophobic bonds while binding with the M<sup>pro</sup>. The second highest number of hydrogen bonds (6) were formed in the CMNPD12721 complex which was also stabilized by seven hydrophobic bonds. All the 5 compounds formed stable interaction with the active site residues and the catalytic dyad comprised of His41 and Cys145 residues of M<sup>pro</sup>. The detailed interaction profile of the top 5 compounds including the N3 ligand with M<sup>pro</sup> is explored in <xref rid="pone.0287179.g005" ref-type="fig">Fig 5</xref>.</p>
      <fig position="float" id="pone.0287179.g005">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.g005</object-id>
        <label>Fig 5</label>
        <caption>
          <p>Two-dimensional (2D) representation of molecular docking analysis between the SARS-CoV-2 M<sup>pro</sup> and (A) N3, (B) CMNPD285, (C) CMNPD20581, (D) CMNPD12721, (E) CMNPD16005, (F) CMNPD6083.</p>
        </caption>
        <graphic xlink:href="pone.0287179.g005" position="float"/>
      </fig>
      <table-wrap position="float" id="pone.0287179.t005">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.t005</object-id>
        <label>Table 5</label>
        <caption>
          <title>Predicted pIC50 and binding affinity score of top 5 compounds from CMNPD database against M<sup>pro</sup>.</title>
        </caption>
        <alternatives>
          <graphic xlink:href="pone.0287179.t005" id="pone.0287179.t005g" position="float"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="center" rowspan="1" colspan="1">Compound</th>
                <th align="center" rowspan="1" colspan="1">Predicted pIC50</th>
                <th align="center" rowspan="1" colspan="1">Docking score (Kcal/mol)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="center" rowspan="1" colspan="1">CMNPD285</td>
                <td align="center" rowspan="1" colspan="1">6.46</td>
                <td align="center" rowspan="1" colspan="1">-10.1</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CMNPD20581</td>
                <td align="center" rowspan="1" colspan="1">7.00</td>
                <td align="center" rowspan="1" colspan="1">-9.6</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CMNPD12721</td>
                <td align="center" rowspan="1" colspan="1">6.49</td>
                <td align="center" rowspan="1" colspan="1">-9.4</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CMNPD16005</td>
                <td align="center" rowspan="1" colspan="1">6.37</td>
                <td align="center" rowspan="1" colspan="1">-9.4</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CMNPD6083</td>
                <td align="center" rowspan="1" colspan="1">6.43</td>
                <td align="center" rowspan="1" colspan="1">-9.4</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
      </table-wrap>
    </sec>
    <sec id="sec018">
      <title>Molecular dynamics (MD) simulation results</title>
      <p>The RMSD of backbone atoms of the protein-ligand complexes were analyzed to view their stability. It can be observed from <xref rid="pone.0287179.g006" ref-type="fig">Fig 6(A)</xref> that CMNPD16005 complex shows the lowest RMSD than all other complexes. Surprisingly, the RMSD of the 6LU7-N3 complex is a bit higher than the CMNPD16005, which denotes the significant stability of CMNPD6083. The RMSD of CMNPD285 complex reaches to ∼0.4 nm from 60 to 85 ns, but the value increases after 85 ns and reaches to 0.3 nm. While viewing into the RMSD of CMNPD12721 complex, a steady increase of RMSD is observed after 60 ns. The value is decreased eventually indicating that CMNPD12721 might change the conformation of protein. Unlike the control and CMNPD16005 complex, RMSD of the CMNPD6083 complex is the mostly stable. Particularly, the CMNPD20581 complex shows the highest RMSD and higher degree of fluctuations throughout the period.</p>
      <fig position="float" id="pone.0287179.g006">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.g006</object-id>
        <label>Fig 6</label>
        <caption>
          <p>The Root-mean-square deviation (A), Root-mean-square fluctuation (B), Radius of gyration (C), Solvent accessible surface area (D) and hydrogen bond (E) analysis of protein-ligand complexes from the molecular simulation of 100 ns at 300 K.</p>
        </caption>
        <graphic xlink:href="pone.0287179.g006" position="float"/>
      </fig>
      <p>As RMSF aids in understanding the region of the receptor that is fluctuated throughout simulation, the flexibility of every residue is determined to gain a better understanding of how ligand binding impacts receptor flexibility. It is understood from <xref rid="pone.0287179.g006" ref-type="fig">Fig 6(B)</xref> that the binding of CMNPD12721 makes the M<sup>pro</sup> most flexible in almost all areas in comparison to all other complexes. Overall, the residues such as Glu47, Met49, Leu50, Tyr154, Ala194, Thr196, Arg222, Asn277 and Phe305 are found flexible in case of both control and the ligand-bonded complexes.</p>
      <p>The Rg represents the compactness of protein-ligand complexes. The lesser the fluctuation across the simulation period, the more compact the system is. The Rg of the 6LU7-N3 and CMNPD285 complexes were found to be nearly stable in case of fluctuation consistency throughout the simulation (<xref rid="pone.0287179.g006" ref-type="fig">Fig 6C</xref>). Besides, the Rg of CMNPD20581 was increased from 40 to 100 ns. The higher change of Rg might be due to protein folding, or distinct structural changes. The remaining complexes showed decreased Rg values indicating greater rigidness throughout the simulation period.</p>
      <p>A higher SASA value implies that the protein volume is expanding, and a lower degree of fluctuation is mostly expected over time. SASA can be altered by the binding of any molecule, and this can have a significant impact on the receptor structure. The SASA values of all the complexes including the control were found lowest during the simulation period suggesting that the presence of these molecules potentially could limit protein expansion (<xref rid="pone.0287179.g006" ref-type="fig">Fig 6D</xref>).</p>
      <p>Since intermolecular hydrogen bonds are known to contribute to conformational stability, the number of total hydrogen bonds in the protein-ligand complexes were determined. Most hydrogen bonds is observed for 6LU7-N3 complex, while the lowest number is observed in CMNPD20581 complex over the simulation period (<xref rid="pone.0287179.g006" ref-type="fig">Fig 6E</xref>). The remaining complexes possessed a significant number of hydrogen bonds (ranging from 3 to 8) compared to the CMNPD20581 complex.</p>
    </sec>
    <sec id="sec019">
      <title>Post simulation binding free energy results</title>
      <p>Using the MM/PBSA method, the binding free energies of the last 20 ns with a 100 ps interval was estimated from MD trajectories. The overall binding energies of all the complexes were negative, showing greater binding (<xref rid="pone.0287179.t006" ref-type="table">Table 6</xref>). The CMNPD16005 complex showed the lowest binding free energy (-296.193 +/- 25.797 KJ/mol), indicating the most stable conformation of the compound. The other complexes similarly had a low binding energy, suggesting that they could be utilized as potential compounds. A comparative analysis of the binding free energies of the complexes were illustrated in <xref rid="pone.0287179.g007" ref-type="fig">Fig 7(A)</xref>. The results for the amino acid residue contribution in the binding of the compounds are shown in <xref rid="pone.0287179.g007" ref-type="fig">Fig 7(B)</xref>. The binding of the compounds to M<sup>pro</sup> involved the notable contribution of leu27, Met49, Cys145, Leu167, Pro168, and Thr190 amino acid residues.</p>
      <fig position="float" id="pone.0287179.g007">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.g007</object-id>
        <label>Fig 7</label>
        <caption>
          <p>Graphical illustration of the binding free energy (A) and per residue contribution plot of protein-ligand complexes (B).</p>
        </caption>
        <graphic xlink:href="pone.0287179.g007" position="float"/>
      </fig>
      <table-wrap position="float" id="pone.0287179.t006">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.t006</object-id>
        <label>Table 6</label>
        <caption>
          <title>Binding free energy calculations (MM/PBSA) for six protein-ligand complexes.</title>
        </caption>
        <alternatives>
          <graphic xlink:href="pone.0287179.t006" id="pone.0287179.t006g" position="float"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="center" rowspan="1" colspan="1">Complex</th>
                <th align="center" rowspan="1" colspan="1">Van der Waal energy<break/>(kJ mol<sup>-1</sup>)</th>
                <th align="center" rowspan="1" colspan="1">Electrostatic energy<break/>(kJ mol<sup>-1</sup>)</th>
                <th align="center" rowspan="1" colspan="1">Polar solvation energy<break/>(kJ mol<sup>-1</sup>)</th>
                <th align="center" rowspan="1" colspan="1">SASA energy<break/>(kJ mol<sup>-1</sup>)</th>
                <th align="center" rowspan="1" colspan="1">Binding energy<break/>(kJ mol<sup>-1</sup>)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="center" rowspan="1" colspan="1">6LU7-N3</td>
                <td align="center" rowspan="1" colspan="1">-224.851 +/- 18.949</td>
                <td align="center" rowspan="1" colspan="1">-162.972 +/- 20.477</td>
                <td align="center" rowspan="1" colspan="1">319.391 +/- 26.396</td>
                <td align="center" rowspan="1" colspan="1">-25.515 +/ 1.955</td>
                <td align="center" rowspan="1" colspan="1">-93.947 +/- 17.448</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CMNPD285</td>
                <td align="center" rowspan="1" colspan="1">-213.039 +/- 18.202</td>
                <td align="center" rowspan="1" colspan="1">-169.860 +/- 27.622</td>
                <td align="center" rowspan="1" colspan="1">342.256 +/- 36.546</td>
                <td align="center" rowspan="1" colspan="1">-22.822 +/- 1.572</td>
                <td align="center" rowspan="1" colspan="1">-63.465 +/- 22.132</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CMNPD20581</td>
                <td align="center" rowspan="1" colspan="1">-230.604 +/- 15.446</td>
                <td align="center" rowspan="1" colspan="1">-7.170 +/- 3.876</td>
                <td align="center" rowspan="1" colspan="1">91.983 +/- 11.163</td>
                <td align="center" rowspan="1" colspan="1">-19.485 +/- 1.290</td>
                <td align="center" rowspan="1" colspan="1">-165.277 +/- 14.898</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CMNPD12721</td>
                <td align="center" rowspan="1" colspan="1">-165.312 +/- 30.586</td>
                <td align="center" rowspan="1" colspan="1">-120.472 +/- 37.904</td>
                <td align="center" rowspan="1" colspan="1">278.799 +/- 47.652</td>
                <td align="center" rowspan="1" colspan="1">-16.485 +/- 2.606</td>
                <td align="center" rowspan="1" colspan="1">-23.469 +/- 26.819</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CMNPD16005</td>
                <td align="center" rowspan="1" colspan="1">-174.597 +/- 15.161</td>
                <td align="center" rowspan="1" colspan="1">-599.461 +/- 34.553</td>
                <td align="center" rowspan="1" colspan="1">499.675 +/- 37.798</td>
                <td align="center" rowspan="1" colspan="1">-21.811 +/- 1.399</td>
                <td align="center" rowspan="1" colspan="1">-296.193 +/- 25.797</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CMNPD6083</td>
                <td align="center" rowspan="1" colspan="1">-90.357 +/- 44.064</td>
                <td align="center" rowspan="1" colspan="1">-28.842 +/- 20.343</td>
                <td align="center" rowspan="1" colspan="1">91.190 +/- 55.611</td>
                <td align="center" rowspan="1" colspan="1">-9.675 +/- 4.522</td>
                <td align="center" rowspan="1" colspan="1">-37.684 +/- 59.575</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
      </table-wrap>
    </sec>
  </sec>
  <sec sec-type="conclusions" id="sec020">
    <title>Discussion</title>
    <p>The COVID-19 pandemic has caused severe damage on the health and daily lives of billions of people around the world over the last two years. We’ve seen a race against time to vaccinate as many people as possible in recent months; however, discrepancies in vaccine distribution between nations, as well as new developing variants, pose an additional public health risk, making it difficult to achieve full immunization [<xref rid="pone.0287179.ref059" ref-type="bibr">59</xref>]. Several vaccine formulations are now available, assisting in the development of immunity [<xref rid="pone.0287179.ref060" ref-type="bibr">60</xref>–<xref rid="pone.0287179.ref063" ref-type="bibr">63</xref>]. Nonetheless, there is an increasing interest in developing new anti-covid medications. The M<sup>pro</sup>, which is responsible for the cleavage of polypeptides during viral genome transcription, is a fascinating drug target in this scenario.</p>
    <p>In the current study, we aimed to develop a classification model that is able to determine active from inactive compounds, and build a web-app for differentiating compounds for M<sup>pro</sup> with selectivity. We followed the Organisation for Economic Co-operation and Development (OECD) recommendations to develop robust QSAR models for this purpose [<xref rid="pone.0287179.ref064" ref-type="bibr">64</xref>]. These guidelines comprise of the following major points: (i) the data set should have a defined endpoint, (ii) it should use an explicit learning algorithm, (iii) there should be a defined applicability domain of the built model, (iv) appropriate measurement of robustness and predictivity and (v) interpretation of the important features of the QSAR model. We initially extracted a dataset of 758 compounds from literature review and thresholds of &lt;0.5 and &gt;10 μM for identifying active compounds from the inactives in order to build a classification model. Upon excluding the intermediate sets of compounds, we obtained a curated set of 478 compounds for detailed analysis. It is feasible to determine if a compound will exhibit the biological or pharmacological property needed for an orally active medicine in humans utilizing the Lipinski’s rule-of-five (Ro5) approach. These characteristics are based on the fact that almost all drugs are relatively large lipophilic compounds with MW, ALogP, the number of hydrogen hydrogen bond donors, and the number of hydrogen bond acceptors. We found that most of the compounds meet the Ro5 criteria (<xref rid="pone.0287179.g002" ref-type="fig">Fig 2B–2E</xref>) and the findings of statistical analysis from Mann–Whitney U test showed a significant difference between the active and inactive compounds (<xref rid="pone.0287179.t001" ref-type="table">Table 1</xref>). Also, the chemical space distribution shows that the external set lies well within the areas of the internal set indicating that the AD is well defined for the developed CSAR model found through PCA analysis results (<xref rid="pone.0287179.g002" ref-type="fig">Fig 2F</xref>).</p>
    <p>Furthermore, we used interpretable molecular fingerprints to develop interpretable QSAR models and evaluated the model performances for all the used 12 fingerprints, following the aforementioned guidelines. Also, it is necessary to identify and address the activity cliffs in the data set using the data set’s modelability score or MODI index before the predictive model can be developed. The data set was found to have a MODI value more than 0.65 for all the 12 fingerprint descriptors, indicating that it is reliable for developing a classification model (<xref rid="pone.0287179.t002" ref-type="table">Table 2</xref>). Then we developed a QSAR model utilizing the random forest (RF) algorithm in order for differentiation of the active and inactive inhibitors for M<sup>pro</sup>. The best averaged values determined by a 10-fold CV analysis was found for the MACCS fingerprint descriptors (Ac of 89%, Sn of 89%, Sc of 73%, and MCC of 79%) (<xref rid="pone.0287179.t003" ref-type="table">Table 3</xref>). Similarly, Klekota–Roth and 2D atom pairs descriptors performed well, with the second and third highest best values for Ac and MCC, respectively, with Klekota–Roth fingerprints providing Ac and MCC values of 83.64% and 0.664, respectively, and 2D atom pairs fingerprints providing Ac and MCC values of 85.74% and 0.713, respectively (<xref rid="pone.0287179.t003" ref-type="table">Table 3</xref>). We found that the MACCS fingerprints were the best choice for model interpretation based on the Ac values, MCC values, overall external and CV.</p>
    <p>Later, an investigation of the important features on selected descriptors was conducted to obtain a better view of the mechanistic details driving M<sup>pro</sup>. The top-ranked MACCS descriptors include descriptors of various classes such as aromatic compounds, nitrogen-containing compounds, oxygen-containing compounds and halogens as obtained from the RF model (<xref rid="pone.0287179.t004" ref-type="table">Table 4</xref>). M<sup>pro</sup> has been shown to be inhibited by a range of N-substituted isatin derivatives, with the highest activity being associated with derivatives having carboxamide groups at C-5 of the isatin core (IC50  =  0.045–17.8 μM) [<xref rid="pone.0287179.ref065" ref-type="bibr">65</xref>]. Several oxygen atoms containing small compounds were also found to inhibit M<sup>pro</sup> and blocks viral transcription [<xref rid="pone.0287179.ref066" ref-type="bibr">66</xref>,<xref rid="pone.0287179.ref067" ref-type="bibr">67</xref>]. Kowit et al. identified halogenated baicalein as a potent inhibitor of the M<sup>pro</sup> and they confirmed its inhibitory activity in an in vitro assay [<xref rid="pone.0287179.ref068" ref-type="bibr">68</xref>]. It was also found that the addition of halogen groups improves binding strength by an order of magnitude [<xref rid="pone.0287179.ref069" ref-type="bibr">69</xref>]. Hossum et al. generated a pharmacophore model and found three acceptor features and one aromatic ring feature as common in all the active hits including the co-crystallized ligand [<xref rid="pone.0287179.ref070" ref-type="bibr">70</xref>]. Thus, the top-ranked MACCS descriptors are in significant correlation with the properties of laboratory validated potent M<sup>pro</sup> inhibitors.</p>
    <p>In a normal predictive model life cycle, after models are validated and outcomes are shown in the publications, the model’s utility is essentially over. In this way, the model has accomplished its goal to make predictions and offer useful insights into the underlying key characteristics. We believed that deployment of the predictive model as a public web-app that allows scientists and researchers, particularly in the fields of computational chemistry and biology, to use the predictive insights from the model would significantly improve its value, while also benefiting scientific communities, would greatly extend the model’s life cycle. We made the web-app available at “Streamlit share” platform (<xref rid="pone.0287179.g004" ref-type="fig">Fig 4</xref>). In order to test the web-app to determine the correlation between predicted pIC50 and the binding affinity, we applied an integrated molecular modeling approach. All the available 31,492 compounds were submitted to the web-app to predict their pIC50 and it was found that top five compounds with highest binding affinity to M<sup>pro</sup> had pIC50 values ranging from 6.37 to 7 (<xref rid="pone.0287179.t005" ref-type="table">Table 5</xref>). They formed sufficient hydrogen bond and hydrophobic interactions and all of them formed stable interactions with the catalytic dyad consisting of His41 and Cys145 (<xref rid="pone.0287179.g005" ref-type="fig">Fig 5</xref>).</p>
    <p>Also, MD simulation results re-confirmed the stability of these five compounds with M<sup>pro</sup>. The RMSD plot indicates that all the five compounds are stable, with no unexpected rises in RMSD values across the simulated time (<xref rid="pone.0287179.g006" ref-type="fig">Fig 6A</xref>). The complexes had fewer fluctuations in the allowed range, according to the RMSF study (<xref rid="pone.0287179.g006" ref-type="fig">Fig 6B</xref>). The radius of gyration (Rg) of the protein-ligand complexes tended to be similar, indicating that every complex had a similar compactness behavior (<xref rid="pone.0287179.g006" ref-type="fig">Fig 6C</xref>). The SASA values showed that the volume of the complexes did not substantially increase (<xref rid="pone.0287179.g006" ref-type="fig">Fig 6D</xref>). Throughout the simulation, a significant number of hydrogen bonds were observed in all of the complexes, further elucidating their conformational stability (<xref rid="pone.0287179.g006" ref-type="fig">Fig 6E</xref>). Furthermore, the binding free energies for all of the complexes were estimated using the MM/PBSA method, and the results suggest that the complexes have a favorable binding energy with M<sup>pro</sup> (<xref rid="pone.0287179.t006" ref-type="table">Table 6</xref> and <xref rid="pone.0287179.g007" ref-type="fig">Fig 7A</xref>). It can be determined from the per-residue interaction energy profile that the leu27, Met49, Cys145, Leu167, Pro168, and Thr190 residues of M<sup>pro</sup> played an important role in protein-ligand stability and contributed significantly to the binding of the compounds (<xref rid="pone.0287179.g007" ref-type="fig">Fig 7B</xref>). As a result, these compounds may have the potential to interfere with and block the activity of SARS-CoV-2 M<sup>pro</sup>.</p>
    <p>Thus, the web-app presented in the current study can be utilized for further research on various compounds to get a view into their anti-M<sup>pro</sup> activity. Also, upon evaluating the toxicity of the five marine derived compounds by various toxicity assays, their inhibition efficacy can be tested through in vitro laboratory validations.</p>
  </sec>
  <sec id="sec021" sec-type="supplementary-material">
    <title>Supporting information</title>
    <supplementary-material id="pone.0287179.s001" position="float" content-type="local-data">
      <label>S1 File</label>
      <caption>
        <title>The SMILES ID and additional details of the 758 compounds.</title>
        <p>(XLSX)</p>
      </caption>
      <media xlink:href="pone.0287179.s001.xlsx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s002" position="float" content-type="local-data">
      <label>S2 File</label>
      <caption>
        <title>Computed AtomPairs2DCount fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s002.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s003" position="float" content-type="local-data">
      <label>S3 File</label>
      <caption>
        <title>Computed AtomPairs2D fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s003.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s004" position="float" content-type="local-data">
      <label>S4 File</label>
      <caption>
        <title>Computed CDK fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s004.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s005" position="float" content-type="local-data">
      <label>S5 File</label>
      <caption>
        <title>Computed CDK Extended fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s005.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s006" position="float" content-type="local-data">
      <label>S6 File</label>
      <caption>
        <title>Computed CDK Graph only fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s006.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s007" position="float" content-type="local-data">
      <label>S7 File</label>
      <caption>
        <title>Computed EState fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s007.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s008" position="float" content-type="local-data">
      <label>S8 File</label>
      <caption>
        <title>Computed KlekotaRothCount fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s008.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s009" position="float" content-type="local-data">
      <label>S9 File</label>
      <caption>
        <title>Computed KlekotaRoth fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s009.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s010" position="float" content-type="local-data">
      <label>S10 File</label>
      <caption>
        <title>Computed MACCS fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s010.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s011" position="float" content-type="local-data">
      <label>S11 File</label>
      <caption>
        <title>Computed PubChem fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s011.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s012" position="float" content-type="local-data">
      <label>S12 File</label>
      <caption>
        <title>Computed Substructure fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s012.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s013" position="float" content-type="local-data">
      <label>S13 File</label>
      <caption>
        <title>Computed SubstructureCount fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s013.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s014" position="float" content-type="local-data">
      <label>S14 File</label>
      <caption>
        <title>The docking score of all the CMNPD compounds with M<sup>pro</sup>.</title>
        <p>(XLSX)</p>
      </caption>
      <media xlink:href="pone.0287179.s014.xlsx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack>
    <p>The author(s) acknowledge the Bioinformatics Division, National Institute of Biotechnology, Bangladesh, for their extended support of supercomputing system during this study.</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="pone.0287179.ref001">
      <label>1</label>
      <mixed-citation publication-type="journal"><name><surname>Lam</surname><given-names>ME</given-names></name>. <article-title>United by the global COVID-19 pandemic: divided by our values and viral identities.</article-title><source>Humanit Soc Sci Commun 2021 81</source>. <year>2021</year>;<volume>8</volume>: <fpage>1</fpage>–<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1057/s41599-020-00679-5</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref002">
      <label>2</label>
      <mixed-citation publication-type="journal"><name><surname>Lambert</surname><given-names>H</given-names></name>, <name><surname>Gupte</surname><given-names>J</given-names></name>, <name><surname>Fletcher</surname><given-names>H</given-names></name>, <name><surname>Hammond</surname><given-names>L</given-names></name>, <name><surname>Lowe</surname><given-names>N</given-names></name>, <name><surname>Pelling</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>COVID-19 as a global challenge: towards an inclusive and sustainable future</article-title>. <source>Lancet Planet Heal</source>. <year>2020</year>;<volume>4</volume>: <fpage>e312</fpage>–<lpage>e314</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S2542-5196(20)30168-6</pub-id><?supplied-pmid 32702296?><pub-id pub-id-type="pmid">32702296</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref003">
      <label>3</label>
      <mixed-citation publication-type="journal"><name><surname>Roberts</surname><given-names>DL</given-names></name>, <name><surname>Rossman</surname><given-names>JS</given-names></name>, <name><surname>Jarić</surname><given-names>I</given-names></name>. <article-title>Dating first cases of COVID-19.</article-title><source>PLOS Pathog</source>. <year>2021</year>;<volume>17</volume>: <fpage>e1009620</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.ppat.1009620</pub-id><?supplied-pmid 34166465?><pub-id pub-id-type="pmid">34166465</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref004">
      <label>4</label>
      <mixed-citation publication-type="journal"><name><surname>Worobey</surname><given-names>M.</given-names></name><article-title>Dissecting the early COVID-19 cases in Wuhan</article-title>. <source>Science (80-).</source><year>2021</year>;<volume>374</volume>: <fpage>1202</fpage>–<lpage>1204</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.abm4454</pub-id><?supplied-pmid 34793199?><pub-id pub-id-type="pmid">34793199</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref005">
      <label>5</label>
      <mixed-citation publication-type="journal"><name><surname>Amicone</surname><given-names>M</given-names></name>, <name><surname>Borges</surname><given-names>V</given-names></name>, <name><surname>Alves</surname><given-names>MJ</given-names></name>, <name><surname>Isidro</surname><given-names>J</given-names></name>, <name><surname>Zé-Zé</surname><given-names>L</given-names></name>, <name><surname>Duarte</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution</article-title>. <source>Evol Med Public Heal</source>. <year>2022</year>;<volume>10</volume>: <fpage>142</fpage>–<lpage>155</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/emph/eoac010</pub-id><?supplied-pmid 35419205?><pub-id pub-id-type="pmid">35419205</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref006">
      <label>6</label>
      <mixed-citation publication-type="journal"><name><surname>Domingo</surname><given-names>E</given-names></name>, <name><surname>Holland</surname><given-names>JJ</given-names></name>. <article-title>RNA VIRUS MUTATIONS AND FITNESS FOR SURVIVAL</article-title>. https://doi.org/101146/annurev.micro511151. <year>2003</year>;<volume>51</volume>: <fpage>151</fpage>–<lpage>178</lpage>. <?supplied-pmid 9343347?><pub-id pub-id-type="pmid">9343347</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref007">
      <label>7</label>
      <mixed-citation publication-type="journal"><name><surname>Sanjuán</surname><given-names>R</given-names></name>, <name><surname>Domingo-Calap</surname><given-names>P</given-names></name>. <article-title>Mechanisms of viral mutation</article-title>. <source>Cell Mol Life Sci 2016 7323.</source><year>2016</year>;<volume>73</volume>: <fpage>4433</fpage>–<lpage>4448</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00018-016-2299-6</pub-id><?supplied-pmid 27392606?><pub-id pub-id-type="pmid">27392606</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref008">
      <label>8</label>
      <mixed-citation publication-type="journal"><name><surname>Duffy</surname><given-names>S</given-names></name>, <name><surname>Shackelton</surname><given-names>LA</given-names></name>, <name><surname>Holmes</surname><given-names>EC</given-names></name>. <article-title>Rates of evolutionary change in viruses: patterns and determinants</article-title>. <source>Nat Rev Genet 2008 94.</source><year>2008</year>;<volume>9</volume>: <fpage>267</fpage>–<lpage>276</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nrg2323</pub-id><?supplied-pmid 18319742?><pub-id pub-id-type="pmid">18319742</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref009">
      <label>9</label>
      <mixed-citation publication-type="journal"><name><surname>Yewdell</surname><given-names>JW</given-names></name>. <article-title>Antigenic drift: Understanding COVID-19</article-title>. <source>Immunity</source>. <year>2021</year>;<volume>54</volume>: <fpage>2681</fpage>–<lpage>2687</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.immuni.2021.11.016</pub-id><?supplied-pmid 34910934?><pub-id pub-id-type="pmid">34910934</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref010">
      <label>10</label>
      <mixed-citation publication-type="journal"><name><surname>Harvey</surname><given-names>WT</given-names></name>, <name><surname>Carabelli</surname><given-names>AM</given-names></name>, <name><surname>Jackson</surname><given-names>B</given-names></name>, <name><surname>Gupta</surname><given-names>RK</given-names></name>, <name><surname>Thomson</surname><given-names>EC</given-names></name>, <name><surname>Harrison</surname><given-names>EM</given-names></name>, <etal>et al</etal>. <article-title>SARS-CoV-2 variants, spike mutations and immune escape</article-title>. <source>Nat Rev Microbiol 2021 197.</source><year>2021</year>;<volume>19</volume>: <fpage>409</fpage>–<lpage>424</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41579-021-00573-0</pub-id><?supplied-pmid 34075212?><pub-id pub-id-type="pmid">34075212</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref011">
      <label>11</label>
      <mixed-citation publication-type="journal"><name><surname>Martin</surname><given-names>DP</given-names></name>, <name><surname>Weaver</surname><given-names>S</given-names></name>, <name><surname>Tegally</surname><given-names>H</given-names></name>, <name><surname>San</surname><given-names>JE</given-names></name>, <name><surname>Shank</surname><given-names>SD</given-names></name>, <name><surname>Wilkinson</surname><given-names>E</given-names></name>, <etal>et al</etal>. <article-title>The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages.</article-title><source>Cell</source>. <year>2021</year>;<volume>184</volume>: <fpage>5189</fpage>–<lpage>5200</lpage>.e7. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cell.2021.09.003</pub-id><?supplied-pmid 34537136?><pub-id pub-id-type="pmid">34537136</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref012">
      <label>12</label>
      <mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>KYA</given-names></name>, <name><surname>Rijal</surname><given-names>P</given-names></name>, <name><surname>Schimanski</surname><given-names>L</given-names></name>, <name><surname>Powell</surname><given-names>TJ</given-names></name>, <name><surname>Lin</surname><given-names>TY</given-names></name>, <name><surname>McCauley</surname><given-names>JW</given-names></name>, <etal>et al</etal>. <article-title>Focused antibody response to influenza linked to antigenic drift</article-title>. <source>J Clin Invest</source>. <year>2015</year>;<volume>125</volume>: <fpage>2631</fpage>–<lpage>2645</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1172/JCI81104</pub-id><?supplied-pmid 26011643?><pub-id pub-id-type="pmid">26011643</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref013">
      <label>13</label>
      <mixed-citation publication-type="journal"><name><surname>Das</surname><given-names>SR</given-names></name>, <name><surname>Hensley</surname><given-names>SE</given-names></name>, <name><surname>Ince</surname><given-names>WL</given-names></name>, <name><surname>Brooke</surname><given-names>CB</given-names></name>, <name><surname>Subba</surname><given-names>A</given-names></name>, <name><surname>Delboy</surname><given-names>MG</given-names></name>, <etal>et al</etal>. <article-title>Defining Influenza A Virus Hemagglutinin Antigenic Drift by Sequential Monoclonal Antibody Selection</article-title>. <source>Cell Host Microbe</source>. <year>2013</year>;<volume>13</volume>: <fpage>314</fpage>–<lpage>323</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.chom.2013.02.008</pub-id><?supplied-pmid 23498956?><pub-id pub-id-type="pmid">23498956</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref014">
      <label>14</label>
      <mixed-citation publication-type="journal"><name><surname>Tahir ul Qamar</surname><given-names>M</given-names></name>, <name><surname>Alqahtani</surname><given-names>SM</given-names></name>, <name><surname>Alamri</surname><given-names>MA</given-names></name>, <name><surname>Chen</surname><given-names>LL</given-names></name>. <article-title>Structural basis of SARS-CoV-2 3CL pro and anti-COVID-19 drug discovery from medicinal plants.</article-title><source>J Pharm Anal</source>. <year>2020</year>;<volume>10</volume>: <fpage>313</fpage>–<lpage>319</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jpha.2020.03.009</pub-id><?supplied-pmid 32296570?><pub-id pub-id-type="pmid">32296570</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref015">
      <label>15</label>
      <mixed-citation publication-type="journal"><name><surname>Pillaiyar</surname><given-names>T</given-names></name>, <name><surname>Manickam</surname><given-names>M</given-names></name>, <name><surname>Namasivayam</surname><given-names>V</given-names></name>, <name><surname>Hayashi</surname><given-names>Y</given-names></name>, <name><surname>Jung</surname><given-names>SH</given-names></name>. <article-title>An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule chemotherapy.</article-title><source>J Med Chem</source>. <year>2016</year>;<volume>59</volume>: <fpage>6595</fpage>–<lpage>6628</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01461</pub-id><?supplied-pmid 26878082?><pub-id pub-id-type="pmid">26878082</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref016">
      <label>16</label>
      <mixed-citation publication-type="journal"><name><surname>Cherkasov</surname><given-names>A</given-names></name>, <name><surname>Muratov</surname><given-names>EN</given-names></name>, <name><surname>Fourches</surname><given-names>D</given-names></name>, <name><surname>Varnek</surname><given-names>A</given-names></name>, <name><surname>Baskin</surname><given-names>II</given-names></name>, <name><surname>Cronin</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>QSAR modeling: where have you been? Where are you going to</article-title>? <source>J Med Chem</source>. <year>2014</year>;<volume>57</volume>: <fpage>4977</fpage>–<lpage>5010</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/jm4004285</pub-id><?supplied-pmid 24351051?><pub-id pub-id-type="pmid">24351051</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref017">
      <label>17</label>
      <mixed-citation publication-type="journal"><name><surname>Prachayasittikul</surname><given-names>V</given-names></name>, <name><surname>Worachartcheewan</surname><given-names>A</given-names></name>, <name><surname>Shoombuatong</surname><given-names>W</given-names></name>, <name><surname>Songtawee</surname><given-names>N</given-names></name>, <name><surname>Simeon</surname><given-names>S</given-names></name>, <name><surname>Prachayasittikul</surname><given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Computer-Aided Drug Design of Bioactive Natural Products</article-title>. <source>Curr Top Med Chem</source>. <year>2015</year>;<volume>15</volume>: <fpage>1780</fpage>–<lpage>1800</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2174/1568026615666150506151101</pub-id><?supplied-pmid 25961523?><pub-id pub-id-type="pmid">25961523</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref018">
      <label>18</label>
      <mixed-citation publication-type="journal"><name><surname>Nantasenamat</surname><given-names>C</given-names></name>, <name><surname>Isarankura-Na-Ayudhya</surname><given-names>C</given-names></name>, <name><surname>Prachayasittikul</surname><given-names>V</given-names></name>. <article-title>Advances in computational methods to predict the biological activity of compounds.</article-title><source>Expert Opin Drug Discov</source>. <year>2010</year>;<volume>5</volume>: <fpage>633</fpage>–<lpage>654</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1517/17460441.2010.492827</pub-id><?supplied-pmid 22823204?><pub-id pub-id-type="pmid">22823204</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref019">
      <label>19</label>
      <mixed-citation publication-type="journal"><name><surname>Dudek</surname><given-names>A</given-names></name>, <name><surname>Arodz</surname><given-names>T</given-names></name>, <name><surname>Galvez</surname><given-names>J</given-names></name>. <article-title>Computational methods in developing quantitative structure-activity relationships (QSAR): a review.</article-title><source>Comb Chem High Throughput Screen</source>. <year>2006</year>;<volume>9</volume>: <fpage>213</fpage>–<lpage>228</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2174/138620706776055539</pub-id><?supplied-pmid 16533155?><pub-id pub-id-type="pmid">16533155</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref020">
      <label>20</label>
      <mixed-citation publication-type="journal"><name><surname>Borsari</surname><given-names>C</given-names></name>, <name><surname>Santarem</surname><given-names>N</given-names></name>, <name><surname>MacEdo</surname><given-names>S</given-names></name>, <name><surname>Jiménez-Antón</surname><given-names>MD</given-names></name>, <name><surname>Torrado</surname><given-names>JJ</given-names></name>, <name><surname>Olías-Molero</surname><given-names>AI</given-names></name>, <etal>et al</etal>. <article-title>SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti- Trypanosoma brucei Agent</article-title>. <source>ACS Med Chem Lett</source>. <year>2019</year>;<volume>10</volume>: <fpage>528</fpage>–<lpage>533</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/acsmedchemlett.8b00565</pub-id><?supplied-pmid 30996791?><pub-id pub-id-type="pmid">30996791</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref021">
      <label>21</label>
      <mixed-citation publication-type="journal"><name><surname>Pir</surname><given-names>M</given-names></name>, <name><surname>Agirbas</surname><given-names>H</given-names></name>, <name><surname>Budak</surname><given-names>F</given-names></name>, <name><surname>Ilter</surname><given-names>M</given-names></name>. <article-title>Synthesis, characterization, antimicrobial activity, and QSAR studies on substituted oxadiazaboroles</article-title>. <source>Med Chem Res</source>. <year>2016</year>;<volume>25</volume>: <fpage>1794</fpage>–<lpage>1812</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/S00044-016-1603-1</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref022">
      <label>22</label>
      <mixed-citation publication-type="journal"><name><surname>De Azevedo</surname><given-names>WF</given-names></name>, <name><surname>Canduri</surname><given-names>F</given-names></name>, <name><surname>Basso</surname><given-names>LA</given-names></name>, <name><surname>Palma</surname><given-names>MS</given-names></name>, <name><surname>Santos</surname><given-names>DS</given-names></name>. <article-title>Determining the structural basis for specificity of ligands using crystallographic screening</article-title>. <source>Cell Biochem Biophys 2006 443.</source><year>2006</year>;<volume>44</volume>: <fpage>405</fpage>–<lpage>411</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1385/CBB:44:3:405</pub-id><?supplied-pmid 16679527?><pub-id pub-id-type="pmid">16679527</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref023">
      <label>23</label>
      <mixed-citation publication-type="journal"><name><surname>Suvannang</surname><given-names>N</given-names></name>, <name><surname>Preeyanon</surname><given-names>L</given-names></name>, <name><surname>Malik</surname><given-names>AA</given-names></name>, <name><surname>Schaduangrat</surname><given-names>N</given-names></name>, <name><surname>Shoombuatong</surname><given-names>W</given-names></name>, <name><surname>Worachartcheewan</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Probing the origin of estrogen receptor alpha inhibition via large-scale QSAR study</article-title>. <source>RSC Adv</source>. <year>2018</year>;<volume>8</volume>: <fpage>11344</fpage>–<lpage>11356</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1039/c7ra10979b</pub-id><?supplied-pmid 35542807?><pub-id pub-id-type="pmid">35542807</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref024">
      <label>24</label>
      <mixed-citation publication-type="journal"><name><surname>Prachayasittikul</surname><given-names>V</given-names></name>, <name><surname>Pingaew</surname><given-names>R</given-names></name>, <name><surname>Worachartcheewan</surname><given-names>A</given-names></name>, <name><surname>Nantasenamat</surname><given-names>C</given-names></name>, <name><surname>Prachayasittikul</surname><given-names>S</given-names></name>, <name><surname>Ruchirawat</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Synthesis, anticancer activity and QSAR study of 1,4-naphthoquinone derivatives</article-title>. <source>Eur J Med Chem</source>. <year>2014</year>;<volume>84</volume>: <fpage>247</fpage>–<lpage>263</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ejmech.2014.07.024</pub-id><?supplied-pmid 25019480?><pub-id pub-id-type="pmid">25019480</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref025">
      <label>25</label>
      <mixed-citation publication-type="journal"><name><surname>da Cunha</surname><given-names>E</given-names></name>, <name><surname>Matos</surname><given-names>K</given-names></name>, <name><surname>Ramalho</surname><given-names>T</given-names></name>. <article-title>QSAR and Docking Studies of HCV NS3 Serine Protease Inhibitors.</article-title><source>Med Chem (Los Angeles).</source><year>2013</year>;<volume>9</volume>: <fpage>774</fpage>–<lpage>805</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2174/1573406411309060003</pub-id><?supplied-pmid 23140577?><pub-id pub-id-type="pmid">23140577</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref026">
      <label>26</label>
      <mixed-citation publication-type="journal"><name><surname>Worachartcheewan</surname><given-names>A</given-names></name>, <name><surname>Prachayasittikul</surname><given-names>V</given-names></name>, <name><surname>Toropova</surname><given-names>AP</given-names></name>, <name><surname>Toropov</surname><given-names>AA</given-names></name>, <name><surname>Nantasenamat</surname><given-names>C</given-names></name>. <article-title>Large-scale structure-activity relationship study of hepatitis C virus NS5B polymerase inhibition using SMILES-based descriptors</article-title>. <source>Mol Divers</source>. <year>2015</year>;<volume>19</volume>: <fpage>955</fpage>–<lpage>964</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11030-015-9614-2</pub-id><?supplied-pmid 26164590?><pub-id pub-id-type="pmid">26164590</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref027">
      <label>27</label>
      <mixed-citation publication-type="journal"><name><surname>Gomes IdS</surname><given-names>Santana CA</given-names></name>, <name><surname>Marcolino LS</surname><given-names>Lima LHFd</given-names></name>, <name><surname>Melo-Minardi RCd</surname><given-names>Dias RS</given-names></name>, <etal>et al</etal>. (<year>2022</year>) <article-title>Computational prediction of potential inhibitors for SARS-COV-2 main protease based on machine learning, docking, MM-PBSA calculations, and metadynamics</article-title>. <source>PLoS ONE</source><volume>17</volume>(<issue>4</issue>): <fpage>e0267471</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0267471</pub-id><?supplied-pmid 35452494?><pub-id pub-id-type="pmid">35452494</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref028">
      <label>28</label>
      <mixed-citation publication-type="journal"><name><surname>Mekni</surname><given-names>N</given-names></name>, <name><surname>Coronnello</surname><given-names>C</given-names></name>, <name><surname>Langer</surname><given-names>T</given-names></name>, <name><surname>De Rosa</surname><given-names>M</given-names></name>, <name><surname>Perricone</surname><given-names>U</given-names></name>. <article-title>Support vector machine as a supervised learning for the prioritization of novel potential sars‐cov‐2 main protease inhibitors.</article-title><source>Int J Mol Sci.</source><year>2021</year>;<volume>22</volume>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/ijms22147714</pub-id><?supplied-pmid 34299333?><pub-id pub-id-type="pmid">34299333</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref029">
      <label>29</label>
      <mixed-citation publication-type="journal"><name><surname>Nand</surname><given-names>M</given-names></name>, <name><surname>Maiti</surname><given-names>P</given-names></name>, <name><surname>Joshi</surname><given-names>T</given-names></name>, <name><surname>Chandra</surname><given-names>S</given-names></name>, <name><surname>Pande</surname><given-names>V</given-names></name>, <name><surname>Kuniyal</surname><given-names>JC</given-names></name>, <etal>et al</etal>. <article-title>Virtual screening of anti-HIV1 compounds against SARS-CoV-2: machine learning modeling, chemoinformatics and molecular dynamics simulation based analysis.</article-title><year>2020</year> [cited 2 Jun 2022]. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-020-77524-x</pub-id>
<?supplied-pmid 33230180?><pub-id pub-id-type="pmid">33230180</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref030">
      <label>30</label>
      <mixed-citation publication-type="journal"><name><surname>Macip</surname><given-names>G</given-names></name>, <name><surname>Garcia-segura</surname><given-names>P</given-names></name>, <name><surname>Mestres-truyol</surname><given-names>J</given-names></name>, <name><surname>Saldivar-espinoza</surname><given-names>B</given-names></name>, <name><surname>Pujadas</surname><given-names>G</given-names></name>, <name><surname>Garcia-Vallvé</surname><given-names>S</given-names></name>. <article-title>A review of the current landscape of SARS-CoV-2 main protease inhibitors: Have we hit the bullseye yet?</article-title><source>Int J Mol Sci.</source><year>2022</year>;<volume>23</volume>: <fpage>259</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/IJMS23010259/S1</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref031">
      <label>31</label>
      <mixed-citation publication-type="journal"><name><surname>Yap</surname><given-names>CW</given-names></name>. <article-title>PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints</article-title>. <source>J Comput Chem</source>. <year>2011</year>;<volume>32</volume>: <fpage>1466</fpage>–<lpage>1474</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jcc.21707</pub-id><?supplied-pmid 21425294?><pub-id pub-id-type="pmid">21425294</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref032">
      <label>32</label>
      <mixed-citation publication-type="journal"><name><surname>Wójcikowski</surname><given-names>M</given-names></name>, <name><surname>Siedlecki</surname><given-names>P</given-names></name>, <name><surname>Ballester</surname><given-names>PJ</given-names></name>. <article-title>Building Machine-Learning Scoring Functions for Structure-Based Prediction of Intermolecular Binding Affinity</article-title>. <source>Methods Mol Biol</source>. <year>2019</year>;<volume>2053</volume>: <fpage>1</fpage>–<lpage>12</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/978-1-4939-9752-7_1</pub-id><?supplied-pmid 31452095?><pub-id pub-id-type="pmid">31452095</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref033">
      <label>33</label>
      <mixed-citation publication-type="journal"><name><surname>Ballester</surname><given-names>PJ</given-names></name>. <article-title>Machine Learning for Molecular Modelling in Drug Design.</article-title><source>Biomol 2019, Vol 9, Page 216</source>. <year>2019</year>;<volume>9</volume>: <fpage>216</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/biom9060216</pub-id><?supplied-pmid 31167503?><pub-id pub-id-type="pmid">31167503</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref034">
      <label>34</label>
      <mixed-citation publication-type="journal"><name><surname>Breiman</surname><given-names>L</given-names></name>, <name><surname>Friedman</surname><given-names>JH</given-names></name>, <name><surname>Olshen</surname><given-names>RA</given-names></name>, <name><surname>Stone</surname><given-names>CJ</given-names></name>. <article-title>Classification and regression trees.</article-title><source>Classif Regres Trees.</source><year>2017</year>; <fpage>1</fpage>–<lpage>358</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1201/9781315139470/CLASSIFICATION-REGRESSION-TREES-LEO-BREIMAN-JEROME-FRIEDMAN-RICHARD-OLSHEN-CHARLES-STONE</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref035">
      <label>35</label>
      <mixed-citation publication-type="journal"><name><surname>Breiman</surname><given-names>L.</given-names></name><article-title>Random Forests</article-title>. <source>Mach Learn 2001 451</source>. <year>2001</year>;<volume>45</volume>: <fpage>5</fpage>–<lpage>32</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1023/A</pub-id>:1010933404324.</mixed-citation>
    </ref>
    <ref id="pone.0287179.ref036">
      <label>36</label>
      <mixed-citation publication-type="journal"><name><surname>Liaw</surname><given-names>A</given-names></name>, <name><surname>Wiener</surname><given-names>M</given-names></name>. <source>Classification and Regression by randomForest</source>. <year>2002</year>;<volume>2</volume>. Available: <ext-link xlink:href="http://www.stat.berkeley.edu/" ext-link-type="uri">http://www.stat.berkeley.edu/</ext-link>.</mixed-citation>
    </ref>
    <ref id="pone.0287179.ref037">
      <label>37</label>
      <mixed-citation publication-type="journal"><name><surname>Golbraikh</surname><given-names>A</given-names></name>, <name><surname>Muratov</surname><given-names>E</given-names></name>, <name><surname>Fourches</surname><given-names>D</given-names></name>, <name><surname>Tropsha</surname><given-names>A</given-names></name>. <article-title>Data set modelability by QSAR.</article-title><source>J Chem Inf Model</source>. <year>2014</year>;<volume>54</volume>: <fpage>1</fpage>–<lpage>4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/ci400572x</pub-id><?supplied-pmid 24251851?><pub-id pub-id-type="pmid">24251851</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref038">
      <label>38</label>
      <mixed-citation publication-type="journal"><name><surname>Malik</surname><given-names>AA</given-names></name>, <name><surname>Phanus-umporn</surname><given-names>C</given-names></name>, <name><surname>Schaduangrat</surname><given-names>N</given-names></name>, <name><surname>Shoombuatong</surname><given-names>W</given-names></name>, <name><surname>Isarankura-Na-Ayudhya</surname><given-names>C</given-names></name>, <name><surname>Nantasenamat</surname><given-names>C</given-names></name>. <article-title>HCVpred: A web server for predicting the bioactivity of hepatitis C virus NS5B inhibitors</article-title>. <source>J Comput Chem</source>. <year>2020</year>;<volume>41</volume>: <fpage>1820</fpage>–<lpage>1834</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jcc.26223</pub-id><?supplied-pmid 32449536?><pub-id pub-id-type="pmid">32449536</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref039">
      <label>39</label>
      <mixed-citation publication-type="journal"><name><surname>Lyu</surname><given-names>C</given-names></name>, <name><surname>Chen</surname><given-names>T</given-names></name>, <name><surname>Qiang</surname><given-names>B</given-names></name>, <name><surname>Liu</surname><given-names>N</given-names></name>, <name><surname>Wang</surname><given-names>H</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>CMNPD: a comprehensive marine natural products database towards facilitating drug discovery from the ocean</article-title>. <source>Nucleic Acids Res</source>. <year>2021</year>;<volume>49</volume>: <fpage>D509</fpage>–<lpage>D515</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkaa763</pub-id><?supplied-pmid 32986829?><pub-id pub-id-type="pmid">32986829</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref040">
      <label>40</label>
      <mixed-citation publication-type="journal"><name><surname>Trott</surname><given-names>O</given-names></name>, <name><surname>Olson</surname><given-names>AJ</given-names></name>. <article-title>AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading</article-title>. <source>J Comput Chem</source>. <year>2010</year>;<volume>31</volume>: <fpage>455</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jcc.21334</pub-id><?supplied-pmid 19499576?><pub-id pub-id-type="pmid">19499576</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref041">
      <label>41</label>
      <mixed-citation publication-type="journal"><name><surname>Ferdous</surname><given-names>N</given-names></name>, <name><surname>Reza</surname><given-names>MN</given-names></name>, <name><surname>Islam</surname><given-names>MS</given-names></name>, <name><surname>Hossain Emon</surname><given-names>MT</given-names></name>, <name><surname>Mohiuddin</surname><given-names>AKM</given-names></name>, <name><surname>Hossain</surname><given-names>MU</given-names></name>. <article-title>Newly designed analogues from SARS-CoV inhibitors mimicking the druggable properties against SARS-CoV-2 and its novel variants.</article-title><source>RSC Adv</source>. <year>2021</year>;<volume>11</volume>: <fpage>31460</fpage>–<lpage>31476</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1039/d1ra04107j</pub-id><?supplied-pmid 35496863?><pub-id pub-id-type="pmid">35496863</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref042">
      <label>42</label>
      <mixed-citation publication-type="journal"><name><surname>Abraham</surname><given-names>MJ</given-names></name>, <name><surname>Murtola</surname><given-names>T</given-names></name>, <name><surname>Schulz</surname><given-names>R</given-names></name>, <name><surname>Páll</surname><given-names>S</given-names></name>, <name><surname>Smith</surname><given-names>JC</given-names></name>, <name><surname>Hess</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers.</article-title><source>SoftwareX.</source><year>2015</year>;<fpage>1</fpage>–<lpage>2</lpage>: 19–25. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/J.SOFTX.2015.06.001</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref043">
      <label>43</label>
      <mixed-citation publication-type="journal"><name><surname>Reza</surname><given-names>MN</given-names></name>, <name><surname>Ferdous</surname><given-names>N</given-names></name>, <name><surname>Emon</surname><given-names>MTH</given-names></name>, <name><surname>Islam</surname><given-names>MS</given-names></name>, <name><surname>Mohiuddin</surname><given-names>AKM</given-names></name>, <name><surname>Hossain</surname><given-names>MU</given-names></name>. <article-title>Pathogenic genetic variants from highly connected cancer susceptibility genes confer the loss of structural stability</article-title>. <source>Sci Reports</source> 2021 111. <year>2021</year>;<volume>11</volume>: <fpage>1</fpage>–<lpage>19</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-021-98547-y</pub-id>
<?supplied-pmid 34584144?><pub-id pub-id-type="pmid">34584144</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref044">
      <label>44</label>
      <mixed-citation publication-type="journal"><name><surname>AW S</surname><given-names>DM</given-names></name> van A. <article-title>PRODRG: a tool for high-throughput crystallography of protein-ligand complexes</article-title>. <source>Acta Crystallogr D Biol Crystallogr</source>. <year>2004</year>;<volume>60</volume>: <fpage>1355</fpage>–<lpage>1363</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1107/S0907444904011679</pub-id>
<?supplied-pmid 15272157?><pub-id pub-id-type="pmid">15272157</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref045">
      <label>45</label>
      <mixed-citation publication-type="journal"><name><surname>N S</surname></name>, <name><surname>AP</surname><given-names>E</given-names></name>, <name><surname>A</surname><given-names>C</given-names></name>, <name><surname>S</surname><given-names>R</given-names></name>, <name><surname>M</surname><given-names>W</given-names></name>, <name><surname>AE</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Definition and testing of the GROMOS force-field versions 54A7 and 54B7</article-title>. <source>Eur Biophys J</source>. <year>2011</year>;<volume>40</volume>: <fpage>843</fpage>–<lpage>856</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00249-011-0700-9</pub-id><?supplied-pmid 21533652?><pub-id pub-id-type="pmid">21533652</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref046">
      <label>46</label>
      <mixed-citation publication-type="journal"><name><surname>Kumari</surname><given-names>R</given-names></name>, <name><surname>Kumar</surname><given-names>R</given-names></name>, <name><surname>Consortium</surname><given-names>OSDD</given-names></name>, <name><surname>Lynn</surname><given-names>A</given-names></name>. <article-title>g_mmpbsa—A GROMACS Tool for High-Throughput MM-PBSA Calculations.</article-title><source>J Chem Inf Model</source>. <year>2014</year>;<volume>54</volume>: <fpage>1951</fpage>–<lpage>1962</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/ci500020m</pub-id><?supplied-pmid 24850022?><pub-id pub-id-type="pmid">24850022</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref047">
      <label>47</label>
      <mixed-citation publication-type="journal"><name><surname>Steinbeck</surname><given-names>C</given-names></name>, <name><surname>Han</surname><given-names>Y</given-names></name>, <name><surname>Kuhn</surname><given-names>S</given-names></name>, <name><surname>Horlacher</surname><given-names>O</given-names></name>, <name><surname>Luttmann</surname><given-names>E</given-names></name>, <name><surname>Willighagen</surname><given-names>E</given-names></name>. <article-title>The Chemistry Development Kit (CDK): an open-source Java library for Chemo- and Bioinformatics.</article-title><source>J Chem Inf Comput Sci</source>. <year>2003</year>;<volume>43</volume>: <fpage>493</fpage>–<lpage>500</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/ci025584y</pub-id><?supplied-pmid 12653513?><pub-id pub-id-type="pmid">12653513</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref048">
      <label>48</label>
      <mixed-citation publication-type="journal"><name><surname>Hall</surname><given-names>LH</given-names></name>, <name><surname>Kier</surname><given-names>LB</given-names></name>. <article-title>Electrotopological State Indices for Atom Types: A Novel Combination of Electronic, Topological, and Valence State Information</article-title>. <source>J Chem Inf Comput Sci</source>. <year>1995</year>;<volume>35</volume>: <fpage>1039</fpage>–<lpage>1045</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/CI00028A014/ASSET/CI00028A014.FP.PNG_V03</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref049">
      <label>49</label>
      <mixed-citation publication-type="journal"><name><surname>Durant</surname><given-names>JL</given-names></name>, <name><surname>Leland</surname><given-names>BA</given-names></name>, <name><surname>Henry</surname><given-names>DR</given-names></name>, <name><surname>Nourse</surname><given-names>JG</given-names></name>. <article-title>Reoptimization of MDL keys for use in drug discovery</article-title>. <source>J Chem Inf Comput Sci</source>. <year>2002</year>;<volume>42</volume>: <fpage>1273</fpage>–<lpage>1280</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/ci010132r</pub-id><?supplied-pmid 12444722?><pub-id pub-id-type="pmid">12444722</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref050">
      <label>50</label>
      <mixed-citation publication-type="other">V1. PubChem Substructure Fingerprint. [cited 3 Jun 2022]. Available: <ext-link xlink:href="http://pubchem" ext-link-type="uri">http://pubchem</ext-link>.</mixed-citation>
    </ref>
    <ref id="pone.0287179.ref051">
      <label>51</label>
      <mixed-citation publication-type="journal"><name><surname>Simeon</surname><given-names>S</given-names></name>, <name><surname>Jongkon</surname><given-names>N</given-names></name>. <article-title>Construction of Quantitative Structure Activity Relationship (QSAR) Models to Predict Potency of Structurally Diversed Janus Kinase 2 Inhibitors.</article-title><source>Molecules</source>. <year>2019</year>;<volume>24</volume>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/molecules24234393</pub-id><?supplied-pmid 31805692?><pub-id pub-id-type="pmid">31805692</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref052">
      <label>52</label>
      <mixed-citation publication-type="journal"><name><surname>Klekota</surname><given-names>J</given-names></name>, <name><surname>Roth</surname><given-names>FP</given-names></name>. <article-title>Chemical substructures that enrich for biological activity</article-title>. <source>Bioinformatics</source>. <year>2008</year>;<volume>24</volume>: <fpage>2518</fpage>–<lpage>2525</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bioinformatics/btn479</pub-id><?supplied-pmid 18784118?><pub-id pub-id-type="pmid">18784118</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref053">
      <label>53</label>
      <mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>DH</given-names></name>, <name><surname>Carhart</surname><given-names>RE</given-names></name>, <name><surname>Venkataraghavan</surname><given-names>R</given-names></name>. <article-title>Atom Pairs as Molecular Features in Structure-Activity Studies: Definition and Applications</article-title>. <source>J Chem Inf Comput Sci</source>. <year>1985</year>;<volume>25</volume>: <fpage>64</fpage>–<lpage>73</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/CI00046A002/ASSET/CI00046A002.FP.PNG_V03</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref054">
      <label>54</label>
      <mixed-citation publication-type="journal"><name><surname>Wishart</surname><given-names>DS</given-names></name>, <name><surname>Knox</surname><given-names>C</given-names></name>, <name><surname>Guo</surname><given-names>AC</given-names></name>, <name><surname>Cheng</surname><given-names>D</given-names></name>, <name><surname>Shrivastava</surname><given-names>S</given-names></name>, <name><surname>Tzur</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>DrugBank: a knowledgebase for drugs, drug actions and drug targets</article-title>. <source>Nucleic Acids Res</source>. <year>2008</year>;<volume>36</volume>: <fpage>D901</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkm958</pub-id><?supplied-pmid 18048412?><pub-id pub-id-type="pmid">18048412</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref055">
      <label>55</label>
      <mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>S</given-names></name>, <name><surname>Thiessen</surname><given-names>PA</given-names></name>, <name><surname>Bolton</surname><given-names>EE</given-names></name>, <name><surname>Chen</surname><given-names>J</given-names></name>, <name><surname>Fu</surname><given-names>G</given-names></name>, <name><surname>Gindulyte</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>PubChem Substance and Compound databases</article-title>. <source>Nucleic Acids Res</source>. <year>2016</year>;<volume>44</volume>: <fpage>D1202</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkv951</pub-id><?supplied-pmid 26400175?><pub-id pub-id-type="pmid">26400175</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref056">
      <label>56</label>
      <mixed-citation publication-type="journal"><name><surname>Pence</surname><given-names>HE</given-names></name>, <name><surname>Williams</surname><given-names>A</given-names></name>. <article-title>ChemSpider: An Online Chemical Information Resource</article-title>. <source>J Chem Educ</source>. <year>2010</year>;<volume>87</volume>: <fpage>1123</fpage>–<lpage>1124</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/ED100697W</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref057">
      <label>57</label>
      <mixed-citation publication-type="journal"><name><surname>Bienfait</surname><given-names>B</given-names></name>, <name><surname>Ertl</surname><given-names>P</given-names></name>. <article-title>JSME: a free molecule editor in JavaScript.</article-title><source>J Cheminform.</source><year>2013</year>;<volume>5</volume>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/1758-2946-5-24</pub-id><?supplied-pmid 23694746?><pub-id pub-id-type="pmid">23694746</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref058">
      <label>58</label>
      <mixed-citation publication-type="journal"><name><surname>Cousins</surname><given-names>KR</given-names></name>. <article-title>Computer review of ChemDraw Ultra 12.0</article-title>. <source>J Am Chem Soc</source>. <year>2011</year>;<volume>133</volume>: <fpage>8388</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/ja204075s</pub-id><?supplied-pmid 21561109?><pub-id pub-id-type="pmid">21561109</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref059">
      <label>59</label>
      <mixed-citation publication-type="journal"><name><surname>Zhu</surname><given-names>N</given-names></name>, <name><surname>Zhang</surname><given-names>D</given-names></name>, <name><surname>Wang</surname><given-names>W</given-names></name>, <name><surname>Li</surname><given-names>X</given-names></name>, <name><surname>Yang</surname><given-names>B</given-names></name>, <name><surname>Song</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>A Novel Coronavirus from Patients with Pneumonia in China, 2019</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>382</volume>: <fpage>727</fpage>–<lpage>733</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa2001017</pub-id><?supplied-pmid 31978945?><pub-id pub-id-type="pmid">31978945</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref060">
      <label>60</label>
      <mixed-citation publication-type="journal"><name><surname>Polack</surname><given-names>FP</given-names></name>, <name><surname>Thomas</surname><given-names>SJ</given-names></name>, <name><surname>Kitchin</surname><given-names>N</given-names></name>, <name><surname>Absalon</surname><given-names>J</given-names></name>, <name><surname>Gurtman</surname><given-names>A</given-names></name>, <name><surname>Lockhart</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>383</volume>: <fpage>2603</fpage>–<lpage>2615</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id><?supplied-pmid 33301246?><pub-id pub-id-type="pmid">33301246</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref061">
      <label>61</label>
      <mixed-citation publication-type="journal"><name><surname>Voysey</surname><given-names>M</given-names></name>, <name><surname>Clemens</surname><given-names>SAC</given-names></name>, <name><surname>Madhi</surname><given-names>SA</given-names></name>, <name><surname>Weckx</surname><given-names>LY</given-names></name>, <name><surname>Folegatti</surname><given-names>PM</given-names></name>, <name><surname>Aley</surname><given-names>PK</given-names></name>, <etal>et al</etal>. <article-title>Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.</article-title><source>Lancet</source>. <year>2021</year>;<volume>397</volume>: <fpage>99</fpage>–<lpage>111</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32661-1</pub-id><?supplied-pmid 33306989?><pub-id pub-id-type="pmid">33306989</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref062">
      <label>62</label>
      <mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Zeng</surname><given-names>G</given-names></name>, <name><surname>Pan</surname><given-names>H</given-names></name>, <name><surname>Li</surname><given-names>C</given-names></name>, <name><surname>Hu</surname><given-names>Y</given-names></name>, <name><surname>Chu</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.</article-title><source>Lancet Infect Dis.</source><year>2021</year>;<volume>21</volume>: <fpage>181</fpage>–<lpage>192</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30843-4</pub-id><?supplied-pmid 33217362?><pub-id pub-id-type="pmid">33217362</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref063">
      <label>63</label>
      <mixed-citation publication-type="journal"><name><surname>Baden</surname><given-names>LR</given-names></name>, <name><surname>El Sahly</surname><given-names>HM</given-names></name>, <name><surname>Essink</surname><given-names>B</given-names></name>, <name><surname>Kotloff</surname><given-names>K</given-names></name>, <name><surname>Frey</surname><given-names>S</given-names></name>, <name><surname>Novak</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>384</volume>: <fpage>403</fpage>–<lpage>416</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa2035389</pub-id><?supplied-pmid 33378609?><pub-id pub-id-type="pmid">33378609</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref064">
      <label>64</label>
      <mixed-citation publication-type="journal"><name><surname>Shoombuatong</surname><given-names>W</given-names></name>, <name><surname>Schaduangrat</surname><given-names>N</given-names></name>, <name><surname>Nantasenamat</surname><given-names>C</given-names></name>. <article-title>Towards understanding aromatase inhibitory activity via QSAR modeling.</article-title><source>EXCLI J</source>. <year>2018</year>;<volume>17</volume>: <fpage>688</fpage>–<lpage>708</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.17179/excli2018-1417</pub-id><?supplied-pmid 30190660?><pub-id pub-id-type="pmid">30190660</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref065">
      <label>65</label>
      <mixed-citation publication-type="journal"><name><surname>Elsaman</surname><given-names>T</given-names></name>, <name><surname>Mohamed</surname><given-names>MS</given-names></name>, <name><surname>Eltayib</surname><given-names>EM</given-names></name>, <name><surname>Abdel-aziz</surname><given-names>HA</given-names></name>, <name><surname>Abdalla</surname><given-names>AE</given-names></name>, <name><surname>Munir</surname><given-names>MU</given-names></name>, <etal>et al</etal>. <article-title>Isatin derivatives as broad-spectrum antiviral agents: the current landscape</article-title>. <source>Med Chem Res</source>. <year>2022</year>;<volume>31</volume>: <fpage>244</fpage>–<lpage>273</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00044-021-02832-4</pub-id><?supplied-pmid 35039740?><pub-id pub-id-type="pmid">35039740</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref066">
      <label>66</label>
      <mixed-citation publication-type="journal"><name><surname>Hattori</surname><given-names>S ichiro</given-names></name>, <name><surname>Higashi-Kuwata</surname><given-names>N</given-names></name>, <name><surname>Hayashi</surname><given-names>H</given-names></name>, <name><surname>Allu</surname><given-names>SR</given-names></name>, <name><surname>Raghavaiah</surname><given-names>J</given-names></name>, <name><surname>Bulut</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication.</article-title><source>Nat Commun 2021 121</source>. <year>2021</year>;<volume>12</volume>: <fpage>1</fpage>–<lpage>12</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-021-20900-6</pub-id><?supplied-pmid 33510133?><pub-id pub-id-type="pmid">33510133</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref067">
      <label>67</label>
      <mixed-citation publication-type="journal"><name><surname>Weglarz-Tomczak</surname><given-names>E</given-names></name>, <name><surname>Tomczak</surname><given-names>JM</given-names></name>, <name><surname>Talma</surname><given-names>M</given-names></name>, <name><surname>Burda-Grabowska</surname><given-names>M</given-names></name>, <name><surname>Giurg</surname><given-names>M</given-names></name>, <name><surname>Brul</surname><given-names>S</given-names></name>. <article-title>Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2.</article-title><source>Sci Reports 2021 111</source>. <year>2021</year>;<volume>11</volume>: <fpage>1</fpage>–<lpage>10</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-021-83229-6</pub-id><?supplied-pmid 33574416?><pub-id pub-id-type="pmid">33574416</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref068">
      <label>68</label>
      <mixed-citation publication-type="journal"><name><surname>Hengphasatporn</surname><given-names>K</given-names></name>, <name><surname>Wilasluck</surname><given-names>P</given-names></name>, <name><surname>Deetanya</surname><given-names>P</given-names></name>, <name><surname>Wangkanont</surname><given-names>K</given-names></name>, <name><surname>Chavasiri</surname><given-names>W</given-names></name>, <name><surname>Visitchanakun</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Halogenated Baicalein as a Promising Antiviral Agent toward SARS-CoV-2 Main Protease.</article-title><source>J Chem Inf Model.</source><year>2022</year>;<volume>62</volume>: <fpage>1498</fpage>–<lpage>1509</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/acs.jcim.1c01304</pub-id><?supplied-pmid 35245424?><pub-id pub-id-type="pmid">35245424</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref069">
      <label>69</label>
      <mixed-citation publication-type="journal"><name><surname>Glaser</surname><given-names>J</given-names></name>, <name><surname>Sedova</surname><given-names>A</given-names></name>, <name><surname>Galanie</surname><given-names>S</given-names></name>, <name><surname>Kneller</surname><given-names>DW</given-names></name>, <name><surname>Davidson</surname><given-names>RB</given-names></name>, <name><surname>Maradzike</surname><given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Hit Expansion of a Noncovalent SARS-CoV-2 Main Protease Inhibitor.</article-title><source>ACS Pharmacol Transl Sci.</source><year>2022</year>;<volume>5</volume>: <fpage>255</fpage>–<lpage>265</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/acsptsci.2c00026</pub-id><?supplied-pmid 35434531?><pub-id pub-id-type="pmid">35434531</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref070">
      <label>70</label>
      <mixed-citation publication-type="journal"><name><surname>Abdallah</surname><given-names>HM</given-names></name>, <name><surname>El-Halawany</surname><given-names>AM</given-names></name>, <name><surname>Sirwi</surname><given-names>A</given-names></name>, <name><surname>El-Araby</surname><given-names>AM</given-names></name>, <name><surname>Mohamed</surname><given-names>GA</given-names></name>, <name><surname>Ibrahim</surname><given-names>SRM</given-names></name>, <etal>et al</etal>. <article-title>Repurposing of Some Natural Product Isolates as SARS-COV-2 Main Protease Inhibitors via In Vitro Cell Free and Cell-Based Antiviral Assessments and Molecular Modeling Approaches</article-title>. <source>Pharm 2021, Vol 14, Page 213.</source><year>2021</year>;<volume>14</volume>: <fpage>213</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/ph14030213</pub-id><?supplied-pmid 33806331?><pub-id pub-id-type="pmid">33806331</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<sub-article article-type="aggregated-review-documents" id="pone.0287179.r001" specific-use="decision-letter">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pone.0287179.r001</article-id>
    <title-group>
      <article-title>Decision Letter 0</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Gallicchio</surname>
          <given-names>Emilio</given-names>
        </name>
        <role>Academic Editor</role>
      </contrib>
    </contrib-group>
    <permissions>
      <copyright-statement>© 2023 Emilio Gallicchio</copyright-statement>
      <copyright-year>2023</copyright-year>
      <copyright-holder>Emilio Gallicchio</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0287179" id="rel-obj001" related-article-type="reviewed-article"/>
    <custom-meta-group>
      <custom-meta>
        <meta-name>Submission Version</meta-name>
        <meta-value>0</meta-value>
      </custom-meta>
    </custom-meta-group>
  </front-stub>
  <body>
    <boxed-text id="pone-0287179-box001" position="float" specific-use="prior_peer_review_unavailable">
      <sec id="sec022">
        <title>Transfer Alert</title>
        <p>This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.</p>
      </sec>
    </boxed-text>
    <p>
      <named-content content-type="letter-date">12 Jan 2023</named-content>
    </p>
    <p><!-- <div> -->PONE-D-22-21799<!-- </div> --><!-- <div> -->Mpropred: A machine learning (ML) driven Web-App for bioactivity prediction of SARS-CoV-2 main protease (Mpro) antagonists<!-- </div> --><!-- <div> -->PLOS ONE</p>
    <p>Dear Dr. Mohiuddin,</p>
    <p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.<!-- </div> --><!-- <div> --> <!-- </div> --><!-- <div> -->Please address the comment of the reviewer, especially the question about the meaning of the fingerprints. Please consider including a figure with a 3D structure of the Mpro receptor site to better convey the structural discussion in the introduction and results. Isabela et al should be probably referenced as Gomes et al. on line 89. Many Mpro inhibitors, including N3 in the structure used for the MD simulations, are covalent inhibitors. It would be beneficial to discuss whether the inhibitors identified by the model are likely covalent inhibitors and which fingerprints recognize such inhibitors.    <!-- </div> --><!-- <div> --> <!-- </div> --><!-- <div> -->Please submit your revised manuscript by Feb 26 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
    <p>Please include the following items when submitting your revised manuscript:<!-- </div> --><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list></p>
    <p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
    <p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link>.</p>
    <p>We look forward to receiving your revised manuscript.</p>
    <p>Kind regards,</p>
    <p>Emilio Gallicchio, Ph.D.</p>
    <p>Academic Editor</p>
    <p>PLOS ONE</p>
    <p>Journal requirements:</p>
    <p>When submitting your revision, we need you to address these additional requirements.</p>
    <p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p>
    <p>
      <ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link>
    </p>
    <p>and <ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link>.</p>
    <p>[Note: HTML markup is below. Please do not edit.]</p>
    <p>Reviewers' comments:</p>
    <p>Reviewer's Responses to Questions</p>
    <p>
      <!-- <font color="black"> -->
      <bold>Comments to the Author</bold>
    </p>
    <p>1. Is the manuscript technically sound, and do the data support the conclusions?</p>
    <p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. <!-- </font> --></p>
    <p>Reviewer #1: Yes</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->2. Has the statistical analysis been performed appropriately and rigorously? <!-- </font> --></p>
    <p>Reviewer #1: Yes</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->3. Have the authors made all data underlying the findings in their manuscript fully available?</p>
    <p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.<!-- </font> --></p>
    <p>Reviewer #1: Yes</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->4. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
    <p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.<!-- </font> --></p>
    <p>Reviewer #1: Yes</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->5. Review Comments to the Author</p>
    <p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)<!-- </font> --></p>
    <p>Reviewer #1: Peer Review of:</p>
    <p>Mpro 1 pred: A machine learning (ML) driven Web-App for bioactivity prediction of SARS-CoV-2 main protease (Mpro) antagonists</p>
    <p>The manuscript, written by Nadim Ferdous and Mahjerin Nasrin Reza et. al discusses about the development of a prediction model to classify inhibitors and non-inhibitors of SARS CoV-2 Main Protease(Mpro) which is a potential drug target to control Coronavirus pandemic that emerged in 2019. The study has its merits and have a great potential to help researchers in the field to identify effective compounds and design specific inhibitors. The authors also developed a web-app to run the model and make it accessible to the research community.</p>
    <p>The authors validated the model by screening existing datasets, and conducting molecule docking, MD simulations and binding free energy estimates. However, the concept underlying the prediction of binding free energies on the select hits , seemed to have some limitation which requires further explanation.</p>
    <p>In line 241 : the authors mentioned “g_mmpbsa” package to compute binding free energies. This was also mentioned in the “Results” section. However, the article cited for “g_mmpbsa” states about computing binding energies of the complex and does not include the entropic terms as stated in the Github page of the tool (<ext-link xlink:href="https://github.com/RashmiKumari/g_mmpbsa" ext-link-type="uri">https://github.com/RashmiKumari/g_mmpbsa</ext-link>).</p>
    <p>The authors also mentioned “binding energy” and “binding free energy” simultaneously to refer to the same quantity that was measured by the “g_mmpbsa” tool.</p>
    <p>Between Line 384 and 387, the authors mentioned that CMNPD16005 is predicted to have the lowest binding free energy of around -296.193 KJ/mol, but in Table 6, it was recorded under the column “Binding energy”. It would be appropriate if the authors use a single term for the quantity measured in this study.</p>
    <p>Table 3 (Docking score) and Table 6 (Binding free energies) are reported with different units (Kcal/mol and KJ/mol respectively). For the ease of reading the article, the authors should use the same unit and conversion, if required, for all data that is tabulated in the study.</p>
    <p>It would be great if the authors explain a little bit more about the difference between binding energy and binding free energies and the type of data that was provided in Table 6. Based on what authors explained about the use of “g_mmpbsa” tool, the data in the last column of Table 6 , is likely to be the interaction energy and not binding free energy that was mentioned in the text.</p>
    <p>For conducting more reliable binding free energy calculations, it will be great if the authors choose a robust method like FEP (Free-Energy Perturbation), or other alchemical approaches and compare the results with the experimental affinities, as the model holds a lot of potential, so, a more robust physics-based prediction approach will be a great addition to this study.</p>
    <p>Line 133 : "…CDK (including extended and graph only version), E-state, PubChem, Klekota–Roth, Substructure and MACCS ": the authors should describe the acronyms in this section, though it seems like these are different fingerprints that are used to describe the structures from different classes. A reference to Table 2 where authors have explained different fingerprints, will be appropriate for the reader to get an idea.</p>
    <p>Few other minor modification and edits may help the readers to understand the manuscript more clearly.</p>
    <p>Line 117 , subheading in Materials and Methods, repeated again in Line 118</p>
    <p>Line 124 : “…with IC50 values that ranged between 1 and 10 were excluded ..” : the authors should mention the concentration units</p>
    <p>Line 135 to 142 : the author mentioned “variables” and “constants” when mentioning about fingerprint descriptors. The authors should explain more about these features as the molecular fingerprinting seems to be a crucial step in the overall design of the model.</p>
    <p>Line 264: The author mentioned “AD” here but did not explain what the acronym means.</p>
    <p>Line 333 : Did the author meant to say “hydrophobic interactions” instead of "hydrophobic bonds" throughout the manuscript?</p>
    <p>In Table 5, units are missing for the IC50 values.</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->6. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
    <p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
    <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.<!-- </font> --></p>
    <p>Reviewer #1: No</p>
    <p>**********</p>
    <p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
    <p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p>
  </body>
</sub-article>
<sub-article article-type="author-comment" id="pone.0287179.r002">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pone.0287179.r002</article-id>
    <title-group>
      <article-title>Author response to Decision Letter 0</article-title>
    </title-group>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0287179" id="rel-obj002" related-article-type="editor-report"/>
    <custom-meta-group>
      <custom-meta>
        <meta-name>Submission Version</meta-name>
        <meta-value>1</meta-value>
      </custom-meta>
    </custom-meta-group>
  </front-stub>
  <body>
    <p>
      <named-content content-type="author-response-date">26 May 2023</named-content>
    </p>
    <p>May 23, 2023</p>
    <p>To </p>
    <p>Editor-in-Chief</p>
    <p>PLOS One</p>
    <p>Re: Resubmission of research article (Submission ID: PONE-D-22-21799)</p>
    <p>Dear Sir,</p>
    <p>Thank you very much for sending us your suggestions and comments. </p>
    <p>We went through the invaluable comments of the honourable editor and tried our best to answer, explain and change the manuscript accordingly. We have addressed the queries each by each in details and listed in the following pages. With the changes made we belief the manuscript is improved substantially. </p>
    <p>We hope that the revised manuscript will be evaluated fairly and considered for publication in your esteemed journal. </p>
    <p>Sincerely yours, </p>
    <p>Dr A. K. M. Mohiuddin</p>
    <p>Professor</p>
    <p>Department of Biotechnology and Genetic Engineering</p>
    <p>Mawlana Bhashani Science and Technology University, Santosh, Tangail-1902, Bangladesh</p>
    <p>E-mail: <email>akmmohiu@yahoo.com</email>
</p>
    <p>Authors Response to honourable Editor Comments</p>
    <p>Editor comments</p>
    <p>In line 241: the authors mentioned “g_mmpbsa” package to compute binding free energies. This was also mentioned in the “Results” section. However, the article cited for “g_mmpbsa” states about computing binding energies of the complex and does not include the entropic terms as stated in the Github page of the tool (<ext-link xlink:href="https://github.com/RashmiKumari/g_mmpbsa" ext-link-type="uri">https://github.com/RashmiKumari/g_mmpbsa</ext-link>).</p>
    <p>The authors also mentioned “binding energy” and “binding free energy” simultaneously to refer to the same quantity that was measured by the “g_mmpbsa” tool.</p>
    <p>Author Response:</p>
    <p>Thank you very much for your suggestions that we feel our manuscript got incredibly improved. We have changed the “binding energy” term to “docking energy” in our revised manuscript. </p>
    <p>Between Line 384 and 387, the authors mentioned that CMNPD16005 is predicted to have the lowest binding free energy of around -296.193 KJ/mol, but in Table 6, it was recorded under the column “Binding energy”. It would be appropriate if the authors use a single term for the quantity measured in this study.</p>
    <p>Author Response:</p>
    <p>Thank you again for your valuable comment. We have changed the title of the last column in Table 6 to “Binding free energy” in our revised manuscript. </p>
    <p>Table 3 (Docking score) and Table 6 (Binding free energies) are reported with different units (Kcal/mol and KJ/mol respectively). For the ease of reading the article, the authors should use the same unit and conversion, if required, for all data that is tabulated in the study.</p>
    <p>Author Response:</p>
    <p>Thank you again for your valuable comment. Binding free energy is the equilibrium constant of complex formation, laws of thermodynamics relate it to the change in Gibbs free energy upon binding: The change in Gibbs free Energy of Binding is equal to - RT times the natural logarithm of the Equilibrium constant, where R is the gas constant and T the absolute temperature. These are experimentally determinable parameters that we predict by calculation. The Docking score is a computational result that is specific for a particular program and energy function, and that in an ideal case allows to predict binding free energy and binding affinity, or to at least rank different complexes according to those parameters. This is why we kept different units for the two different scores.</p>
    <p>It would be great if the authors explain a little bit more about the difference between binding energy and binding free energies and the type of data that was provided in Table 6. Based on what authors explained about the use of “g_mmpbsa” tool, the data in the last column of Table 6, is likely to be the interaction energy and not binding free energy that was mentioned in the text.</p>
    <p>Author Response:</p>
    <p>Thank you again for your valuable comment. The method that the “g_mmpbsa” tool uses, the MM/PBSA method, is widely used in the calculation of receptor-ligand binding free energy. The full name of this method is Molecular Mechanics/Poisson Boltzmann Surface Area. As the name suggests, this method splits the binding free energy into molecular mechanics terms and solvation energies to be calculated separately. The basic principle is to calculate the difference between the binding free energy of two solvated molecules in the bound and unbound states or to compare the free energy of different solvation conformations of the same molecule. We have changed the “binding energy” term to “docking energy” and kept the “binding free energy” term only in case of the g_mmpbsa tool in our revised manuscript.</p>
    <p>For conducting more reliable binding free energy calculations, it will be great if the authors choose a robust method like FEP (Free-Energy Perturbation), or other alchemical approaches and compare the results with the experimental affinities, as the model holds a lot of potential, so, a more robust physics-based prediction approach will be a great addition to this study.</p>
    <p>Author Response:</p>
    <p>Thank you again for your valuable comment. We agree with the authors that addition of the Free-Energy Perturbation method to calculate binding free energy calculations would be a great addition to our study. Unfortunately, due to lack of supercomputing power, we are unable to perform that at this moment.</p>
    <p>Line 133: "…CDK (including extended and graph only version), E-state, PubChem, Klekota–Roth, Substructure and MACCS ": the authors should describe the acronyms in this section, though it seems like these are different fingerprints that are used to describe the structures from different classes. A reference to Table 2 where authors have explained different fingerprints, will be appropriate for the reader to get an idea.</p>
    <p>Author Response:</p>
    <p>Thank you again for your valuable comment. We have added the available acronyms of the fingerprints in Table 2 of our revised manuscript.</p>
    <p>Few other minor modification and edits may help the readers to understand the manuscript more clearly.</p>
    <p>Line 117, subheading in Materials and Methods, repeated again in Line 118</p>
    <p>Author Response:</p>
    <p>Thank you again for your valuable comment. We removed the repeated line in Line 118 in the revised manuscript.</p>
    <p>Line 124: “…with IC50 values that ranged between 1 and 10 were excluded ..” : the authors should mention the concentration units</p>
    <p>Author Response:</p>
    <p>Thank you again for your valuable comment. We added the concentration unit (μM) of the IC50 values in the revised manuscript.</p>
    <p>Line 135 to 142: the author mentioned “variables” and “constants” when mentioning about fingerprint descriptors. The authors should explain more about these features as the molecular fingerprinting seems to be a crucial step in the overall design of the model.</p>
    <p>Author Response:</p>
    <p>Thank you again for your valuable comment. We added the citations of the publications that used the method we followed in selecting the fingerprint descriptors in the revised manuscript</p>
    <p>Line 264: The author mentioned “AD” here but did not explain what the acronym means.</p>
    <p>Author Response:</p>
    <p>Thank you again for your valuable comment. We mentioned the acronym of AD in line 195-196.</p>
    <p>Line 333: Did the author meant to say “hydrophobic interactions” instead of "hydrophobic bonds" throughout the manuscript?</p>
    <p>Author Response:</p>
    <p>Thank you again for your valuable comment. We meant "hydrophobic interactions" instead of "hydrophobic bonds" throughout the manuscript.</p>
    <p>In Table 5, units are missing for the IC50 values.</p>
    <p>Author Response:</p>
    <p>Thank you again for your valuable comment. We added the units for the IC50 values in Table 5 of our revised manuscript.</p>
    <supplementary-material id="pone.0287179.s015" position="float" content-type="local-data">
      <label>Attachment</label>
      <caption>
        <p>Submitted filename: <named-content content-type="submitted-filename">Author Response to reviewers.docx</named-content></p>
      </caption>
      <media xlink:href="pone.0287179.s015.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </body>
</sub-article>
<sub-article article-type="editor-report" id="pone.0287179.r003" specific-use="decision-letter">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pone.0287179.r003</article-id>
    <title-group>
      <article-title>Decision Letter 1</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Gallicchio</surname>
          <given-names>Emilio</given-names>
        </name>
        <role>Academic Editor</role>
      </contrib>
    </contrib-group>
    <permissions>
      <copyright-statement>© 2023 Emilio Gallicchio</copyright-statement>
      <copyright-year>2023</copyright-year>
      <copyright-holder>Emilio Gallicchio</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0287179" id="rel-obj003" related-article-type="reviewed-article"/>
    <custom-meta-group>
      <custom-meta>
        <meta-name>Submission Version</meta-name>
        <meta-value>1</meta-value>
      </custom-meta>
    </custom-meta-group>
  </front-stub>
  <body>
    <p>
      <named-content content-type="letter-date">1 Jun 2023</named-content>
    </p>
    <p>Mpropred: A machine learning (ML) driven Web-App for bioactivity prediction of SARS-CoV-2 main protease (Mpro) antagonists</p>
    <p>PONE-D-22-21799R1</p>
    <p>Dear Dr. Mohiuddin,</p>
    <p>We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p>
    <p>Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p>
    <p>An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <ext-link xlink:href="http://www.editorialmanager.com/pone/" ext-link-type="uri">http://www.editorialmanager.com/pone/</ext-link>, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <email>authorbilling@plos.org</email>.</p>
    <p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email>onepress@plos.org</email>.</p>
    <p>Kind regards,</p>
    <p>Emilio Gallicchio, Ph.D.</p>
    <p>Academic Editor</p>
    <p>PLOS ONE</p>
    <p>Additional Editor Comments (optional):</p>
    <p>Reviewers' comments:</p>
  </body>
</sub-article>
<sub-article article-type="editor-report" id="pone.0287179.r004" specific-use="acceptance-letter">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pone.0287179.r004</article-id>
    <title-group>
      <article-title>Acceptance letter</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Gallicchio</surname>
          <given-names>Emilio</given-names>
        </name>
        <role>Academic Editor</role>
      </contrib>
    </contrib-group>
    <permissions>
      <copyright-statement>© 2023 Emilio Gallicchio</copyright-statement>
      <copyright-year>2023</copyright-year>
      <copyright-holder>Emilio Gallicchio</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0287179" id="rel-obj004" related-article-type="reviewed-article"/>
  </front-stub>
  <body>
    <p>
      <named-content content-type="letter-date">8 Jun 2023</named-content>
    </p>
    <p>PONE-D-22-21799R1 </p>
    <p>M<sup>pro</sup>pred: A machine learning (ML) driven Web-App for bioactivity prediction of SARS-CoV-2 main protease (M<sup>pro</sup>) antagonists </p>
    <p>Dear Dr. Mohiuddin:</p>
    <p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. </p>
    <p>If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <email>onepress@plos.org</email>.</p>
    <p>If we can help with anything else, please email us at <email>plosone@plos.org</email>. </p>
    <p>Thank you for submitting your work to PLOS ONE and supporting open access. </p>
    <p>Kind regards, </p>
    <p>PLOS ONE Editorial Office Staff</p>
    <p>on behalf of</p>
    <p>Dr Emilio Gallicchio </p>
    <p>Academic Editor</p>
    <p>PLOS ONE</p>
  </body>
</sub-article>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 39.96?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?covid-19-tdm?>
<?subarticle pone.0287179.r001?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
    <journal-id journal-id-type="iso-abbrev">PLoS One</journal-id>
    <journal-id journal-id-type="publisher-id">plos</journal-id>
    <journal-title-group>
      <journal-title>PLOS ONE</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1932-6203</issn>
    <publisher>
      <publisher-name>Public Library of Science</publisher-name>
      <publisher-loc>San Francisco, CA USA</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10289339</article-id>
    <article-id pub-id-type="doi">10.1371/journal.pone.0287179</article-id>
    <article-id pub-id-type="publisher-id">PONE-D-22-21799</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Research Article</subject>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and life sciences</subject>
        <subj-group>
          <subject>Organisms</subject>
          <subj-group>
            <subject>Viruses</subject>
            <subj-group>
              <subject>RNA viruses</subject>
              <subj-group>
                <subject>Coronaviruses</subject>
                <subj-group>
                  <subject>SARS coronavirus</subject>
                  <subj-group>
                    <subject>SARS CoV 2</subject>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and life sciences</subject>
        <subj-group>
          <subject>Microbiology</subject>
          <subj-group>
            <subject>Medical microbiology</subject>
            <subj-group>
              <subject>Microbial pathogens</subject>
              <subj-group>
                <subject>Viral pathogens</subject>
                <subj-group>
                  <subject>Coronaviruses</subject>
                  <subj-group>
                    <subject>SARS coronavirus</subject>
                    <subj-group>
                      <subject>SARS CoV 2</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Medicine and health sciences</subject>
        <subj-group>
          <subject>Pathology and laboratory medicine</subject>
          <subj-group>
            <subject>Pathogens</subject>
            <subj-group>
              <subject>Microbial pathogens</subject>
              <subj-group>
                <subject>Viral pathogens</subject>
                <subj-group>
                  <subject>Coronaviruses</subject>
                  <subj-group>
                    <subject>SARS coronavirus</subject>
                    <subj-group>
                      <subject>SARS CoV 2</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and life sciences</subject>
        <subj-group>
          <subject>Organisms</subject>
          <subj-group>
            <subject>Viruses</subject>
            <subj-group>
              <subject>Viral pathogens</subject>
              <subj-group>
                <subject>Coronaviruses</subject>
                <subj-group>
                  <subject>SARS coronavirus</subject>
                  <subj-group>
                    <subject>SARS CoV 2</subject>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Physical Sciences</subject>
        <subj-group>
          <subject>Physics</subject>
          <subj-group>
            <subject>Thermodynamics</subject>
            <subj-group>
              <subject>Free Energy</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Research and Analysis Methods</subject>
        <subj-group>
          <subject>Mathematical and Statistical Techniques</subject>
          <subj-group>
            <subject>Statistical Methods</subject>
            <subj-group>
              <subject>Forecasting</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Physical Sciences</subject>
        <subj-group>
          <subject>Mathematics</subject>
          <subj-group>
            <subject>Statistics</subject>
            <subj-group>
              <subject>Statistical Methods</subject>
              <subj-group>
                <subject>Forecasting</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Physical Sciences</subject>
        <subj-group>
          <subject>Chemistry</subject>
          <subj-group>
            <subject>Physical Chemistry</subject>
            <subj-group>
              <subject>Chemical Bonding</subject>
              <subj-group>
                <subject>Hydrogen Bonding</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Biochemistry</subject>
          <subj-group>
            <subject>Biochemical Simulations</subject>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Computational Biology</subject>
          <subj-group>
            <subject>Biochemical Simulations</subject>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Biochemistry</subject>
          <subj-group>
            <subject>Enzymology</subject>
            <subj-group>
              <subject>Enzymes</subject>
              <subj-group>
                <subject>Proteases</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Biochemistry</subject>
          <subj-group>
            <subject>Proteins</subject>
            <subj-group>
              <subject>Enzymes</subject>
              <subj-group>
                <subject>Proteases</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Physical Sciences</subject>
        <subj-group>
          <subject>Chemistry</subject>
          <subj-group>
            <subject>Computational Chemistry</subject>
            <subj-group>
              <subject>Molecular Dynamics</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Physical Sciences</subject>
        <subj-group>
          <subject>Chemistry</subject>
          <subj-group>
            <subject>Computational Chemistry</subject>
            <subj-group>
              <subject>Molecular Docking</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>M<sup>pro</sup>pred: A machine learning (ML) driven Web-App for bioactivity prediction of SARS-CoV-2 main protease (M<sup>pro</sup>) antagonists</article-title>
      <alt-title alt-title-type="running-head">A Web-App for bioactivity prediction of SARS-CoV-2 main protease (M<sub>pro</sub>) antagonists</alt-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" equal-contrib="yes">
        <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4240-6829</contrib-id>
        <name>
          <surname>Ferdous</surname>
          <given-names>Nadim</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
        <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
        <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Reza</surname>
          <given-names>Mahjerin Nasrin</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
        <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
        <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
        <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Hossain</surname>
          <given-names>Mohammad Uzzal</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff002" ref-type="aff">
          <sup>2</sup>
        </xref>
        <xref rid="aff003" ref-type="aff">
          <sup>3</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Mahmud</surname>
          <given-names>Shahin</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
        <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Napis</surname>
          <given-names>Suhami</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <xref rid="aff004" ref-type="aff">
          <sup>4</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chowdhury</surname>
          <given-names>Kamal</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff005" ref-type="aff">
          <sup>5</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4188-6592</contrib-id>
        <name>
          <surname>Mohiuddin</surname>
          <given-names>A. K. M.</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="cor001" ref-type="corresp">*</xref>
      </contrib>
    </contrib-group>
    <aff id="aff001">
      <label>1</label>
      <addr-line>Department of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Santosh, Tangail, Bangladesh</addr-line>
    </aff>
    <aff id="aff002">
      <label>2</label>
      <addr-line>Department of Pharmacology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom</addr-line>
    </aff>
    <aff id="aff003">
      <label>3</label>
      <addr-line>Bioinformatics Division, National Institute of Biotechnology, Ashulia, Ganakbari, Savar, Dhaka, Bangladesh</addr-line>
    </aff>
    <aff id="aff004">
      <label>4</label>
      <addr-line>Department of Molecular Biology, Universiti Putra Malaysia, Serdang, Selangor D.E., Malaysia</addr-line>
    </aff>
    <aff id="aff005">
      <label>5</label>
      <addr-line>Biology Department, Claflin University, Orangeburg, SC, United States of America</addr-line>
    </aff>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Gallicchio</surname>
          <given-names>Emilio</given-names>
        </name>
        <role>Editor</role>
        <xref rid="edit1" ref-type="aff"/>
      </contrib>
    </contrib-group>
    <aff id="edit1">
      <addr-line>Brooklyn College of the City University of New York, UNITED STATES</addr-line>
    </aff>
    <author-notes>
      <fn fn-type="COI-statement" id="coi001">
        <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
      </fn>
      <corresp id="cor001">* E-mail: <email>akmmohiu@yahoo.com</email></corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>23</day>
      <month>6</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>23</day>
      <month>6</month>
      <year>2023</year>
    </pub-date>
    <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
    <volume>18</volume>
    <issue>6</issue>
    <elocation-id>e0287179</elocation-id>
    <history>
      <date date-type="received">
        <day>29</day>
        <month>8</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>31</day>
        <month>5</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2023 Ferdous et al</copyright-statement>
      <copyright-year>2023</copyright-year>
      <copyright-holder>Ferdous et al</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <self-uri content-type="pdf" xlink:href="pone.0287179.pdf"/>
    <abstract>
      <p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic emerged in 2019 and still requiring treatments with fast clinical translatability. Frequent occurrence of mutations in spike glycoprotein of SARS-CoV-2 led the consideration of an alternative therapeutic target to combat the ongoing pandemic. The main protease (M<sup>pro</sup>) is such an attractive drug target due to its importance in maturating several polyproteins during the replication process. In the present study, we used a classification structure–activity relationship (CSAR) model to find substructures that leads to to anti-M<sup>pro</sup> activities among 758 non-redundant compounds. A set of 12 fingerprints were used to describe M<sup>pro</sup> inhibitors, and the random forest approach was used to build prediction models from 100 distinct data splits. The data set’s modelability (MODI index) was found to be robust, with a value of 0.79 above the 0.65 threshold. The accuracy (89%), sensitivity (89%), specificity (73%), and Matthews correlation coefficient (79%) used to calculate the prediction performance, was also found to be statistically robust. An extensive analysis of the top significant descriptors unveiled the significance of methyl side chains, aromatic ring and halogen groups for M<sup>pro</sup> inhibition. Finally, the predictive model is made publicly accessible as a web-app named M<sup>pro</sup>pred in order to allow users to predict the bioactivity of compounds against SARS-CoV-2 M<sup>pro</sup>. Later, CMNPD, a marine compound database was screened by our app to predict bioactivity of all the compounds and results revealed significant correlation with their binding affinity to M<sup>pro</sup>. Molecular dynamics (MD) simulation and molecular mechanics/Poisson Boltzmann surface area (MM/PBSA) analysis showed improved properties of the complexes. Thus, the knowledge and web-app shown herein can be used to develop more effective and specific inhibitors against the SARS-CoV-2 M<sup>pro</sup>. The web-app can be accessed from <ext-link xlink:href="https://share.streamlit.io/nadimfrds/mpropred/Mpropred_app.py" ext-link-type="uri">https://share.streamlit.io/nadimfrds/mpropred/Mpropred_app.py</ext-link>.</p>
    </abstract>
    <funding-group>
      <funding-statement>The author(s) received no specific funding for this work.</funding-statement>
    </funding-group>
    <counts>
      <fig-count count="7"/>
      <table-count count="6"/>
      <page-count count="21"/>
    </counts>
    <custom-meta-group>
      <custom-meta id="data-availability">
        <meta-name>Data Availability</meta-name>
        <meta-value>All relevant data are within the paper and its <xref rid="sec021" ref-type="sec">Supporting Information</xref> files.</meta-value>
      </custom-meta>
      <custom-meta id="outbreaks">
        <meta-name>Outbreaks</meta-name>
        <meta-value>COVID-19</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
  <notes>
    <title>Data Availability</title>
    <p>All relevant data are within the paper and its <xref rid="sec021" ref-type="sec">Supporting Information</xref> files.</p>
  </notes>
</front>
<body>
  <sec sec-type="intro" id="sec001">
    <title>Introduction</title>
    <p>The COVID-19 pandemic, which was triggered by SARS-CoV-2, is still having a disastrous impact on public health and the worldwide economy [<xref rid="pone.0287179.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0287179.ref002" ref-type="bibr">2</xref>]. On earlier march of 2020, the outbreak was declared as a pandemic after initially discovering the virus in end of 2019 in Wuhan, China [<xref rid="pone.0287179.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0287179.ref004" ref-type="bibr">4</xref>]. SARS-CoV-2 is a single-stranded RNA virus with an increased mutation rate, a short period of replication, and a high production of virion [<xref rid="pone.0287179.ref005" ref-type="bibr">5</xref>–<xref rid="pone.0287179.ref008" ref-type="bibr">8</xref>]. The virus acquires a significant amount of genetic variation as it spreads, enabling it to adapt quickly to stresses brought on by natural selection, particularly those imposed by the immune system of the host. Mutations build up over time, resulting in alterations to the amino acids that make immune-targeted proteins less antigenic. This process is known as “antigenic drift”, that is the gradual alteration in viral protein antigenicity caused by selective immunological pressure [<xref rid="pone.0287179.ref009" ref-type="bibr">9</xref>]. Antigenic drift permits viruses to avoid host immunity continuously, allowing for recurring viral outbreaks. In cases of acute infectious disease, antibody responses are mostly responsible, resulting in the selection of escape mutants [<xref rid="pone.0287179.ref009" ref-type="bibr">9</xref>]. The spike protein contains several variations in amino acids identified in SARS-CoV-2 variants, is the main target that antibodies neutralize [<xref rid="pone.0287179.ref010" ref-type="bibr">10</xref>]. These antibodies are the sole immune system component capable of providing sterilizing immunity, preventing infection of host cells by the virus. The SARS-CoV-2 spike protein has evolved at a considerably faster rate than similar proteins in additional known viruses that cause severe infectious diseases in humans [<xref rid="pone.0287179.ref011" ref-type="bibr">11</xref>]. In addition, SARS-CoV-2 proteins have accumulated a substantial number of amino acid modifications that are not recognized antibody targets. In acute viral infections, antibody responses are predominantly responsible for antigenic drift; therefore, these amino acid alterations may have given the virus a fitness benefit independent to antibody immunity [<xref rid="pone.0287179.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0287179.ref013" ref-type="bibr">13</xref>].</p>
    <p>As a result, structural and functional research of SARS-CoV-2 infection processes have primarily shifted to the main protease (M<sup>pro</sup>), which cleaves native polypeptides and forms active fragments that are crucial for viral replication, transcription, and translation process [<xref rid="pone.0287179.ref014" ref-type="bibr">14</xref>]. The protease is consists of three domains [<xref rid="pone.0287179.ref015" ref-type="bibr">15</xref>]. A loop (residues 185–200) connects domain II with domain III. The ligand binding site is found in the loop between the first two domains, where the catalytic dyad consisting of Cys 145 and His 41 is crucial for ligand management [<xref rid="pone.0287179.ref015" ref-type="bibr">15</xref>]. SARS-CoV-2 replication is significantly facilitated by M<sup>pro</sup> [<xref rid="pone.0287179.ref015" ref-type="bibr">15</xref>]. Moreover, it is not functionally associated with human homologue proteases, implying that M<sup>pro</sup> is a promising target for therapeutic development [<xref rid="pone.0287179.ref015" ref-type="bibr">15</xref>].</p>
    <p>The functions of compounds both at structural and chemical level, are crucial in understanding the impact of physicochemical qualities on bioactivity. Computer-aided drug design (CADD) portrays a set of computational techniques that has proven useful in chemical biology and computational approaches to understanding the structure–activity relationship [<xref rid="pone.0287179.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0287179.ref017" ref-type="bibr">17</xref>]. Computational tools are used to decipher bioactivity using ligands, which are known as chemical descriptors [<xref rid="pone.0287179.ref018" ref-type="bibr">18</xref>]. Molecular descriptors computation softwares can also be used to calculate the physicochemical properties of different compounds. The QSAR (quantitative structure activity relationship) is considered a widely used computational technique to construct prediction models which can distinguish the impact of important molecular fingerprints regulating their bioactivities and properties [<xref rid="pone.0287179.ref019" ref-type="bibr">19</xref>]. A variety of targets, including antioxidant [<xref rid="pone.0287179.ref020" ref-type="bibr">20</xref>], antibacterial [<xref rid="pone.0287179.ref021" ref-type="bibr">21</xref>,<xref rid="pone.0287179.ref022" ref-type="bibr">22</xref>], anticancer [<xref rid="pone.0287179.ref023" ref-type="bibr">23</xref>,<xref rid="pone.0287179.ref024" ref-type="bibr">24</xref>], and antiviral [<xref rid="pone.0287179.ref025" ref-type="bibr">25</xref>,<xref rid="pone.0287179.ref026" ref-type="bibr">26</xref>] activities, have been successfully modeled using QSAR models.</p>
    <p>In silico strategies such as QSAR, pharmacophore modeling, docking and molecular dynamics (MD) simulation have extensively studied for identifying new inhibitors of M<sup>pro</sup>. Isabela et al. used an in-house designed machine learning technique, molecular docking, MM-PBSA calculations, and meta dynamics to find FDA-approved compounds that could potentially suppress the enzyme activity of the M<sup>pro</sup> [<xref rid="pone.0287179.ref027" ref-type="bibr">27</xref>]. Nedra et al. developed a machine learning approach by employing the support vector machine (SVM) classification model to categorize two hundred novel chemo-types as potentially active against the viral protease using a dataset of two million commercially accessible drugs [<xref rid="pone.0287179.ref028" ref-type="bibr">28</xref>]. Mahesha et al. used an integrative strategy to screen 1528 anti-HIV1 compounds, using a machine learning predictive model, molecular docking, and a deep learning model that considered the IC50 values of known inhibitors [<xref rid="pone.0287179.ref029" ref-type="bibr">29</xref>]. But the models developed in these works are not accessible as readily available web-apps for the scientific community to further apply on different sets of compounds in order to identify more potent anti-M<sup>pro</sup> inhibitors.</p>
    <p>In the present study, we collected a set of compounds (non-redundant) with known IC50 values against the SARS-CoV-2 M<sup>pro</sup>. Several fingerprint descriptors were used to describe the examined compounds binning the IC50 values to qualitative labels such as active and inactive. Following that, the RF algorithm was used to build prediction models. The sensitivity, specificity, accuracy and Matthews correlation coefficient of the built QSAR model were tested in classifying active or inactive compounds against SARS-CoV-2 M<sup>pro</sup>. In addition, the underlying key substructures that are critical for bioactivity were identified and defined. A web-app was built based on the model and made publicly accessible. We also utilized our app to view into the correlation of predicted bioactivity of compounds with their binding affinity to M<sup>pro</sup>. As a result, this knowledge can be exploited to develop more potent and specialized drugs against SARS-CoV-2 M<sup>pro</sup>.</p>
  </sec>
  <sec sec-type="materials|methods" id="sec002">
    <title>Materials and methods</title>
    <p>A step-wise protocol was followed to build a web-app in order to predict bioactivities of compounds against the M<sup>pro</sup> of SARS-CoV-2. The work flow is shown in <xref rid="pone.0287179.g001" ref-type="fig">Fig 1</xref>.</p>
    <fig position="float" id="pone.0287179.g001">
      <object-id pub-id-type="doi">10.1371/journal.pone.0287179.g001</object-id>
      <label>Fig 1</label>
      <caption>
        <title>Schematic workflow of building a web-app to predict bioactivities of compounds against the M<sup>pro</sup> of SARS-CoV-2.</title>
        <p>The upper side of the flowchart depicts the methodology of building the web-app while the lower side shows the molecular modeling protocol that was used to view into the correlation of predicted bioactivity of compounds with their corresponding binding affinity.</p>
      </caption>
      <graphic xlink:href="pone.0287179.g001" position="float"/>
    </fig>
    <sec id="sec003">
      <title>Dataset preparation and curation</title>
      <p>A data set consisting of antagonists against SARS-CoV-2 main protease (M<sup>pro</sup>) was compiled from an extensive literature review that was initially comprised of 758 compounds [<xref rid="pone.0287179.ref030" ref-type="bibr">30</xref>]. The mean value was calculated in the event that multiple IC50 values were found for the same compound. As our study aims to developing a classification model of M<sup>pro</sup> antagonists, we defined the thresholds as &lt;0.5 and &gt;10 μM to distinguish active compounds from inactive ones, respectively. Also, intermediate bioactivities with IC50 values that ranged between 1 and 10 were excluded from the study, consisting of 284 inhibitors. Finally, the curated set of compounds consisting of 478 inhibitors was obtained and analyzed.</p>
    </sec>
    <sec id="sec004">
      <title>Calculation of molecular descriptors</title>
      <p>The PaDEL-Descriptor software was utilized briefly to compute the fingerprints of the data set [<xref rid="pone.0287179.ref031" ref-type="bibr">31</xref>]. Generally, molecular descriptors are very crucial for QSAR studies because they are used to characterize the various properties of compounds and aid in the structural information analyses. In the present study, 12 molecular fingerprints that belong to 9 classes were used to describe the structures, and these consisted of 2D AtomPairs, CDK (including extended and graph only version), E-state, PubChem, Klekota–Roth, Substructure and MACCS.</p>
    </sec>
    <sec id="sec005">
      <title>Data filtering and balancing</title>
      <p>To choose the fingerprint descriptor sets, variables that were constant or nearly constant were used with a view to removing the bias and complexity in building the model. Using 0.1 as the SD cut-off value, all the constants of each fingerprint descriptor were calculated. For further investigation, fingerprints having SD values of &gt;0.1 were chosen. The undersampling technique was employed by random selection of subset of the active compounds from the starting set to avoid the propensity for overfitting of imbalanced data. Additionally, the data was divided into two sets, with the internal set being 80% of the total data set and the external set comprising the remaining 20% to avoid any possibility of getting a predicted model that is biased.</p>
    </sec>
    <sec id="sec006">
      <title>Multivariate analysis of model</title>
      <p>A CSAR model’s prediction performance is influenced by both the predictor and the compound descriptors. Considering the success in various models and the interpretability in many applications, we employed RF in this study.</p>
      <p>Random forest is an ensemble classifier that uses a randomly selected subset of training samples and variables to generate a number of decision trees. The classification of RF begins at the root node, where the value of particular descriptors is used to divide the data set at every node, with the descriptors of various activities being primarily transported to distinct branches [<xref rid="pone.0287179.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0287179.ref033" ref-type="bibr">33</xref>]. The classification is then obtained by averaging the outcomes of all trees using a majority vote from each tree [<xref rid="pone.0287179.ref034" ref-type="bibr">34</xref>,<xref rid="pone.0287179.ref035" ref-type="bibr">35</xref>]. The <italic toggle="yes">randomForest</italic> package of the R language was used to create the RF classifier. To effectively predict M<sup>pro</sup> inhibitor activity, two RF model parameters must be tuned: the number of trees used to form the RF classifier (ntree) and the number of random candidate features (<italic toggle="yes">mtry</italic>). The parameter “<italic toggle="yes">mtry”</italic> was created using the <italic toggle="yes">randomForest</italic> package’s tuneRF function, while the ntree parameter was tuned using a 10-fold CV technique from the range of ntree € {100,200,…,1,000} [<xref rid="pone.0287179.ref036" ref-type="bibr">36</xref>]. The importance estimator, an efficient built-in component of the RF model, was also utilized to find informative descriptors to better explain the bioactivity of M<sup>pro</sup> inhibitors.</p>
    </sec>
    <sec id="sec007">
      <title>Modelability of data set</title>
      <p>The underlying relatedness of chemical structures and their bioactivities is required for modelability. Activity cliffs, also known as two compounds with remarkably different bioactivities (i.e., one pair of compounds has favorable biological activity while the other in the pair has low bioactivity), are detrimental to machine learning algorithms that try to correlate structures with related biological activity. Similar compounds having comparable bioactivities would, on the other hand, contribute favorably to the data set’s modelability. Golbraikh et al. developed this modelability index (MODI) [<xref rid="pone.0287179.ref037" ref-type="bibr">37</xref>]. The following formula can be used to calculate the statistical metric:</p>
      <p>Step 1: The normalized Euclidean distance (Dnormalized) for each pair of the compounds, Ci and Cj described by m-dimensional vector is calculated as follows:
<disp-formula id="pone.0287179.e001"><alternatives><graphic xlink:href="pone.0287179.e001.jpg" id="pone.0287179.e001g" position="anchor"/><mml:math id="M1" display="block" overflow="scroll"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mo>=</mml:mo><mml:msqrt><mml:mrow><mml:msubsup><mml:mo stretchy="true">∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:msqrt></mml:math></alternatives><label>(1)</label></disp-formula>
<disp-formula id="pone.0287179.e002"><alternatives><graphic xlink:href="pone.0287179.e002.jpg" id="pone.0287179.e002g" position="anchor"/><mml:math id="M2" display="block" overflow="scroll"><mml:mover accent="true"><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>¯</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:msubsup><mml:mo stretchy="true">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfrac></mml:math></alternatives><label>(2)</label></disp-formula>
<disp-formula id="pone.0287179.e003"><alternatives><graphic xlink:href="pone.0287179.e003.jpg" id="pone.0287179.e003g" position="anchor"/><mml:math id="M3" display="block" overflow="scroll"><mml:msub><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>z</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>¯</mml:mo></mml:mover><mml:mo>−</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mo>(</mml:mo><mml:mover accent="true"><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>¯</mml:mo></mml:mover><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">max</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>−</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mo>(</mml:mo><mml:mover accent="true"><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>¯</mml:mo></mml:mover><mml:mo>)</mml:mo></mml:mrow></mml:mfrac></mml:math></alternatives><label>(3)</label></disp-formula>
where d<sub>ij</sub>, <inline-formula id="pone.0287179.e004"><alternatives><graphic xlink:href="pone.0287179.e004.jpg" id="pone.0287179.e004g" position="anchor"/><mml:math id="M4" display="inline" overflow="scroll"><mml:mover accent="true"><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>¯</mml:mo></mml:mover></mml:math></alternatives></inline-formula> shows distance scores between two compounds and the n represent mean Euclidean distance.</p>
      <p>Step 2: The MODI can be calculated for each compound in a data set by determining whether its first nearest neighbor belongs to the same class as the compound or a different class:
<disp-formula id="pone.0287179.e005"><alternatives><graphic xlink:href="pone.0287179.e005.jpg" id="pone.0287179.e005g" position="anchor"/><mml:math id="M5" display="block" overflow="scroll"><mml:mi>M</mml:mi><mml:mi>O</mml:mi><mml:mi>D</mml:mi><mml:mi>I</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mrow><mml:msubsup><mml:mo stretchy="false">∑</mml:mo><mml:mrow><mml:mi>I</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msubsup><mml:mrow><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math></alternatives><label>(4)</label></disp-formula></p>
      <p>Where the <italic toggle="yes">N</italic><sub><italic toggle="yes">C</italic></sub> denotes the number of classes, <italic toggle="yes">N</italic><sub><italic toggle="yes">i</italic></sub><sup>same</sup> denotes the number of total compounds in the <italic toggle="yes">i</italic>th class having the same <italic toggle="yes">i</italic>th class as their first nearest neighbors, and <italic toggle="yes">Ni</italic><sup>total</sup> denotes number of total compounds in the <italic toggle="yes">i</italic>th class. Any data set is deemed modelable provided that MODI index falls beyond the cutoff value of 0.65. Here, the MODI index was calculated using a R code that was used for assessing modelibility of the HCVpred [<xref rid="pone.0287179.ref038" ref-type="bibr">38</xref>] server.</p>
    </sec>
    <sec id="sec008">
      <title>Model validation (Statistical approach)</title>
      <p>Several statistical measures, such as overall prediction sensitivity (Sn), specificity (Sp), accuracy (Ac) and Matthew’s correlation coefficient (MCC), were used to evaluate the model’s fitness.
<disp-formula id="pone.0287179.e006"><alternatives><graphic xlink:href="pone.0287179.e006.jpg" id="pone.0287179.e006g" position="anchor"/><mml:math id="M6" display="block" overflow="scroll"><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>N</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mfrac><mml:mo>×</mml:mo><mml:mn>100</mml:mn></mml:math></alternatives><label>(5)</label></disp-formula>
<disp-formula id="pone.0287179.e007"><alternatives><graphic xlink:href="pone.0287179.e007.jpg" id="pone.0287179.e007g" position="anchor"/><mml:math id="M7" display="block" overflow="scroll"><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mfrac><mml:mo>×</mml:mo><mml:mn>100</mml:mn></mml:math></alternatives><label>(6)</label></disp-formula>
<disp-formula id="pone.0287179.e008"><alternatives><graphic xlink:href="pone.0287179.e008.jpg" id="pone.0287179.e008g" position="anchor"/><mml:math id="M8" display="block" overflow="scroll"><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>T</mml:mi><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>N</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mfrac><mml:mo>×</mml:mo><mml:mn>100</mml:mn></mml:math></alternatives><label>(7)</label></disp-formula>
<disp-formula id="pone.0287179.e009"><alternatives><graphic xlink:href="pone.0287179.e009.jpg" id="pone.0287179.e009g" position="anchor"/><mml:math id="M9" display="block" overflow="scroll"><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mo>×</mml:mo><mml:mi>T</mml:mi><mml:mi>N</mml:mi><mml:mo>−</mml:mo><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mo>×</mml:mo><mml:mi mathvariant="normal">F</mml:mi><mml:mi mathvariant="normal">N</mml:mi></mml:mrow><mml:mrow><mml:msqrt><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mo>)</mml:mo><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>N</mml:mi><mml:mo>)</mml:mo><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mo>)</mml:mo><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>N</mml:mi><mml:mo>)</mml:mo></mml:msqrt></mml:mrow></mml:mfrac></mml:math></alternatives><label>(8)</label></disp-formula>
where True positives, false positives, true negatives, and false negatives are denoted by the abbreviations TP, FP, TN and FN, respectively.</p>
    </sec>
    <sec id="sec009">
      <title>Applicability domain analysis</title>
      <p>The boundaries within which the model may produce precise predictions for compounds based on similarity towards the compounds on which the model was built are established by the applicability domain (AD). Only those compounds are found inside the AD that match the model’s parameters. In this study, the AD of the compounds from both the training and testing sets were analyzed using the PCA bounding box.</p>
    </sec>
    <sec id="sec010">
      <title>Deployment of model as web-app</title>
      <p>Finally, we deployed the developed RF model as a web-app with a view to enabling easy access for the research community. The web-app named “M<sup>pro</sup>pred” was built in the Streamlit python package (<ext-link xlink:href="https://www.streamlit.io/" ext-link-type="uri">https://www.streamlit.io/</ext-link>) and deployed on the “Streamlit Share” cloud application platform while the source-code is maintained in a GitHub repository. The web-app can accept SMILES IDs and compound names in the form of a text (.txt) file and return the predicted pIC50 values of the compounds.</p>
    </sec>
    <sec id="sec011">
      <title>Correlation of predicted bioactivity with binding affinity (Molecular modeling and simulation)</title>
      <p>We further tested the correlation of predicted bioactivity of compounds with their corresponding binding affinity to M<sup>pro</sup> via an integrated molecular modeling and simulation approach with the utilization of our developed web-app. A new comprehensive marine natural products database named CMNPD was used for this purpose [<xref rid="pone.0287179.ref039" ref-type="bibr">39</xref>]. As no previous research was published on testing the efficacy of the compounds from this database against M<sup>pro</sup>, we downloaded all the available 31,492 compounds from the database, collected their SMILES IDs, and submitted them to the M<sup>pro</sup>pred web-app for bioactivity (pIC50) prediction. Later, the 3D structures of the top compounds with high pIC50 values were generated using Open Babel and prepared for molecular docking upon energy minimization using the MMFF94 forcefield. The 3D-structure of SARS-CoV-2 M<sup>pro</sup> in complexed with an inhibitor N3 (PDB ID: 6LU7) was used as receptor. Molecular docking was run using Autodock Vina with the same grid box parameters covering the ligand binding residues that were used in our previous work [<xref rid="pone.0287179.ref040" ref-type="bibr">40</xref>,<xref rid="pone.0287179.ref041" ref-type="bibr">41</xref>]. The exhaustiveness value was set to 100. The aim of this approach was to assess whether the compounds with predicted high pIC50 bind to the protease with high affinity.</p>
      <p>The top 5 complexes with high binding interaction with M<sup>pro</sup> were subjected to MD simulation to view their conformational changes. The GROningen MAchine for Chemical Simulations (GROMACS) version 5.1.2 was utilized to perform the MD simulations with the parameters that we previously used [<xref rid="pone.0287179.ref042" ref-type="bibr">42</xref>,<xref rid="pone.0287179.ref043" ref-type="bibr">43</xref>]. The topologies of proteins and the ligands were generated using the ‘pdb2gmx’ script and the PRODRG server, respectively [<xref rid="pone.0287179.ref044" ref-type="bibr">44</xref>]. The GROMOS96 54a7 force field was used to get the energy minimized conformations of complexes and, further, they were solvated in a square box with 1.0 nm of padding using a single point charge (SPC) water model [<xref rid="pone.0287179.ref045" ref-type="bibr">45</xref>]. The net charges in the systems were neutralized using the ‘gmx genion’ script of GROMACS. The steepest descent algorithm was employed to minimize energy of the complexes with &lt; 10.0 kJ/mol force and a maximum of 50,000 steps. Later, NVT and NPT ensembles were performed to equilibrate the systems, both at 300 K temperature and 1 atm for 100 picoseconds (ps). In the simulation, the thermostat and barostat were chosen as the V-rescale and Parrinello-Rahman, respectively. The final production run was performed for 100 nanoseconds (ns) in the HPC cluster of National Institute of Biotechnology, Savar, Bangladesh at 300 K with a 2-fs time step. The simulations were accelerated using a “NVIDIA GTX 3070” graphics processing unit (GPU). The root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (Rg), solvent accessible surface area (SASA) and number of hydrogen bonds were analyzed to evaluate the stability of the complexes after completion of the simulation. The GRACE software was used to plot the graphs.</p>
      <p>We also calculated the binding free energies (MM/PBSA) using the ‘g_mmpbsa’ package of GROMACS followed after the final production run [<xref rid="pone.0287179.ref046" ref-type="bibr">46</xref>]. The following equation is used to calculate the binding energies in this method:
<disp-formula id="pone.0287179.e010"><alternatives><graphic xlink:href="pone.0287179.e010.jpg" id="pone.0287179.e010g" position="anchor"/><mml:math id="M10" display="block" overflow="scroll"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:msub><mml:mi mathvariant="normal">G</mml:mi><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">G</mml:mi><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="normal">G</mml:mi><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">G</mml:mi><mml:mrow><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives><label>(9)</label></disp-formula>
where ΔG<sub>binding</sub> is the overall binding energy of the complex, G<sub>protein</sub> is the free protein binding energy, and G<sub>ligand</sub> is the unbounded ligand binding energy.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="sec012">
    <title>Results</title>
    <sec id="sec013">
      <title>Chemical space analysis</title>
      <p>The dataset that we used in this study is contained in <xref rid="pone.0287179.s001" ref-type="supplementary-material">S1 File</xref> including the SMILES ID of the 758 compounds with references. Exploration of the typical distinctions between active and inactive compounds is one of the major motives for undertaking chemical space analysis. We visualized the actives and inactives distribution as the function of molecular weight (MW) vs. the Ghose–Crippen–Viswanadhan octanol–water partition coefficient to investigate the general chemical space (ALogP). Then, using Lipinski’s rule-of-five (Ro5), we compared the actives and inactives. <xref rid="pone.0287179.g002" ref-type="fig">Fig 2(A)</xref> depicts the MW as the function of ALogP. As can be seen, the majority of the compounds are located in the MW range of 250–600 Da and have an ALogP of 0–6. (<xref rid="pone.0287179.g002" ref-type="fig">Fig 2B–2E</xref>) includes visualization of data and the statistical analysis of the Ro5. The majority of the compounds meet the Ro5 criteria, having a MW of 500 Da, nHBDon and nHBAcc and ALogP values of &lt;10. Furthermore, the findings of statistical analysis show a noteworthy difference among the active and inactive compounds from employment of the Mann–Whitney U test (<xref rid="pone.0287179.t001" ref-type="table">Table 1</xref>). The ALogP values of inactive compounds were found to be higher than the active ones. The nHBDon values of both the active and inactive compounds were similar, however the nHBAcc values of the active compounds were found to be lower than the values of inactive ones.</p>
      <fig position="float" id="pone.0287179.g002">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.g002</object-id>
        <label>Fig 2</label>
        <caption>
          <p>Chemical space analysis (A), box plot of Lipinski’s rule-of five descriptors (B-E) and applicability domain analysis (F) for analyzed M<sup>pro</sup> inhibitors.</p>
        </caption>
        <graphic xlink:href="pone.0287179.g002" position="float"/>
      </fig>
      <table-wrap position="float" id="pone.0287179.t001">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.t001</object-id>
        <label>Table 1</label>
        <caption>
          <title>Mann–Whitney U test results of various properties of the compounds.</title>
        </caption>
        <alternatives>
          <graphic xlink:href="pone.0287179.t001" id="pone.0287179.t001g" position="float"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="center" rowspan="1" colspan="1">Properties</th>
                <th align="center" rowspan="1" colspan="1">Mann–Whitney U test result</th>
                <th align="center" rowspan="1" colspan="1">P value</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="center" rowspan="1" colspan="1">Molecular weight (MW)</td>
                <td align="center" rowspan="1" colspan="1">Different distribution</td>
                <td align="center" rowspan="1" colspan="1">0.016141739</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Octanol–water partition coefficient (AlogP)</td>
                <td align="center" rowspan="1" colspan="1">Different distribution</td>
                <td align="center" rowspan="1" colspan="1">4.12E-10</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Number of Hydrogen bond donors (nHBDon)</td>
                <td align="center" rowspan="1" colspan="1">Different distribution</td>
                <td align="center" rowspan="1" colspan="1">0.033026915</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Number of Hydrogen bond acceptors (nHBAcc)</td>
                <td align="center" rowspan="1" colspan="1">Same distribution</td>
                <td align="center" rowspan="1" colspan="1">0.095506873</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
      </table-wrap>
      <p>Furthermore, the AD of the built model was determined using the MACCS fingerprints as the starting input for PCA analysis, as shown in <xref rid="pone.0287179.g002" ref-type="fig">Fig 2(F)</xref>. After balancing, the data set of 478 compounds was randomly divided into internal and external (80% and 20% respectively) subsets. It’s important to note that the internal set (80%) is used as the training set for building predictive models to predict on the external set. The external set’s chemical space distribution was revealed to be well inside the internal set’s boundaries. As a result, the AD for the CSAR model described herein appears to be well defined.</p>
    </sec>
    <sec id="sec014">
      <title>QSAR modeling</title>
      <p>To develop an interpretable QSAR model, we used fingerprints computed through the PaDEL-Descriptor software. <xref rid="pone.0287179.s002" ref-type="supplementary-material">S2</xref>–<xref rid="pone.0287179.s013" ref-type="supplementary-material">S13 Files</xref> contains the computed 12 molecular fingerprints of our dataset. The data set’s modelability score or MODI index sorts active compounds from inactive compounds to determine the likelihood of obtaining the CSAR model. It was found that all the fingerprint descriptors have a MODI value greater than 0.65, proving that the data set is reliable for developing a classification model. <xref rid="pone.0287179.t002" ref-type="table">Table 2</xref> lists all of these fingerprints, as well as their descriptions and MODI indices.</p>
      <table-wrap position="float" id="pone.0287179.t002">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.t002</object-id>
        <label>Table 2</label>
        <caption>
          <title>List of molecular fingerprints employed in the current study for representing chemical structures of the M<sup>pro</sup> inhibitor dataset along with their MODI indices.</title>
        </caption>
        <alternatives>
          <graphic xlink:href="pone.0287179.t002" id="pone.0287179.t002g" position="float"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="center" rowspan="1" colspan="1">Fingerprint</th>
                <th align="center" rowspan="1" colspan="1">Number<break/>of features</th>
                <th align="center" rowspan="1" colspan="1">Description</th>
                <th align="center" rowspan="1" colspan="1">MODI Index</th>
                <th align="center" rowspan="1" colspan="1">References</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="center" rowspan="1" colspan="1">CDK</td>
                <td align="center" rowspan="1" colspan="1">1,024</td>
                <td align="center" rowspan="1" colspan="1">Fingerprint having length of 1,024, with a search depth of 8</td>
                <td align="center" rowspan="1" colspan="1">0.77</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref047" ref-type="bibr">47</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CDK extended</td>
                <td align="center" rowspan="1" colspan="1">1,024</td>
                <td align="center" rowspan="1" colspan="1">Extends the CDK fingerprint with additional bits that describes ring features</td>
                <td align="center" rowspan="1" colspan="1">0.78</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref047" ref-type="bibr">47</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CDK graph only</td>
                <td align="center" rowspan="1" colspan="1">1,024</td>
                <td align="center" rowspan="1" colspan="1">A special CDK version considering only the connectivity, not bond order</td>
                <td align="center" rowspan="1" colspan="1">0.77</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref047" ref-type="bibr">47</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">E-state</td>
                <td align="center" rowspan="1" colspan="1">79</td>
                <td align="center" rowspan="1" colspan="1">Atom types of electrotopological state</td>
                <td align="center" rowspan="1" colspan="1">0.73</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref048" ref-type="bibr">48</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCS</td>
                <td align="center" rowspan="1" colspan="1">166</td>
                <td align="center" rowspan="1" colspan="1">MACCS keys defined binary representation of chemical features</td>
                <td align="center" rowspan="1" colspan="1">0.79</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref049" ref-type="bibr">49</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">PubChem</td>
                <td align="center" rowspan="1" colspan="1">881</td>
                <td align="center" rowspan="1" colspan="1">PubChem defined binary representation of substructures</td>
                <td align="center" rowspan="1" colspan="1">0.75</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref050" ref-type="bibr">50</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Substructure</td>
                <td align="center" rowspan="1" colspan="1">307</td>
                <td align="center" rowspan="1" colspan="1">Presence of the SMARTS patterns for various functional groups</td>
                <td align="center" rowspan="1" colspan="1">0.76</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref051" ref-type="bibr">51</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Substructure count</td>
                <td align="center" rowspan="1" colspan="1">307</td>
                <td align="center" rowspan="1" colspan="1">Count of the SMARTS patterns for various functional groups</td>
                <td align="center" rowspan="1" colspan="1">0.79</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref051" ref-type="bibr">51</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Klekota–Roth</td>
                <td align="center" rowspan="1" colspan="1">4,860</td>
                <td align="center" rowspan="1" colspan="1">Presence of various chemical substructures</td>
                <td align="center" rowspan="1" colspan="1">0.79</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref052" ref-type="bibr">52</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Klekota–Roth count</td>
                <td align="center" rowspan="1" colspan="1">4,860</td>
                <td align="center" rowspan="1" colspan="1">Count of various chemical substructures</td>
                <td align="center" rowspan="1" colspan="1">0.75</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref052" ref-type="bibr">52</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">2D atom pairs</td>
                <td align="center" rowspan="1" colspan="1">780</td>
                <td align="center" rowspan="1" colspan="1">Presence of atom pairs at various topological distances</td>
                <td align="center" rowspan="1" colspan="1">0.79</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref053" ref-type="bibr">53</xref>]</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">2D atom pairs count</td>
                <td align="center" rowspan="1" colspan="1">780</td>
                <td align="center" rowspan="1" colspan="1">Count of atom pairs at different topological distances</td>
                <td align="center" rowspan="1" colspan="1">0.73</td>
                <td align="center" rowspan="1" colspan="1">[<xref rid="pone.0287179.ref053" ref-type="bibr">53</xref>]</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
      </table-wrap>
      <p>To distinguish between active and inactive M<sup>pro</sup> inhibitors, we created the CSAR model using the RF algorithm in this work. <xref rid="pone.0287179.t003" ref-type="table">Table 3</xref> displays the results of 100 independent runs with all the distinct categories of fingerprints, including internal validation test, 10-fold CV, and external validation test. Best averaged values for the MACCS fingerprints were Ac 84.69% and MCC 0.691, as determined by a 10-fold CV analysis. The external validation for the MACCS, Klekota–Roth, and 2D atom pairs fingerprint descriptors, as shown in <xref rid="pone.0287179.t003" ref-type="table">Table 3</xref>, was also better than the rest of the descriptors. Taking into account the results from 10-fold CV as well as the external validation tests, it is found that the MACCS fingerprint descriptors outperform the other fingerprint classes. <xref rid="pone.0287179.g003" ref-type="fig">Fig 3</xref> contains the plot of experimental vs predicted pIC50 values for model that was constructed with MACCS fingerprint descriptors.</p>
      <fig position="float" id="pone.0287179.g003">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.g003</object-id>
        <label>Fig 3</label>
        <caption>
          <title>Plot showing experimental versus predicted pIC50 values for model constructed with MACCS fingerprint descriptors.</title>
        </caption>
        <graphic xlink:href="pone.0287179.g003" position="float"/>
      </fig>
      <table-wrap position="float" id="pone.0287179.t003">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.t003</object-id>
        <label>Table 3</label>
        <caption>
          <title>Performance summary of CSAR models for predicting M<sup>pro</sup> inhibitors of SARS-CoV-2.</title>
        </caption>
        <alternatives>
          <graphic xlink:href="pone.0287179.t003" id="pone.0287179.t003g" position="float"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="center" rowspan="2" colspan="1">Descriptor class</th>
                <th align="center" colspan="5" rowspan="1">Training set</th>
                <th align="center" colspan="4" rowspan="1">10-fold CV set</th>
                <th align="center" colspan="4" rowspan="1">External set</th>
              </tr>
              <tr>
                <th align="center" rowspan="1" colspan="1">Ac<break/>(%)</th>
                <th align="center" rowspan="1" colspan="1">RMSE</th>
                <th align="center" rowspan="1" colspan="1">Sn</th>
                <th align="center" rowspan="1" colspan="1">Sc</th>
                <th align="center" rowspan="1" colspan="1">MCC</th>
                <th align="center" rowspan="1" colspan="1">Ac (%)</th>
                <th align="center" rowspan="1" colspan="1">Sn</th>
                <th align="center" rowspan="1" colspan="1">Sc</th>
                <th align="center" rowspan="1" colspan="1">MCC</th>
                <th align="center" rowspan="1" colspan="1">Ac (%)</th>
                <th align="center" rowspan="1" colspan="1">Sn</th>
                <th align="center" rowspan="1" colspan="1">Sc</th>
                <th align="center" rowspan="1" colspan="1">MCC</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="center" rowspan="1" colspan="1">CDK</td>
                <td align="center" rowspan="1" colspan="1">99.79</td>
                <td align="center" rowspan="1" colspan="1">0.1045</td>
                <td align="center" rowspan="1" colspan="1">0.998</td>
                <td align="center" rowspan="1" colspan="1">0.99</td>
                <td align="center" rowspan="1" colspan="1">0.996</td>
                <td align="center" rowspan="1" colspan="1">83.43</td>
                <td align="center" rowspan="1" colspan="1">0.834</td>
                <td align="center" rowspan="1" colspan="1">0.864</td>
                <td align="center" rowspan="1" colspan="1">0.670</td>
                <td align="center" rowspan="1" colspan="1">76.84</td>
                <td align="center" rowspan="1" colspan="1">0.768</td>
                <td align="center" rowspan="1" colspan="1">0.744</td>
                <td align="center" rowspan="1" colspan="1">0.537</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CDK extended</td>
                <td align="center" rowspan="1" colspan="1">99.58</td>
                <td align="center" rowspan="1" colspan="1">0.107</td>
                <td align="center" rowspan="1" colspan="1">0.996</td>
                <td align="center" rowspan="1" colspan="1">1</td>
                <td align="center" rowspan="1" colspan="1">0.991</td>
                <td align="center" rowspan="1" colspan="1">81.55</td>
                <td align="center" rowspan="1" colspan="1">0.816</td>
                <td align="center" rowspan="1" colspan="1">0.834</td>
                <td align="center" rowspan="1" colspan="1">0.630</td>
                <td align="center" rowspan="1" colspan="1">83.15</td>
                <td align="center" rowspan="1" colspan="1">0.832</td>
                <td align="center" rowspan="1" colspan="1">0.826</td>
                <td align="center" rowspan="1" colspan="1">0.663</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CDK graph only</td>
                <td align="center" rowspan="1" colspan="1">99.16</td>
                <td align="center" rowspan="1" colspan="1">0.1124</td>
                <td align="center" rowspan="1" colspan="1">0.992</td>
                <td align="center" rowspan="1" colspan="1">0.99</td>
                <td align="center" rowspan="1" colspan="1">0.983</td>
                <td align="center" rowspan="1" colspan="1">84.06</td>
                <td align="center" rowspan="1" colspan="1">0.841</td>
                <td align="center" rowspan="1" colspan="1">0.884</td>
                <td align="center" rowspan="1" colspan="1">0.686</td>
                <td align="center" rowspan="1" colspan="1">84.21</td>
                <td align="center" rowspan="1" colspan="1">0.842</td>
                <td align="center" rowspan="1" colspan="1">0.840</td>
                <td align="center" rowspan="1" colspan="1">0.684</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">E-state</td>
                <td align="center" rowspan="1" colspan="1">96.43</td>
                <td align="center" rowspan="1" colspan="1">0.1247</td>
                <td align="center" rowspan="1" colspan="1">0.964</td>
                <td align="center" rowspan="1" colspan="1">0.96</td>
                <td align="center" rowspan="1" colspan="1">0.927</td>
                <td align="center" rowspan="1" colspan="1">88.46</td>
                <td align="center" rowspan="1" colspan="1">0.885</td>
                <td align="center" rowspan="1" colspan="1">0.861</td>
                <td align="center" rowspan="1" colspan="1">0.766</td>
                <td align="center" rowspan="1" colspan="1">80.00</td>
                <td align="center" rowspan="1" colspan="1">0.800</td>
                <td align="center" rowspan="1" colspan="1">0.714</td>
                <td align="center" rowspan="1" colspan="1">0.613</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCS</td>
                <td align="center" rowspan="1" colspan="1">99.37</td>
                <td align="center" rowspan="1" colspan="1">0.1057</td>
                <td align="center" rowspan="1" colspan="1">0.994</td>
                <td align="center" rowspan="1" colspan="1">0.99</td>
                <td align="center" rowspan="1" colspan="1">0.987</td>
                <td align="center" rowspan="1" colspan="1">84.69</td>
                <td align="center" rowspan="1" colspan="1">0.847</td>
                <td align="center" rowspan="1" colspan="1">0.884</td>
                <td align="center" rowspan="1" colspan="1">0.691</td>
                <td align="center" rowspan="1" colspan="1">89.47</td>
                <td align="center" rowspan="1" colspan="1">0.895</td>
                <td align="center" rowspan="1" colspan="1">0.733</td>
                <td align="center" rowspan="1" colspan="1">0.790</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">PubChem</td>
                <td align="center" rowspan="1" colspan="1">99.79</td>
                <td align="center" rowspan="1" colspan="1">0.1449</td>
                <td align="center" rowspan="1" colspan="1">0.998</td>
                <td align="center" rowspan="1" colspan="1">0.995</td>
                <td align="center" rowspan="1" colspan="1">0.996</td>
                <td align="center" rowspan="1" colspan="1">80.08</td>
                <td align="center" rowspan="1" colspan="1">0.801</td>
                <td align="center" rowspan="1" colspan="1">0.810</td>
                <td align="center" rowspan="1" colspan="1">0.599</td>
                <td align="center" rowspan="1" colspan="1">75.78</td>
                <td align="center" rowspan="1" colspan="1">0.758</td>
                <td align="center" rowspan="1" colspan="1">0.717</td>
                <td align="center" rowspan="1" colspan="1">0.515</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Substructure</td>
                <td align="center" rowspan="1" colspan="1">97.68</td>
                <td align="center" rowspan="1" colspan="1">0.1702</td>
                <td align="center" rowspan="1" colspan="1">0.977</td>
                <td align="center" rowspan="1" colspan="1">0.97</td>
                <td align="center" rowspan="1" colspan="1">0.953</td>
                <td align="center" rowspan="1" colspan="1">78.57</td>
                <td align="center" rowspan="1" colspan="1">0.786</td>
                <td align="center" rowspan="1" colspan="1">0.745</td>
                <td align="center" rowspan="1" colspan="1">0.560</td>
                <td align="center" rowspan="1" colspan="1">78.94</td>
                <td align="center" rowspan="1" colspan="1">0.789</td>
                <td align="center" rowspan="1" colspan="1">0.711</td>
                <td align="center" rowspan="1" colspan="1">0.580</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Substructure count</td>
                <td align="center" rowspan="1" colspan="1">99.78</td>
                <td align="center" rowspan="1" colspan="1">0.144</td>
                <td align="center" rowspan="1" colspan="1">0.998</td>
                <td align="center" rowspan="1" colspan="1">0.995</td>
                <td align="center" rowspan="1" colspan="1">0.996</td>
                <td align="center" rowspan="1" colspan="1">79.41</td>
                <td align="center" rowspan="1" colspan="1">0.794</td>
                <td align="center" rowspan="1" colspan="1">0.750</td>
                <td align="center" rowspan="1" colspan="1">0.577</td>
                <td align="center" rowspan="1" colspan="1">82.1</td>
                <td align="center" rowspan="1" colspan="1">0.821</td>
                <td align="center" rowspan="1" colspan="1">0.777</td>
                <td align="center" rowspan="1" colspan="1">0.641</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Klekota-Roth</td>
                <td align="center" rowspan="1" colspan="1">99.58</td>
                <td align="center" rowspan="1" colspan="1">0.1349</td>
                <td align="center" rowspan="1" colspan="1">0.996</td>
                <td align="center" rowspan="1" colspan="1">0.99</td>
                <td align="center" rowspan="1" colspan="1">0.991</td>
                <td align="center" rowspan="1" colspan="1">83.64</td>
                <td align="center" rowspan="1" colspan="1">0.836</td>
                <td align="center" rowspan="1" colspan="1">0.796</td>
                <td align="center" rowspan="1" colspan="1">0.664</td>
                <td align="center" rowspan="1" colspan="1">83.15</td>
                <td align="center" rowspan="1" colspan="1">0.832</td>
                <td align="center" rowspan="1" colspan="1">0.782</td>
                <td align="center" rowspan="1" colspan="1">0.664</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">Klekota-Roth count</td>
                <td align="center" rowspan="1" colspan="1">99.58</td>
                <td align="center" rowspan="1" colspan="1">0.137</td>
                <td align="center" rowspan="1" colspan="1">0.996</td>
                <td align="center" rowspan="1" colspan="1">0.99</td>
                <td align="center" rowspan="1" colspan="1">0.991</td>
                <td align="center" rowspan="1" colspan="1">81.97</td>
                <td align="center" rowspan="1" colspan="1">0.82</td>
                <td align="center" rowspan="1" colspan="1">0.796</td>
                <td align="center" rowspan="1" colspan="1">0.631</td>
                <td align="center" rowspan="1" colspan="1">87.36</td>
                <td align="center" rowspan="1" colspan="1">0.874</td>
                <td align="center" rowspan="1" colspan="1">0.869</td>
                <td align="center" rowspan="1" colspan="1">0.747</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">2D atom pairs</td>
                <td align="center" rowspan="1" colspan="1">96.64</td>
                <td align="center" rowspan="1" colspan="1">0.1955</td>
                <td align="center" rowspan="1" colspan="1">0.966</td>
                <td align="center" rowspan="1" colspan="1">0.965</td>
                <td align="center" rowspan="1" colspan="1">0.931</td>
                <td align="center" rowspan="1" colspan="1">85.74</td>
                <td align="center" rowspan="1" colspan="1">0.860</td>
                <td align="center" rowspan="1" colspan="1">0.854</td>
                <td align="center" rowspan="1" colspan="1">0.713</td>
                <td align="center" rowspan="1" colspan="1">84.21</td>
                <td align="center" rowspan="1" colspan="1">0.842</td>
                <td align="center" rowspan="1" colspan="1">0.822</td>
                <td align="center" rowspan="1" colspan="1">0.683</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">2D atom pairs count</td>
                <td align="center" rowspan="1" colspan="1">99.79</td>
                <td align="center" rowspan="1" colspan="1">0.1471</td>
                <td align="center" rowspan="1" colspan="1">0.998</td>
                <td align="center" rowspan="1" colspan="1">1</td>
                <td align="center" rowspan="1" colspan="1">0.996</td>
                <td align="center" rowspan="1" colspan="1">80.29</td>
                <td align="center" rowspan="1" colspan="1">0.803</td>
                <td align="center" rowspan="1" colspan="1">0.791</td>
                <td align="center" rowspan="1" colspan="1">0.602</td>
                <td align="center" rowspan="1" colspan="1">81.05</td>
                <td align="center" rowspan="1" colspan="1">0.811</td>
                <td align="center" rowspan="1" colspan="1">0.804</td>
                <td align="center" rowspan="1" colspan="1">0.621</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
      </table-wrap>
    </sec>
    <sec id="sec015">
      <title>Interpretation of feature importance</title>
      <p>The top-ranked MACCS fingerprints as obtained from the RF model are mentioned in <xref rid="pone.0287179.t004" ref-type="table">Table 4</xref>, comprised of fingerprints pertaining to different classes such as aromatic compounds, nitrogen-containing compounds, oxygen-containing compounds, halogens etc.</p>
      <table-wrap position="float" id="pone.0287179.t004">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.t004</object-id>
        <label>Table 4</label>
        <caption>
          <title>List of the top-ranking MACCS fingerprints and their corresponding description.</title>
        </caption>
        <alternatives>
          <graphic xlink:href="pone.0287179.t004" id="pone.0287179.t004g" position="float"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="center" rowspan="1" colspan="1">Fingerprint</th>
                <th align="center" rowspan="1" colspan="1">SMARTS pattern</th>
                <th align="center" rowspan="1" colspan="1">Substructure description</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCSFP16</td>
                <td align="center" rowspan="1" colspan="1">(’[!#6;!#1]1~*~*~1’,0)</td>
                <td align="center" rowspan="1" colspan="1">Heteroatom + any 2 heteroatoms + linkage to first atom</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCSFP23</td>
                <td align="center" rowspan="1" colspan="1">(’[#7]~[#6](~[#8])~[#8]’,0)</td>
                <td align="center" rowspan="1" colspan="1">NC(O)O</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCSFP82</td>
                <td align="center" rowspan="1" colspan="1">(’*~[CH<sub>2</sub>]~[!#6;!#1;!H0]’,0)</td>
                <td align="center" rowspan="1" colspan="1">Any heavy atom + CH<sub>2</sub>-heteroatom + H</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCSFP87</td>
                <td align="center" rowspan="1" colspan="1">(’[F,Cl,Br,I]!@*@*’,0)</td>
                <td align="center" rowspan="1" colspan="1">Halogen (part of chain) + any heteroatom connected to another heteroatom with an aromatic bond</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCSFP89</td>
                <td align="center" rowspan="1" colspan="1">(’[#8]~*~*~*~[#8]’,0)</td>
                <td align="center" rowspan="1" colspan="1">O + any 2 heteroatoms + O</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCSFP103</td>
                <td align="center" rowspan="1" colspan="1">(’Cl’,0)</td>
                <td align="center" rowspan="1" colspan="1">Cl</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCSFP107</td>
                <td align="center" rowspan="1" colspan="1">(’[F,Cl,Br,I]~*(~*)~*’,0)</td>
                <td align="center" rowspan="1" colspan="1">Halogen + heteroatom (heteroatom) heteroatom</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCSFP115</td>
                <td align="center" rowspan="1" colspan="1">(’[CH<sub>3</sub>]~*~[CH<sub>2</sub>]~*’,0)</td>
                <td align="center" rowspan="1" colspan="1">CH<sub>3</sub> + any heteroatom + CH<sub>2</sub> + any heteroatom</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCSFP125</td>
                <td align="center" rowspan="1" colspan="1">(’?’,0)</td>
                <td align="center" rowspan="1" colspan="1">Aromatic Ring &gt; 1</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCSFP134</td>
                <td align="center" rowspan="1" colspan="1">(’[F,Cl,Br,I]’,0)</td>
                <td align="center" rowspan="1" colspan="1">Halogen</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">MACCSFP145</td>
                <td align="center" rowspan="1" colspan="1">(’*1~*~*~*~*~*~1’,1)</td>
                <td align="center" rowspan="1" colspan="1">6-member ring &gt; 1</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
      </table-wrap>
    </sec>
    <sec id="sec016">
      <title>Model deployment as the M<sup>pro</sup>pred web-app and assessment</title>
      <p>In order to allow biologists or chemists without a computer science background to apply the prediction model in their research, we deployed it as a public web-app known as the M<sup>pro</sup>pred and is available at <ext-link xlink:href="https://share.streamlit.io/nadimfrds/mpropred/Mpropred_app.py" ext-link-type="uri">https://share.streamlit.io/nadimfrds/mpropred/Mpropred_app.py</ext-link>. Briefly, a guide on using the M<sup>pro</sup>pred web-app (<xref rid="pone.0287179.g004" ref-type="fig">Fig 4</xref>) is given below:</p>
      <p><bold>Step 1</bold>. A text file (.txt) should be created containing the SMILES ID of the desired compounds space separated by a given name/ID (<xref rid="pone.0287179.g004" ref-type="fig">Fig 4A</xref>). SMILES IDs for any desired small compounds can be acquired from various databases e.g. Drugbank [<xref rid="pone.0287179.ref054" ref-type="bibr">54</xref>], PubChem [<xref rid="pone.0287179.ref055" ref-type="bibr">55</xref>] or ChemSpider [<xref rid="pone.0287179.ref056" ref-type="bibr">56</xref>] whereas custom compounds can be drawn on JSME structure editor [<xref rid="pone.0287179.ref057" ref-type="bibr">57</xref>] or ChemDraw [<xref rid="pone.0287179.ref058" ref-type="bibr">58</xref>] so as to create the SMILES notation of unknown compounds.</p>
      <p><bold>Step 2</bold>. The above-mentioned URL should be typed into any web browser to view homepage of the web-app (<xref rid="pone.0287179.g004" ref-type="fig">Fig 4B</xref>).</p>
      <p><bold>Step 3</bold>. The created text file should be uploaded to the web-app by clicking on the “Browse files” button (<xref rid="pone.0287179.g004" ref-type="fig">Fig 4C</xref>).</p>
      <p><bold>Step 4</bold>. The process of prediction can be started upon clicking on the “Predict!” button (<xref rid="pone.0287179.g004" ref-type="fig">Fig 4C</xref>).</p>
      <p><bold>Step 5</bold>. The results are showed in a box found below the “Prediction results” heading (<xref rid="pone.0287179.g004" ref-type="fig">Fig 4D</xref>). Typically, only a few seconds is required for the web-app to process the task. The users can also download the predicted results in the form of a CSV file by clicking the “Download Predictions” button.</p>
      <fig position="float" id="pone.0287179.g004">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.g004</object-id>
        <label>Fig 4</label>
        <graphic xlink:href="pone.0287179.g004" position="float"/>
      </fig>
    </sec>
    <sec id="sec017">
      <title>Binding affinity of CMNPD compounds with M<sup>pro</sup></title>
      <p>Out of the various possible binding positions of each compound predicted by Autodock Vina, the best one was picked considering the lowest binding energy. The molecular docking score of top 200 CMNPD compounds with M<sup>pro</sup> ranged from -4.3 Kcal/mol to -10 Kcal/mol shown in <xref rid="pone.0287179.s014" ref-type="supplementary-material">S14 File</xref> while the result of top 5 compounds is presented in <xref rid="pone.0287179.t005" ref-type="table">Table 5</xref>. The amino acid interactions of M<sup>pro</sup> with the top 5 compounds was also identified. The lowest binding energy was found for the compound CMNPD285. The CMNPD16005 is stabilized by a highest number of seven hydrogen bonds and four hydrophobic bonds while binding with the M<sup>pro</sup>. The second highest number of hydrogen bonds (6) were formed in the CMNPD12721 complex which was also stabilized by seven hydrophobic bonds. All the 5 compounds formed stable interaction with the active site residues and the catalytic dyad comprised of His41 and Cys145 residues of M<sup>pro</sup>. The detailed interaction profile of the top 5 compounds including the N3 ligand with M<sup>pro</sup> is explored in <xref rid="pone.0287179.g005" ref-type="fig">Fig 5</xref>.</p>
      <fig position="float" id="pone.0287179.g005">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.g005</object-id>
        <label>Fig 5</label>
        <caption>
          <p>Two-dimensional (2D) representation of molecular docking analysis between the SARS-CoV-2 M<sup>pro</sup> and (A) N3, (B) CMNPD285, (C) CMNPD20581, (D) CMNPD12721, (E) CMNPD16005, (F) CMNPD6083.</p>
        </caption>
        <graphic xlink:href="pone.0287179.g005" position="float"/>
      </fig>
      <table-wrap position="float" id="pone.0287179.t005">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.t005</object-id>
        <label>Table 5</label>
        <caption>
          <title>Predicted pIC50 and binding affinity score of top 5 compounds from CMNPD database against M<sup>pro</sup>.</title>
        </caption>
        <alternatives>
          <graphic xlink:href="pone.0287179.t005" id="pone.0287179.t005g" position="float"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="center" rowspan="1" colspan="1">Compound</th>
                <th align="center" rowspan="1" colspan="1">Predicted pIC50</th>
                <th align="center" rowspan="1" colspan="1">Docking score (Kcal/mol)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="center" rowspan="1" colspan="1">CMNPD285</td>
                <td align="center" rowspan="1" colspan="1">6.46</td>
                <td align="center" rowspan="1" colspan="1">-10.1</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CMNPD20581</td>
                <td align="center" rowspan="1" colspan="1">7.00</td>
                <td align="center" rowspan="1" colspan="1">-9.6</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CMNPD12721</td>
                <td align="center" rowspan="1" colspan="1">6.49</td>
                <td align="center" rowspan="1" colspan="1">-9.4</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CMNPD16005</td>
                <td align="center" rowspan="1" colspan="1">6.37</td>
                <td align="center" rowspan="1" colspan="1">-9.4</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CMNPD6083</td>
                <td align="center" rowspan="1" colspan="1">6.43</td>
                <td align="center" rowspan="1" colspan="1">-9.4</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
      </table-wrap>
    </sec>
    <sec id="sec018">
      <title>Molecular dynamics (MD) simulation results</title>
      <p>The RMSD of backbone atoms of the protein-ligand complexes were analyzed to view their stability. It can be observed from <xref rid="pone.0287179.g006" ref-type="fig">Fig 6(A)</xref> that CMNPD16005 complex shows the lowest RMSD than all other complexes. Surprisingly, the RMSD of the 6LU7-N3 complex is a bit higher than the CMNPD16005, which denotes the significant stability of CMNPD6083. The RMSD of CMNPD285 complex reaches to ∼0.4 nm from 60 to 85 ns, but the value increases after 85 ns and reaches to 0.3 nm. While viewing into the RMSD of CMNPD12721 complex, a steady increase of RMSD is observed after 60 ns. The value is decreased eventually indicating that CMNPD12721 might change the conformation of protein. Unlike the control and CMNPD16005 complex, RMSD of the CMNPD6083 complex is the mostly stable. Particularly, the CMNPD20581 complex shows the highest RMSD and higher degree of fluctuations throughout the period.</p>
      <fig position="float" id="pone.0287179.g006">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.g006</object-id>
        <label>Fig 6</label>
        <caption>
          <p>The Root-mean-square deviation (A), Root-mean-square fluctuation (B), Radius of gyration (C), Solvent accessible surface area (D) and hydrogen bond (E) analysis of protein-ligand complexes from the molecular simulation of 100 ns at 300 K.</p>
        </caption>
        <graphic xlink:href="pone.0287179.g006" position="float"/>
      </fig>
      <p>As RMSF aids in understanding the region of the receptor that is fluctuated throughout simulation, the flexibility of every residue is determined to gain a better understanding of how ligand binding impacts receptor flexibility. It is understood from <xref rid="pone.0287179.g006" ref-type="fig">Fig 6(B)</xref> that the binding of CMNPD12721 makes the M<sup>pro</sup> most flexible in almost all areas in comparison to all other complexes. Overall, the residues such as Glu47, Met49, Leu50, Tyr154, Ala194, Thr196, Arg222, Asn277 and Phe305 are found flexible in case of both control and the ligand-bonded complexes.</p>
      <p>The Rg represents the compactness of protein-ligand complexes. The lesser the fluctuation across the simulation period, the more compact the system is. The Rg of the 6LU7-N3 and CMNPD285 complexes were found to be nearly stable in case of fluctuation consistency throughout the simulation (<xref rid="pone.0287179.g006" ref-type="fig">Fig 6C</xref>). Besides, the Rg of CMNPD20581 was increased from 40 to 100 ns. The higher change of Rg might be due to protein folding, or distinct structural changes. The remaining complexes showed decreased Rg values indicating greater rigidness throughout the simulation period.</p>
      <p>A higher SASA value implies that the protein volume is expanding, and a lower degree of fluctuation is mostly expected over time. SASA can be altered by the binding of any molecule, and this can have a significant impact on the receptor structure. The SASA values of all the complexes including the control were found lowest during the simulation period suggesting that the presence of these molecules potentially could limit protein expansion (<xref rid="pone.0287179.g006" ref-type="fig">Fig 6D</xref>).</p>
      <p>Since intermolecular hydrogen bonds are known to contribute to conformational stability, the number of total hydrogen bonds in the protein-ligand complexes were determined. Most hydrogen bonds is observed for 6LU7-N3 complex, while the lowest number is observed in CMNPD20581 complex over the simulation period (<xref rid="pone.0287179.g006" ref-type="fig">Fig 6E</xref>). The remaining complexes possessed a significant number of hydrogen bonds (ranging from 3 to 8) compared to the CMNPD20581 complex.</p>
    </sec>
    <sec id="sec019">
      <title>Post simulation binding free energy results</title>
      <p>Using the MM/PBSA method, the binding free energies of the last 20 ns with a 100 ps interval was estimated from MD trajectories. The overall binding energies of all the complexes were negative, showing greater binding (<xref rid="pone.0287179.t006" ref-type="table">Table 6</xref>). The CMNPD16005 complex showed the lowest binding free energy (-296.193 +/- 25.797 KJ/mol), indicating the most stable conformation of the compound. The other complexes similarly had a low binding energy, suggesting that they could be utilized as potential compounds. A comparative analysis of the binding free energies of the complexes were illustrated in <xref rid="pone.0287179.g007" ref-type="fig">Fig 7(A)</xref>. The results for the amino acid residue contribution in the binding of the compounds are shown in <xref rid="pone.0287179.g007" ref-type="fig">Fig 7(B)</xref>. The binding of the compounds to M<sup>pro</sup> involved the notable contribution of leu27, Met49, Cys145, Leu167, Pro168, and Thr190 amino acid residues.</p>
      <fig position="float" id="pone.0287179.g007">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.g007</object-id>
        <label>Fig 7</label>
        <caption>
          <p>Graphical illustration of the binding free energy (A) and per residue contribution plot of protein-ligand complexes (B).</p>
        </caption>
        <graphic xlink:href="pone.0287179.g007" position="float"/>
      </fig>
      <table-wrap position="float" id="pone.0287179.t006">
        <object-id pub-id-type="doi">10.1371/journal.pone.0287179.t006</object-id>
        <label>Table 6</label>
        <caption>
          <title>Binding free energy calculations (MM/PBSA) for six protein-ligand complexes.</title>
        </caption>
        <alternatives>
          <graphic xlink:href="pone.0287179.t006" id="pone.0287179.t006g" position="float"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="center" rowspan="1" colspan="1">Complex</th>
                <th align="center" rowspan="1" colspan="1">Van der Waal energy<break/>(kJ mol<sup>-1</sup>)</th>
                <th align="center" rowspan="1" colspan="1">Electrostatic energy<break/>(kJ mol<sup>-1</sup>)</th>
                <th align="center" rowspan="1" colspan="1">Polar solvation energy<break/>(kJ mol<sup>-1</sup>)</th>
                <th align="center" rowspan="1" colspan="1">SASA energy<break/>(kJ mol<sup>-1</sup>)</th>
                <th align="center" rowspan="1" colspan="1">Binding energy<break/>(kJ mol<sup>-1</sup>)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="center" rowspan="1" colspan="1">6LU7-N3</td>
                <td align="center" rowspan="1" colspan="1">-224.851 +/- 18.949</td>
                <td align="center" rowspan="1" colspan="1">-162.972 +/- 20.477</td>
                <td align="center" rowspan="1" colspan="1">319.391 +/- 26.396</td>
                <td align="center" rowspan="1" colspan="1">-25.515 +/ 1.955</td>
                <td align="center" rowspan="1" colspan="1">-93.947 +/- 17.448</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CMNPD285</td>
                <td align="center" rowspan="1" colspan="1">-213.039 +/- 18.202</td>
                <td align="center" rowspan="1" colspan="1">-169.860 +/- 27.622</td>
                <td align="center" rowspan="1" colspan="1">342.256 +/- 36.546</td>
                <td align="center" rowspan="1" colspan="1">-22.822 +/- 1.572</td>
                <td align="center" rowspan="1" colspan="1">-63.465 +/- 22.132</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CMNPD20581</td>
                <td align="center" rowspan="1" colspan="1">-230.604 +/- 15.446</td>
                <td align="center" rowspan="1" colspan="1">-7.170 +/- 3.876</td>
                <td align="center" rowspan="1" colspan="1">91.983 +/- 11.163</td>
                <td align="center" rowspan="1" colspan="1">-19.485 +/- 1.290</td>
                <td align="center" rowspan="1" colspan="1">-165.277 +/- 14.898</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CMNPD12721</td>
                <td align="center" rowspan="1" colspan="1">-165.312 +/- 30.586</td>
                <td align="center" rowspan="1" colspan="1">-120.472 +/- 37.904</td>
                <td align="center" rowspan="1" colspan="1">278.799 +/- 47.652</td>
                <td align="center" rowspan="1" colspan="1">-16.485 +/- 2.606</td>
                <td align="center" rowspan="1" colspan="1">-23.469 +/- 26.819</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CMNPD16005</td>
                <td align="center" rowspan="1" colspan="1">-174.597 +/- 15.161</td>
                <td align="center" rowspan="1" colspan="1">-599.461 +/- 34.553</td>
                <td align="center" rowspan="1" colspan="1">499.675 +/- 37.798</td>
                <td align="center" rowspan="1" colspan="1">-21.811 +/- 1.399</td>
                <td align="center" rowspan="1" colspan="1">-296.193 +/- 25.797</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">CMNPD6083</td>
                <td align="center" rowspan="1" colspan="1">-90.357 +/- 44.064</td>
                <td align="center" rowspan="1" colspan="1">-28.842 +/- 20.343</td>
                <td align="center" rowspan="1" colspan="1">91.190 +/- 55.611</td>
                <td align="center" rowspan="1" colspan="1">-9.675 +/- 4.522</td>
                <td align="center" rowspan="1" colspan="1">-37.684 +/- 59.575</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
      </table-wrap>
    </sec>
  </sec>
  <sec sec-type="conclusions" id="sec020">
    <title>Discussion</title>
    <p>The COVID-19 pandemic has caused severe damage on the health and daily lives of billions of people around the world over the last two years. We’ve seen a race against time to vaccinate as many people as possible in recent months; however, discrepancies in vaccine distribution between nations, as well as new developing variants, pose an additional public health risk, making it difficult to achieve full immunization [<xref rid="pone.0287179.ref059" ref-type="bibr">59</xref>]. Several vaccine formulations are now available, assisting in the development of immunity [<xref rid="pone.0287179.ref060" ref-type="bibr">60</xref>–<xref rid="pone.0287179.ref063" ref-type="bibr">63</xref>]. Nonetheless, there is an increasing interest in developing new anti-covid medications. The M<sup>pro</sup>, which is responsible for the cleavage of polypeptides during viral genome transcription, is a fascinating drug target in this scenario.</p>
    <p>In the current study, we aimed to develop a classification model that is able to determine active from inactive compounds, and build a web-app for differentiating compounds for M<sup>pro</sup> with selectivity. We followed the Organisation for Economic Co-operation and Development (OECD) recommendations to develop robust QSAR models for this purpose [<xref rid="pone.0287179.ref064" ref-type="bibr">64</xref>]. These guidelines comprise of the following major points: (i) the data set should have a defined endpoint, (ii) it should use an explicit learning algorithm, (iii) there should be a defined applicability domain of the built model, (iv) appropriate measurement of robustness and predictivity and (v) interpretation of the important features of the QSAR model. We initially extracted a dataset of 758 compounds from literature review and thresholds of &lt;0.5 and &gt;10 μM for identifying active compounds from the inactives in order to build a classification model. Upon excluding the intermediate sets of compounds, we obtained a curated set of 478 compounds for detailed analysis. It is feasible to determine if a compound will exhibit the biological or pharmacological property needed for an orally active medicine in humans utilizing the Lipinski’s rule-of-five (Ro5) approach. These characteristics are based on the fact that almost all drugs are relatively large lipophilic compounds with MW, ALogP, the number of hydrogen hydrogen bond donors, and the number of hydrogen bond acceptors. We found that most of the compounds meet the Ro5 criteria (<xref rid="pone.0287179.g002" ref-type="fig">Fig 2B–2E</xref>) and the findings of statistical analysis from Mann–Whitney U test showed a significant difference between the active and inactive compounds (<xref rid="pone.0287179.t001" ref-type="table">Table 1</xref>). Also, the chemical space distribution shows that the external set lies well within the areas of the internal set indicating that the AD is well defined for the developed CSAR model found through PCA analysis results (<xref rid="pone.0287179.g002" ref-type="fig">Fig 2F</xref>).</p>
    <p>Furthermore, we used interpretable molecular fingerprints to develop interpretable QSAR models and evaluated the model performances for all the used 12 fingerprints, following the aforementioned guidelines. Also, it is necessary to identify and address the activity cliffs in the data set using the data set’s modelability score or MODI index before the predictive model can be developed. The data set was found to have a MODI value more than 0.65 for all the 12 fingerprint descriptors, indicating that it is reliable for developing a classification model (<xref rid="pone.0287179.t002" ref-type="table">Table 2</xref>). Then we developed a QSAR model utilizing the random forest (RF) algorithm in order for differentiation of the active and inactive inhibitors for M<sup>pro</sup>. The best averaged values determined by a 10-fold CV analysis was found for the MACCS fingerprint descriptors (Ac of 89%, Sn of 89%, Sc of 73%, and MCC of 79%) (<xref rid="pone.0287179.t003" ref-type="table">Table 3</xref>). Similarly, Klekota–Roth and 2D atom pairs descriptors performed well, with the second and third highest best values for Ac and MCC, respectively, with Klekota–Roth fingerprints providing Ac and MCC values of 83.64% and 0.664, respectively, and 2D atom pairs fingerprints providing Ac and MCC values of 85.74% and 0.713, respectively (<xref rid="pone.0287179.t003" ref-type="table">Table 3</xref>). We found that the MACCS fingerprints were the best choice for model interpretation based on the Ac values, MCC values, overall external and CV.</p>
    <p>Later, an investigation of the important features on selected descriptors was conducted to obtain a better view of the mechanistic details driving M<sup>pro</sup>. The top-ranked MACCS descriptors include descriptors of various classes such as aromatic compounds, nitrogen-containing compounds, oxygen-containing compounds and halogens as obtained from the RF model (<xref rid="pone.0287179.t004" ref-type="table">Table 4</xref>). M<sup>pro</sup> has been shown to be inhibited by a range of N-substituted isatin derivatives, with the highest activity being associated with derivatives having carboxamide groups at C-5 of the isatin core (IC50  =  0.045–17.8 μM) [<xref rid="pone.0287179.ref065" ref-type="bibr">65</xref>]. Several oxygen atoms containing small compounds were also found to inhibit M<sup>pro</sup> and blocks viral transcription [<xref rid="pone.0287179.ref066" ref-type="bibr">66</xref>,<xref rid="pone.0287179.ref067" ref-type="bibr">67</xref>]. Kowit et al. identified halogenated baicalein as a potent inhibitor of the M<sup>pro</sup> and they confirmed its inhibitory activity in an in vitro assay [<xref rid="pone.0287179.ref068" ref-type="bibr">68</xref>]. It was also found that the addition of halogen groups improves binding strength by an order of magnitude [<xref rid="pone.0287179.ref069" ref-type="bibr">69</xref>]. Hossum et al. generated a pharmacophore model and found three acceptor features and one aromatic ring feature as common in all the active hits including the co-crystallized ligand [<xref rid="pone.0287179.ref070" ref-type="bibr">70</xref>]. Thus, the top-ranked MACCS descriptors are in significant correlation with the properties of laboratory validated potent M<sup>pro</sup> inhibitors.</p>
    <p>In a normal predictive model life cycle, after models are validated and outcomes are shown in the publications, the model’s utility is essentially over. In this way, the model has accomplished its goal to make predictions and offer useful insights into the underlying key characteristics. We believed that deployment of the predictive model as a public web-app that allows scientists and researchers, particularly in the fields of computational chemistry and biology, to use the predictive insights from the model would significantly improve its value, while also benefiting scientific communities, would greatly extend the model’s life cycle. We made the web-app available at “Streamlit share” platform (<xref rid="pone.0287179.g004" ref-type="fig">Fig 4</xref>). In order to test the web-app to determine the correlation between predicted pIC50 and the binding affinity, we applied an integrated molecular modeling approach. All the available 31,492 compounds were submitted to the web-app to predict their pIC50 and it was found that top five compounds with highest binding affinity to M<sup>pro</sup> had pIC50 values ranging from 6.37 to 7 (<xref rid="pone.0287179.t005" ref-type="table">Table 5</xref>). They formed sufficient hydrogen bond and hydrophobic interactions and all of them formed stable interactions with the catalytic dyad consisting of His41 and Cys145 (<xref rid="pone.0287179.g005" ref-type="fig">Fig 5</xref>).</p>
    <p>Also, MD simulation results re-confirmed the stability of these five compounds with M<sup>pro</sup>. The RMSD plot indicates that all the five compounds are stable, with no unexpected rises in RMSD values across the simulated time (<xref rid="pone.0287179.g006" ref-type="fig">Fig 6A</xref>). The complexes had fewer fluctuations in the allowed range, according to the RMSF study (<xref rid="pone.0287179.g006" ref-type="fig">Fig 6B</xref>). The radius of gyration (Rg) of the protein-ligand complexes tended to be similar, indicating that every complex had a similar compactness behavior (<xref rid="pone.0287179.g006" ref-type="fig">Fig 6C</xref>). The SASA values showed that the volume of the complexes did not substantially increase (<xref rid="pone.0287179.g006" ref-type="fig">Fig 6D</xref>). Throughout the simulation, a significant number of hydrogen bonds were observed in all of the complexes, further elucidating their conformational stability (<xref rid="pone.0287179.g006" ref-type="fig">Fig 6E</xref>). Furthermore, the binding free energies for all of the complexes were estimated using the MM/PBSA method, and the results suggest that the complexes have a favorable binding energy with M<sup>pro</sup> (<xref rid="pone.0287179.t006" ref-type="table">Table 6</xref> and <xref rid="pone.0287179.g007" ref-type="fig">Fig 7A</xref>). It can be determined from the per-residue interaction energy profile that the leu27, Met49, Cys145, Leu167, Pro168, and Thr190 residues of M<sup>pro</sup> played an important role in protein-ligand stability and contributed significantly to the binding of the compounds (<xref rid="pone.0287179.g007" ref-type="fig">Fig 7B</xref>). As a result, these compounds may have the potential to interfere with and block the activity of SARS-CoV-2 M<sup>pro</sup>.</p>
    <p>Thus, the web-app presented in the current study can be utilized for further research on various compounds to get a view into their anti-M<sup>pro</sup> activity. Also, upon evaluating the toxicity of the five marine derived compounds by various toxicity assays, their inhibition efficacy can be tested through in vitro laboratory validations.</p>
  </sec>
  <sec id="sec021" sec-type="supplementary-material">
    <title>Supporting information</title>
    <supplementary-material id="pone.0287179.s001" position="float" content-type="local-data">
      <label>S1 File</label>
      <caption>
        <title>The SMILES ID and additional details of the 758 compounds.</title>
        <p>(XLSX)</p>
      </caption>
      <media xlink:href="pone.0287179.s001.xlsx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s002" position="float" content-type="local-data">
      <label>S2 File</label>
      <caption>
        <title>Computed AtomPairs2DCount fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s002.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s003" position="float" content-type="local-data">
      <label>S3 File</label>
      <caption>
        <title>Computed AtomPairs2D fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s003.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s004" position="float" content-type="local-data">
      <label>S4 File</label>
      <caption>
        <title>Computed CDK fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s004.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s005" position="float" content-type="local-data">
      <label>S5 File</label>
      <caption>
        <title>Computed CDK Extended fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s005.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s006" position="float" content-type="local-data">
      <label>S6 File</label>
      <caption>
        <title>Computed CDK Graph only fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s006.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s007" position="float" content-type="local-data">
      <label>S7 File</label>
      <caption>
        <title>Computed EState fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s007.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s008" position="float" content-type="local-data">
      <label>S8 File</label>
      <caption>
        <title>Computed KlekotaRothCount fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s008.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s009" position="float" content-type="local-data">
      <label>S9 File</label>
      <caption>
        <title>Computed KlekotaRoth fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s009.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s010" position="float" content-type="local-data">
      <label>S10 File</label>
      <caption>
        <title>Computed MACCS fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s010.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s011" position="float" content-type="local-data">
      <label>S11 File</label>
      <caption>
        <title>Computed PubChem fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s011.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s012" position="float" content-type="local-data">
      <label>S12 File</label>
      <caption>
        <title>Computed Substructure fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s012.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s013" position="float" content-type="local-data">
      <label>S13 File</label>
      <caption>
        <title>Computed SubstructureCount fingerprint of our dataset.</title>
        <p>(CSV)</p>
      </caption>
      <media xlink:href="pone.0287179.s013.csv">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0287179.s014" position="float" content-type="local-data">
      <label>S14 File</label>
      <caption>
        <title>The docking score of all the CMNPD compounds with M<sup>pro</sup>.</title>
        <p>(XLSX)</p>
      </caption>
      <media xlink:href="pone.0287179.s014.xlsx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack>
    <p>The author(s) acknowledge the Bioinformatics Division, National Institute of Biotechnology, Bangladesh, for their extended support of supercomputing system during this study.</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="pone.0287179.ref001">
      <label>1</label>
      <mixed-citation publication-type="journal"><name><surname>Lam</surname><given-names>ME</given-names></name>. <article-title>United by the global COVID-19 pandemic: divided by our values and viral identities.</article-title><source>Humanit Soc Sci Commun 2021 81</source>. <year>2021</year>;<volume>8</volume>: <fpage>1</fpage>–<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1057/s41599-020-00679-5</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref002">
      <label>2</label>
      <mixed-citation publication-type="journal"><name><surname>Lambert</surname><given-names>H</given-names></name>, <name><surname>Gupte</surname><given-names>J</given-names></name>, <name><surname>Fletcher</surname><given-names>H</given-names></name>, <name><surname>Hammond</surname><given-names>L</given-names></name>, <name><surname>Lowe</surname><given-names>N</given-names></name>, <name><surname>Pelling</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>COVID-19 as a global challenge: towards an inclusive and sustainable future</article-title>. <source>Lancet Planet Heal</source>. <year>2020</year>;<volume>4</volume>: <fpage>e312</fpage>–<lpage>e314</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S2542-5196(20)30168-6</pub-id><?supplied-pmid 32702296?><pub-id pub-id-type="pmid">32702296</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref003">
      <label>3</label>
      <mixed-citation publication-type="journal"><name><surname>Roberts</surname><given-names>DL</given-names></name>, <name><surname>Rossman</surname><given-names>JS</given-names></name>, <name><surname>Jarić</surname><given-names>I</given-names></name>. <article-title>Dating first cases of COVID-19.</article-title><source>PLOS Pathog</source>. <year>2021</year>;<volume>17</volume>: <fpage>e1009620</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.ppat.1009620</pub-id><?supplied-pmid 34166465?><pub-id pub-id-type="pmid">34166465</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref004">
      <label>4</label>
      <mixed-citation publication-type="journal"><name><surname>Worobey</surname><given-names>M.</given-names></name><article-title>Dissecting the early COVID-19 cases in Wuhan</article-title>. <source>Science (80-).</source><year>2021</year>;<volume>374</volume>: <fpage>1202</fpage>–<lpage>1204</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.abm4454</pub-id><?supplied-pmid 34793199?><pub-id pub-id-type="pmid">34793199</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref005">
      <label>5</label>
      <mixed-citation publication-type="journal"><name><surname>Amicone</surname><given-names>M</given-names></name>, <name><surname>Borges</surname><given-names>V</given-names></name>, <name><surname>Alves</surname><given-names>MJ</given-names></name>, <name><surname>Isidro</surname><given-names>J</given-names></name>, <name><surname>Zé-Zé</surname><given-names>L</given-names></name>, <name><surname>Duarte</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution</article-title>. <source>Evol Med Public Heal</source>. <year>2022</year>;<volume>10</volume>: <fpage>142</fpage>–<lpage>155</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/emph/eoac010</pub-id><?supplied-pmid 35419205?><pub-id pub-id-type="pmid">35419205</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref006">
      <label>6</label>
      <mixed-citation publication-type="journal"><name><surname>Domingo</surname><given-names>E</given-names></name>, <name><surname>Holland</surname><given-names>JJ</given-names></name>. <article-title>RNA VIRUS MUTATIONS AND FITNESS FOR SURVIVAL</article-title>. https://doi.org/101146/annurev.micro511151. <year>2003</year>;<volume>51</volume>: <fpage>151</fpage>–<lpage>178</lpage>. <?supplied-pmid 9343347?><pub-id pub-id-type="pmid">9343347</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref007">
      <label>7</label>
      <mixed-citation publication-type="journal"><name><surname>Sanjuán</surname><given-names>R</given-names></name>, <name><surname>Domingo-Calap</surname><given-names>P</given-names></name>. <article-title>Mechanisms of viral mutation</article-title>. <source>Cell Mol Life Sci 2016 7323.</source><year>2016</year>;<volume>73</volume>: <fpage>4433</fpage>–<lpage>4448</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00018-016-2299-6</pub-id><?supplied-pmid 27392606?><pub-id pub-id-type="pmid">27392606</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref008">
      <label>8</label>
      <mixed-citation publication-type="journal"><name><surname>Duffy</surname><given-names>S</given-names></name>, <name><surname>Shackelton</surname><given-names>LA</given-names></name>, <name><surname>Holmes</surname><given-names>EC</given-names></name>. <article-title>Rates of evolutionary change in viruses: patterns and determinants</article-title>. <source>Nat Rev Genet 2008 94.</source><year>2008</year>;<volume>9</volume>: <fpage>267</fpage>–<lpage>276</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nrg2323</pub-id><?supplied-pmid 18319742?><pub-id pub-id-type="pmid">18319742</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref009">
      <label>9</label>
      <mixed-citation publication-type="journal"><name><surname>Yewdell</surname><given-names>JW</given-names></name>. <article-title>Antigenic drift: Understanding COVID-19</article-title>. <source>Immunity</source>. <year>2021</year>;<volume>54</volume>: <fpage>2681</fpage>–<lpage>2687</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.immuni.2021.11.016</pub-id><?supplied-pmid 34910934?><pub-id pub-id-type="pmid">34910934</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref010">
      <label>10</label>
      <mixed-citation publication-type="journal"><name><surname>Harvey</surname><given-names>WT</given-names></name>, <name><surname>Carabelli</surname><given-names>AM</given-names></name>, <name><surname>Jackson</surname><given-names>B</given-names></name>, <name><surname>Gupta</surname><given-names>RK</given-names></name>, <name><surname>Thomson</surname><given-names>EC</given-names></name>, <name><surname>Harrison</surname><given-names>EM</given-names></name>, <etal>et al</etal>. <article-title>SARS-CoV-2 variants, spike mutations and immune escape</article-title>. <source>Nat Rev Microbiol 2021 197.</source><year>2021</year>;<volume>19</volume>: <fpage>409</fpage>–<lpage>424</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41579-021-00573-0</pub-id><?supplied-pmid 34075212?><pub-id pub-id-type="pmid">34075212</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref011">
      <label>11</label>
      <mixed-citation publication-type="journal"><name><surname>Martin</surname><given-names>DP</given-names></name>, <name><surname>Weaver</surname><given-names>S</given-names></name>, <name><surname>Tegally</surname><given-names>H</given-names></name>, <name><surname>San</surname><given-names>JE</given-names></name>, <name><surname>Shank</surname><given-names>SD</given-names></name>, <name><surname>Wilkinson</surname><given-names>E</given-names></name>, <etal>et al</etal>. <article-title>The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages.</article-title><source>Cell</source>. <year>2021</year>;<volume>184</volume>: <fpage>5189</fpage>–<lpage>5200</lpage>.e7. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cell.2021.09.003</pub-id><?supplied-pmid 34537136?><pub-id pub-id-type="pmid">34537136</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref012">
      <label>12</label>
      <mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>KYA</given-names></name>, <name><surname>Rijal</surname><given-names>P</given-names></name>, <name><surname>Schimanski</surname><given-names>L</given-names></name>, <name><surname>Powell</surname><given-names>TJ</given-names></name>, <name><surname>Lin</surname><given-names>TY</given-names></name>, <name><surname>McCauley</surname><given-names>JW</given-names></name>, <etal>et al</etal>. <article-title>Focused antibody response to influenza linked to antigenic drift</article-title>. <source>J Clin Invest</source>. <year>2015</year>;<volume>125</volume>: <fpage>2631</fpage>–<lpage>2645</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1172/JCI81104</pub-id><?supplied-pmid 26011643?><pub-id pub-id-type="pmid">26011643</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref013">
      <label>13</label>
      <mixed-citation publication-type="journal"><name><surname>Das</surname><given-names>SR</given-names></name>, <name><surname>Hensley</surname><given-names>SE</given-names></name>, <name><surname>Ince</surname><given-names>WL</given-names></name>, <name><surname>Brooke</surname><given-names>CB</given-names></name>, <name><surname>Subba</surname><given-names>A</given-names></name>, <name><surname>Delboy</surname><given-names>MG</given-names></name>, <etal>et al</etal>. <article-title>Defining Influenza A Virus Hemagglutinin Antigenic Drift by Sequential Monoclonal Antibody Selection</article-title>. <source>Cell Host Microbe</source>. <year>2013</year>;<volume>13</volume>: <fpage>314</fpage>–<lpage>323</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.chom.2013.02.008</pub-id><?supplied-pmid 23498956?><pub-id pub-id-type="pmid">23498956</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref014">
      <label>14</label>
      <mixed-citation publication-type="journal"><name><surname>Tahir ul Qamar</surname><given-names>M</given-names></name>, <name><surname>Alqahtani</surname><given-names>SM</given-names></name>, <name><surname>Alamri</surname><given-names>MA</given-names></name>, <name><surname>Chen</surname><given-names>LL</given-names></name>. <article-title>Structural basis of SARS-CoV-2 3CL pro and anti-COVID-19 drug discovery from medicinal plants.</article-title><source>J Pharm Anal</source>. <year>2020</year>;<volume>10</volume>: <fpage>313</fpage>–<lpage>319</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jpha.2020.03.009</pub-id><?supplied-pmid 32296570?><pub-id pub-id-type="pmid">32296570</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref015">
      <label>15</label>
      <mixed-citation publication-type="journal"><name><surname>Pillaiyar</surname><given-names>T</given-names></name>, <name><surname>Manickam</surname><given-names>M</given-names></name>, <name><surname>Namasivayam</surname><given-names>V</given-names></name>, <name><surname>Hayashi</surname><given-names>Y</given-names></name>, <name><surname>Jung</surname><given-names>SH</given-names></name>. <article-title>An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule chemotherapy.</article-title><source>J Med Chem</source>. <year>2016</year>;<volume>59</volume>: <fpage>6595</fpage>–<lpage>6628</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01461</pub-id><?supplied-pmid 26878082?><pub-id pub-id-type="pmid">26878082</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref016">
      <label>16</label>
      <mixed-citation publication-type="journal"><name><surname>Cherkasov</surname><given-names>A</given-names></name>, <name><surname>Muratov</surname><given-names>EN</given-names></name>, <name><surname>Fourches</surname><given-names>D</given-names></name>, <name><surname>Varnek</surname><given-names>A</given-names></name>, <name><surname>Baskin</surname><given-names>II</given-names></name>, <name><surname>Cronin</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>QSAR modeling: where have you been? Where are you going to</article-title>? <source>J Med Chem</source>. <year>2014</year>;<volume>57</volume>: <fpage>4977</fpage>–<lpage>5010</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/jm4004285</pub-id><?supplied-pmid 24351051?><pub-id pub-id-type="pmid">24351051</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref017">
      <label>17</label>
      <mixed-citation publication-type="journal"><name><surname>Prachayasittikul</surname><given-names>V</given-names></name>, <name><surname>Worachartcheewan</surname><given-names>A</given-names></name>, <name><surname>Shoombuatong</surname><given-names>W</given-names></name>, <name><surname>Songtawee</surname><given-names>N</given-names></name>, <name><surname>Simeon</surname><given-names>S</given-names></name>, <name><surname>Prachayasittikul</surname><given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Computer-Aided Drug Design of Bioactive Natural Products</article-title>. <source>Curr Top Med Chem</source>. <year>2015</year>;<volume>15</volume>: <fpage>1780</fpage>–<lpage>1800</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2174/1568026615666150506151101</pub-id><?supplied-pmid 25961523?><pub-id pub-id-type="pmid">25961523</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref018">
      <label>18</label>
      <mixed-citation publication-type="journal"><name><surname>Nantasenamat</surname><given-names>C</given-names></name>, <name><surname>Isarankura-Na-Ayudhya</surname><given-names>C</given-names></name>, <name><surname>Prachayasittikul</surname><given-names>V</given-names></name>. <article-title>Advances in computational methods to predict the biological activity of compounds.</article-title><source>Expert Opin Drug Discov</source>. <year>2010</year>;<volume>5</volume>: <fpage>633</fpage>–<lpage>654</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1517/17460441.2010.492827</pub-id><?supplied-pmid 22823204?><pub-id pub-id-type="pmid">22823204</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref019">
      <label>19</label>
      <mixed-citation publication-type="journal"><name><surname>Dudek</surname><given-names>A</given-names></name>, <name><surname>Arodz</surname><given-names>T</given-names></name>, <name><surname>Galvez</surname><given-names>J</given-names></name>. <article-title>Computational methods in developing quantitative structure-activity relationships (QSAR): a review.</article-title><source>Comb Chem High Throughput Screen</source>. <year>2006</year>;<volume>9</volume>: <fpage>213</fpage>–<lpage>228</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2174/138620706776055539</pub-id><?supplied-pmid 16533155?><pub-id pub-id-type="pmid">16533155</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref020">
      <label>20</label>
      <mixed-citation publication-type="journal"><name><surname>Borsari</surname><given-names>C</given-names></name>, <name><surname>Santarem</surname><given-names>N</given-names></name>, <name><surname>MacEdo</surname><given-names>S</given-names></name>, <name><surname>Jiménez-Antón</surname><given-names>MD</given-names></name>, <name><surname>Torrado</surname><given-names>JJ</given-names></name>, <name><surname>Olías-Molero</surname><given-names>AI</given-names></name>, <etal>et al</etal>. <article-title>SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti- Trypanosoma brucei Agent</article-title>. <source>ACS Med Chem Lett</source>. <year>2019</year>;<volume>10</volume>: <fpage>528</fpage>–<lpage>533</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/acsmedchemlett.8b00565</pub-id><?supplied-pmid 30996791?><pub-id pub-id-type="pmid">30996791</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref021">
      <label>21</label>
      <mixed-citation publication-type="journal"><name><surname>Pir</surname><given-names>M</given-names></name>, <name><surname>Agirbas</surname><given-names>H</given-names></name>, <name><surname>Budak</surname><given-names>F</given-names></name>, <name><surname>Ilter</surname><given-names>M</given-names></name>. <article-title>Synthesis, characterization, antimicrobial activity, and QSAR studies on substituted oxadiazaboroles</article-title>. <source>Med Chem Res</source>. <year>2016</year>;<volume>25</volume>: <fpage>1794</fpage>–<lpage>1812</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/S00044-016-1603-1</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref022">
      <label>22</label>
      <mixed-citation publication-type="journal"><name><surname>De Azevedo</surname><given-names>WF</given-names></name>, <name><surname>Canduri</surname><given-names>F</given-names></name>, <name><surname>Basso</surname><given-names>LA</given-names></name>, <name><surname>Palma</surname><given-names>MS</given-names></name>, <name><surname>Santos</surname><given-names>DS</given-names></name>. <article-title>Determining the structural basis for specificity of ligands using crystallographic screening</article-title>. <source>Cell Biochem Biophys 2006 443.</source><year>2006</year>;<volume>44</volume>: <fpage>405</fpage>–<lpage>411</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1385/CBB:44:3:405</pub-id><?supplied-pmid 16679527?><pub-id pub-id-type="pmid">16679527</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref023">
      <label>23</label>
      <mixed-citation publication-type="journal"><name><surname>Suvannang</surname><given-names>N</given-names></name>, <name><surname>Preeyanon</surname><given-names>L</given-names></name>, <name><surname>Malik</surname><given-names>AA</given-names></name>, <name><surname>Schaduangrat</surname><given-names>N</given-names></name>, <name><surname>Shoombuatong</surname><given-names>W</given-names></name>, <name><surname>Worachartcheewan</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Probing the origin of estrogen receptor alpha inhibition via large-scale QSAR study</article-title>. <source>RSC Adv</source>. <year>2018</year>;<volume>8</volume>: <fpage>11344</fpage>–<lpage>11356</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1039/c7ra10979b</pub-id><?supplied-pmid 35542807?><pub-id pub-id-type="pmid">35542807</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref024">
      <label>24</label>
      <mixed-citation publication-type="journal"><name><surname>Prachayasittikul</surname><given-names>V</given-names></name>, <name><surname>Pingaew</surname><given-names>R</given-names></name>, <name><surname>Worachartcheewan</surname><given-names>A</given-names></name>, <name><surname>Nantasenamat</surname><given-names>C</given-names></name>, <name><surname>Prachayasittikul</surname><given-names>S</given-names></name>, <name><surname>Ruchirawat</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Synthesis, anticancer activity and QSAR study of 1,4-naphthoquinone derivatives</article-title>. <source>Eur J Med Chem</source>. <year>2014</year>;<volume>84</volume>: <fpage>247</fpage>–<lpage>263</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ejmech.2014.07.024</pub-id><?supplied-pmid 25019480?><pub-id pub-id-type="pmid">25019480</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref025">
      <label>25</label>
      <mixed-citation publication-type="journal"><name><surname>da Cunha</surname><given-names>E</given-names></name>, <name><surname>Matos</surname><given-names>K</given-names></name>, <name><surname>Ramalho</surname><given-names>T</given-names></name>. <article-title>QSAR and Docking Studies of HCV NS3 Serine Protease Inhibitors.</article-title><source>Med Chem (Los Angeles).</source><year>2013</year>;<volume>9</volume>: <fpage>774</fpage>–<lpage>805</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2174/1573406411309060003</pub-id><?supplied-pmid 23140577?><pub-id pub-id-type="pmid">23140577</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref026">
      <label>26</label>
      <mixed-citation publication-type="journal"><name><surname>Worachartcheewan</surname><given-names>A</given-names></name>, <name><surname>Prachayasittikul</surname><given-names>V</given-names></name>, <name><surname>Toropova</surname><given-names>AP</given-names></name>, <name><surname>Toropov</surname><given-names>AA</given-names></name>, <name><surname>Nantasenamat</surname><given-names>C</given-names></name>. <article-title>Large-scale structure-activity relationship study of hepatitis C virus NS5B polymerase inhibition using SMILES-based descriptors</article-title>. <source>Mol Divers</source>. <year>2015</year>;<volume>19</volume>: <fpage>955</fpage>–<lpage>964</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11030-015-9614-2</pub-id><?supplied-pmid 26164590?><pub-id pub-id-type="pmid">26164590</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref027">
      <label>27</label>
      <mixed-citation publication-type="journal"><name><surname>Gomes IdS</surname><given-names>Santana CA</given-names></name>, <name><surname>Marcolino LS</surname><given-names>Lima LHFd</given-names></name>, <name><surname>Melo-Minardi RCd</surname><given-names>Dias RS</given-names></name>, <etal>et al</etal>. (<year>2022</year>) <article-title>Computational prediction of potential inhibitors for SARS-COV-2 main protease based on machine learning, docking, MM-PBSA calculations, and metadynamics</article-title>. <source>PLoS ONE</source><volume>17</volume>(<issue>4</issue>): <fpage>e0267471</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0267471</pub-id><?supplied-pmid 35452494?><pub-id pub-id-type="pmid">35452494</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref028">
      <label>28</label>
      <mixed-citation publication-type="journal"><name><surname>Mekni</surname><given-names>N</given-names></name>, <name><surname>Coronnello</surname><given-names>C</given-names></name>, <name><surname>Langer</surname><given-names>T</given-names></name>, <name><surname>De Rosa</surname><given-names>M</given-names></name>, <name><surname>Perricone</surname><given-names>U</given-names></name>. <article-title>Support vector machine as a supervised learning for the prioritization of novel potential sars‐cov‐2 main protease inhibitors.</article-title><source>Int J Mol Sci.</source><year>2021</year>;<volume>22</volume>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/ijms22147714</pub-id><?supplied-pmid 34299333?><pub-id pub-id-type="pmid">34299333</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref029">
      <label>29</label>
      <mixed-citation publication-type="journal"><name><surname>Nand</surname><given-names>M</given-names></name>, <name><surname>Maiti</surname><given-names>P</given-names></name>, <name><surname>Joshi</surname><given-names>T</given-names></name>, <name><surname>Chandra</surname><given-names>S</given-names></name>, <name><surname>Pande</surname><given-names>V</given-names></name>, <name><surname>Kuniyal</surname><given-names>JC</given-names></name>, <etal>et al</etal>. <article-title>Virtual screening of anti-HIV1 compounds against SARS-CoV-2: machine learning modeling, chemoinformatics and molecular dynamics simulation based analysis.</article-title><year>2020</year> [cited 2 Jun 2022]. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-020-77524-x</pub-id>
<?supplied-pmid 33230180?><pub-id pub-id-type="pmid">33230180</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref030">
      <label>30</label>
      <mixed-citation publication-type="journal"><name><surname>Macip</surname><given-names>G</given-names></name>, <name><surname>Garcia-segura</surname><given-names>P</given-names></name>, <name><surname>Mestres-truyol</surname><given-names>J</given-names></name>, <name><surname>Saldivar-espinoza</surname><given-names>B</given-names></name>, <name><surname>Pujadas</surname><given-names>G</given-names></name>, <name><surname>Garcia-Vallvé</surname><given-names>S</given-names></name>. <article-title>A review of the current landscape of SARS-CoV-2 main protease inhibitors: Have we hit the bullseye yet?</article-title><source>Int J Mol Sci.</source><year>2022</year>;<volume>23</volume>: <fpage>259</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/IJMS23010259/S1</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref031">
      <label>31</label>
      <mixed-citation publication-type="journal"><name><surname>Yap</surname><given-names>CW</given-names></name>. <article-title>PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints</article-title>. <source>J Comput Chem</source>. <year>2011</year>;<volume>32</volume>: <fpage>1466</fpage>–<lpage>1474</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jcc.21707</pub-id><?supplied-pmid 21425294?><pub-id pub-id-type="pmid">21425294</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref032">
      <label>32</label>
      <mixed-citation publication-type="journal"><name><surname>Wójcikowski</surname><given-names>M</given-names></name>, <name><surname>Siedlecki</surname><given-names>P</given-names></name>, <name><surname>Ballester</surname><given-names>PJ</given-names></name>. <article-title>Building Machine-Learning Scoring Functions for Structure-Based Prediction of Intermolecular Binding Affinity</article-title>. <source>Methods Mol Biol</source>. <year>2019</year>;<volume>2053</volume>: <fpage>1</fpage>–<lpage>12</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/978-1-4939-9752-7_1</pub-id><?supplied-pmid 31452095?><pub-id pub-id-type="pmid">31452095</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref033">
      <label>33</label>
      <mixed-citation publication-type="journal"><name><surname>Ballester</surname><given-names>PJ</given-names></name>. <article-title>Machine Learning for Molecular Modelling in Drug Design.</article-title><source>Biomol 2019, Vol 9, Page 216</source>. <year>2019</year>;<volume>9</volume>: <fpage>216</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/biom9060216</pub-id><?supplied-pmid 31167503?><pub-id pub-id-type="pmid">31167503</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref034">
      <label>34</label>
      <mixed-citation publication-type="journal"><name><surname>Breiman</surname><given-names>L</given-names></name>, <name><surname>Friedman</surname><given-names>JH</given-names></name>, <name><surname>Olshen</surname><given-names>RA</given-names></name>, <name><surname>Stone</surname><given-names>CJ</given-names></name>. <article-title>Classification and regression trees.</article-title><source>Classif Regres Trees.</source><year>2017</year>; <fpage>1</fpage>–<lpage>358</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1201/9781315139470/CLASSIFICATION-REGRESSION-TREES-LEO-BREIMAN-JEROME-FRIEDMAN-RICHARD-OLSHEN-CHARLES-STONE</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref035">
      <label>35</label>
      <mixed-citation publication-type="journal"><name><surname>Breiman</surname><given-names>L.</given-names></name><article-title>Random Forests</article-title>. <source>Mach Learn 2001 451</source>. <year>2001</year>;<volume>45</volume>: <fpage>5</fpage>–<lpage>32</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1023/A</pub-id>:1010933404324.</mixed-citation>
    </ref>
    <ref id="pone.0287179.ref036">
      <label>36</label>
      <mixed-citation publication-type="journal"><name><surname>Liaw</surname><given-names>A</given-names></name>, <name><surname>Wiener</surname><given-names>M</given-names></name>. <source>Classification and Regression by randomForest</source>. <year>2002</year>;<volume>2</volume>. Available: <ext-link xlink:href="http://www.stat.berkeley.edu/" ext-link-type="uri">http://www.stat.berkeley.edu/</ext-link>.</mixed-citation>
    </ref>
    <ref id="pone.0287179.ref037">
      <label>37</label>
      <mixed-citation publication-type="journal"><name><surname>Golbraikh</surname><given-names>A</given-names></name>, <name><surname>Muratov</surname><given-names>E</given-names></name>, <name><surname>Fourches</surname><given-names>D</given-names></name>, <name><surname>Tropsha</surname><given-names>A</given-names></name>. <article-title>Data set modelability by QSAR.</article-title><source>J Chem Inf Model</source>. <year>2014</year>;<volume>54</volume>: <fpage>1</fpage>–<lpage>4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/ci400572x</pub-id><?supplied-pmid 24251851?><pub-id pub-id-type="pmid">24251851</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref038">
      <label>38</label>
      <mixed-citation publication-type="journal"><name><surname>Malik</surname><given-names>AA</given-names></name>, <name><surname>Phanus-umporn</surname><given-names>C</given-names></name>, <name><surname>Schaduangrat</surname><given-names>N</given-names></name>, <name><surname>Shoombuatong</surname><given-names>W</given-names></name>, <name><surname>Isarankura-Na-Ayudhya</surname><given-names>C</given-names></name>, <name><surname>Nantasenamat</surname><given-names>C</given-names></name>. <article-title>HCVpred: A web server for predicting the bioactivity of hepatitis C virus NS5B inhibitors</article-title>. <source>J Comput Chem</source>. <year>2020</year>;<volume>41</volume>: <fpage>1820</fpage>–<lpage>1834</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jcc.26223</pub-id><?supplied-pmid 32449536?><pub-id pub-id-type="pmid">32449536</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref039">
      <label>39</label>
      <mixed-citation publication-type="journal"><name><surname>Lyu</surname><given-names>C</given-names></name>, <name><surname>Chen</surname><given-names>T</given-names></name>, <name><surname>Qiang</surname><given-names>B</given-names></name>, <name><surname>Liu</surname><given-names>N</given-names></name>, <name><surname>Wang</surname><given-names>H</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>CMNPD: a comprehensive marine natural products database towards facilitating drug discovery from the ocean</article-title>. <source>Nucleic Acids Res</source>. <year>2021</year>;<volume>49</volume>: <fpage>D509</fpage>–<lpage>D515</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkaa763</pub-id><?supplied-pmid 32986829?><pub-id pub-id-type="pmid">32986829</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref040">
      <label>40</label>
      <mixed-citation publication-type="journal"><name><surname>Trott</surname><given-names>O</given-names></name>, <name><surname>Olson</surname><given-names>AJ</given-names></name>. <article-title>AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading</article-title>. <source>J Comput Chem</source>. <year>2010</year>;<volume>31</volume>: <fpage>455</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jcc.21334</pub-id><?supplied-pmid 19499576?><pub-id pub-id-type="pmid">19499576</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref041">
      <label>41</label>
      <mixed-citation publication-type="journal"><name><surname>Ferdous</surname><given-names>N</given-names></name>, <name><surname>Reza</surname><given-names>MN</given-names></name>, <name><surname>Islam</surname><given-names>MS</given-names></name>, <name><surname>Hossain Emon</surname><given-names>MT</given-names></name>, <name><surname>Mohiuddin</surname><given-names>AKM</given-names></name>, <name><surname>Hossain</surname><given-names>MU</given-names></name>. <article-title>Newly designed analogues from SARS-CoV inhibitors mimicking the druggable properties against SARS-CoV-2 and its novel variants.</article-title><source>RSC Adv</source>. <year>2021</year>;<volume>11</volume>: <fpage>31460</fpage>–<lpage>31476</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1039/d1ra04107j</pub-id><?supplied-pmid 35496863?><pub-id pub-id-type="pmid">35496863</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref042">
      <label>42</label>
      <mixed-citation publication-type="journal"><name><surname>Abraham</surname><given-names>MJ</given-names></name>, <name><surname>Murtola</surname><given-names>T</given-names></name>, <name><surname>Schulz</surname><given-names>R</given-names></name>, <name><surname>Páll</surname><given-names>S</given-names></name>, <name><surname>Smith</surname><given-names>JC</given-names></name>, <name><surname>Hess</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers.</article-title><source>SoftwareX.</source><year>2015</year>;<fpage>1</fpage>–<lpage>2</lpage>: 19–25. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/J.SOFTX.2015.06.001</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref043">
      <label>43</label>
      <mixed-citation publication-type="journal"><name><surname>Reza</surname><given-names>MN</given-names></name>, <name><surname>Ferdous</surname><given-names>N</given-names></name>, <name><surname>Emon</surname><given-names>MTH</given-names></name>, <name><surname>Islam</surname><given-names>MS</given-names></name>, <name><surname>Mohiuddin</surname><given-names>AKM</given-names></name>, <name><surname>Hossain</surname><given-names>MU</given-names></name>. <article-title>Pathogenic genetic variants from highly connected cancer susceptibility genes confer the loss of structural stability</article-title>. <source>Sci Reports</source> 2021 111. <year>2021</year>;<volume>11</volume>: <fpage>1</fpage>–<lpage>19</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-021-98547-y</pub-id>
<?supplied-pmid 34584144?><pub-id pub-id-type="pmid">34584144</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref044">
      <label>44</label>
      <mixed-citation publication-type="journal"><name><surname>AW S</surname><given-names>DM</given-names></name> van A. <article-title>PRODRG: a tool for high-throughput crystallography of protein-ligand complexes</article-title>. <source>Acta Crystallogr D Biol Crystallogr</source>. <year>2004</year>;<volume>60</volume>: <fpage>1355</fpage>–<lpage>1363</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1107/S0907444904011679</pub-id>
<?supplied-pmid 15272157?><pub-id pub-id-type="pmid">15272157</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref045">
      <label>45</label>
      <mixed-citation publication-type="journal"><name><surname>N S</surname></name>, <name><surname>AP</surname><given-names>E</given-names></name>, <name><surname>A</surname><given-names>C</given-names></name>, <name><surname>S</surname><given-names>R</given-names></name>, <name><surname>M</surname><given-names>W</given-names></name>, <name><surname>AE</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Definition and testing of the GROMOS force-field versions 54A7 and 54B7</article-title>. <source>Eur Biophys J</source>. <year>2011</year>;<volume>40</volume>: <fpage>843</fpage>–<lpage>856</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00249-011-0700-9</pub-id><?supplied-pmid 21533652?><pub-id pub-id-type="pmid">21533652</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref046">
      <label>46</label>
      <mixed-citation publication-type="journal"><name><surname>Kumari</surname><given-names>R</given-names></name>, <name><surname>Kumar</surname><given-names>R</given-names></name>, <name><surname>Consortium</surname><given-names>OSDD</given-names></name>, <name><surname>Lynn</surname><given-names>A</given-names></name>. <article-title>g_mmpbsa—A GROMACS Tool for High-Throughput MM-PBSA Calculations.</article-title><source>J Chem Inf Model</source>. <year>2014</year>;<volume>54</volume>: <fpage>1951</fpage>–<lpage>1962</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/ci500020m</pub-id><?supplied-pmid 24850022?><pub-id pub-id-type="pmid">24850022</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref047">
      <label>47</label>
      <mixed-citation publication-type="journal"><name><surname>Steinbeck</surname><given-names>C</given-names></name>, <name><surname>Han</surname><given-names>Y</given-names></name>, <name><surname>Kuhn</surname><given-names>S</given-names></name>, <name><surname>Horlacher</surname><given-names>O</given-names></name>, <name><surname>Luttmann</surname><given-names>E</given-names></name>, <name><surname>Willighagen</surname><given-names>E</given-names></name>. <article-title>The Chemistry Development Kit (CDK): an open-source Java library for Chemo- and Bioinformatics.</article-title><source>J Chem Inf Comput Sci</source>. <year>2003</year>;<volume>43</volume>: <fpage>493</fpage>–<lpage>500</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/ci025584y</pub-id><?supplied-pmid 12653513?><pub-id pub-id-type="pmid">12653513</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref048">
      <label>48</label>
      <mixed-citation publication-type="journal"><name><surname>Hall</surname><given-names>LH</given-names></name>, <name><surname>Kier</surname><given-names>LB</given-names></name>. <article-title>Electrotopological State Indices for Atom Types: A Novel Combination of Electronic, Topological, and Valence State Information</article-title>. <source>J Chem Inf Comput Sci</source>. <year>1995</year>;<volume>35</volume>: <fpage>1039</fpage>–<lpage>1045</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/CI00028A014/ASSET/CI00028A014.FP.PNG_V03</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref049">
      <label>49</label>
      <mixed-citation publication-type="journal"><name><surname>Durant</surname><given-names>JL</given-names></name>, <name><surname>Leland</surname><given-names>BA</given-names></name>, <name><surname>Henry</surname><given-names>DR</given-names></name>, <name><surname>Nourse</surname><given-names>JG</given-names></name>. <article-title>Reoptimization of MDL keys for use in drug discovery</article-title>. <source>J Chem Inf Comput Sci</source>. <year>2002</year>;<volume>42</volume>: <fpage>1273</fpage>–<lpage>1280</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/ci010132r</pub-id><?supplied-pmid 12444722?><pub-id pub-id-type="pmid">12444722</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref050">
      <label>50</label>
      <mixed-citation publication-type="other">V1. PubChem Substructure Fingerprint. [cited 3 Jun 2022]. Available: <ext-link xlink:href="http://pubchem" ext-link-type="uri">http://pubchem</ext-link>.</mixed-citation>
    </ref>
    <ref id="pone.0287179.ref051">
      <label>51</label>
      <mixed-citation publication-type="journal"><name><surname>Simeon</surname><given-names>S</given-names></name>, <name><surname>Jongkon</surname><given-names>N</given-names></name>. <article-title>Construction of Quantitative Structure Activity Relationship (QSAR) Models to Predict Potency of Structurally Diversed Janus Kinase 2 Inhibitors.</article-title><source>Molecules</source>. <year>2019</year>;<volume>24</volume>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/molecules24234393</pub-id><?supplied-pmid 31805692?><pub-id pub-id-type="pmid">31805692</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref052">
      <label>52</label>
      <mixed-citation publication-type="journal"><name><surname>Klekota</surname><given-names>J</given-names></name>, <name><surname>Roth</surname><given-names>FP</given-names></name>. <article-title>Chemical substructures that enrich for biological activity</article-title>. <source>Bioinformatics</source>. <year>2008</year>;<volume>24</volume>: <fpage>2518</fpage>–<lpage>2525</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bioinformatics/btn479</pub-id><?supplied-pmid 18784118?><pub-id pub-id-type="pmid">18784118</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref053">
      <label>53</label>
      <mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>DH</given-names></name>, <name><surname>Carhart</surname><given-names>RE</given-names></name>, <name><surname>Venkataraghavan</surname><given-names>R</given-names></name>. <article-title>Atom Pairs as Molecular Features in Structure-Activity Studies: Definition and Applications</article-title>. <source>J Chem Inf Comput Sci</source>. <year>1985</year>;<volume>25</volume>: <fpage>64</fpage>–<lpage>73</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/CI00046A002/ASSET/CI00046A002.FP.PNG_V03</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref054">
      <label>54</label>
      <mixed-citation publication-type="journal"><name><surname>Wishart</surname><given-names>DS</given-names></name>, <name><surname>Knox</surname><given-names>C</given-names></name>, <name><surname>Guo</surname><given-names>AC</given-names></name>, <name><surname>Cheng</surname><given-names>D</given-names></name>, <name><surname>Shrivastava</surname><given-names>S</given-names></name>, <name><surname>Tzur</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>DrugBank: a knowledgebase for drugs, drug actions and drug targets</article-title>. <source>Nucleic Acids Res</source>. <year>2008</year>;<volume>36</volume>: <fpage>D901</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkm958</pub-id><?supplied-pmid 18048412?><pub-id pub-id-type="pmid">18048412</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref055">
      <label>55</label>
      <mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>S</given-names></name>, <name><surname>Thiessen</surname><given-names>PA</given-names></name>, <name><surname>Bolton</surname><given-names>EE</given-names></name>, <name><surname>Chen</surname><given-names>J</given-names></name>, <name><surname>Fu</surname><given-names>G</given-names></name>, <name><surname>Gindulyte</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>PubChem Substance and Compound databases</article-title>. <source>Nucleic Acids Res</source>. <year>2016</year>;<volume>44</volume>: <fpage>D1202</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkv951</pub-id><?supplied-pmid 26400175?><pub-id pub-id-type="pmid">26400175</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref056">
      <label>56</label>
      <mixed-citation publication-type="journal"><name><surname>Pence</surname><given-names>HE</given-names></name>, <name><surname>Williams</surname><given-names>A</given-names></name>. <article-title>ChemSpider: An Online Chemical Information Resource</article-title>. <source>J Chem Educ</source>. <year>2010</year>;<volume>87</volume>: <fpage>1123</fpage>–<lpage>1124</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/ED100697W</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref057">
      <label>57</label>
      <mixed-citation publication-type="journal"><name><surname>Bienfait</surname><given-names>B</given-names></name>, <name><surname>Ertl</surname><given-names>P</given-names></name>. <article-title>JSME: a free molecule editor in JavaScript.</article-title><source>J Cheminform.</source><year>2013</year>;<volume>5</volume>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/1758-2946-5-24</pub-id><?supplied-pmid 23694746?><pub-id pub-id-type="pmid">23694746</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref058">
      <label>58</label>
      <mixed-citation publication-type="journal"><name><surname>Cousins</surname><given-names>KR</given-names></name>. <article-title>Computer review of ChemDraw Ultra 12.0</article-title>. <source>J Am Chem Soc</source>. <year>2011</year>;<volume>133</volume>: <fpage>8388</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/ja204075s</pub-id><?supplied-pmid 21561109?><pub-id pub-id-type="pmid">21561109</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref059">
      <label>59</label>
      <mixed-citation publication-type="journal"><name><surname>Zhu</surname><given-names>N</given-names></name>, <name><surname>Zhang</surname><given-names>D</given-names></name>, <name><surname>Wang</surname><given-names>W</given-names></name>, <name><surname>Li</surname><given-names>X</given-names></name>, <name><surname>Yang</surname><given-names>B</given-names></name>, <name><surname>Song</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>A Novel Coronavirus from Patients with Pneumonia in China, 2019</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>382</volume>: <fpage>727</fpage>–<lpage>733</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa2001017</pub-id><?supplied-pmid 31978945?><pub-id pub-id-type="pmid">31978945</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref060">
      <label>60</label>
      <mixed-citation publication-type="journal"><name><surname>Polack</surname><given-names>FP</given-names></name>, <name><surname>Thomas</surname><given-names>SJ</given-names></name>, <name><surname>Kitchin</surname><given-names>N</given-names></name>, <name><surname>Absalon</surname><given-names>J</given-names></name>, <name><surname>Gurtman</surname><given-names>A</given-names></name>, <name><surname>Lockhart</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>383</volume>: <fpage>2603</fpage>–<lpage>2615</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id><?supplied-pmid 33301246?><pub-id pub-id-type="pmid">33301246</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref061">
      <label>61</label>
      <mixed-citation publication-type="journal"><name><surname>Voysey</surname><given-names>M</given-names></name>, <name><surname>Clemens</surname><given-names>SAC</given-names></name>, <name><surname>Madhi</surname><given-names>SA</given-names></name>, <name><surname>Weckx</surname><given-names>LY</given-names></name>, <name><surname>Folegatti</surname><given-names>PM</given-names></name>, <name><surname>Aley</surname><given-names>PK</given-names></name>, <etal>et al</etal>. <article-title>Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.</article-title><source>Lancet</source>. <year>2021</year>;<volume>397</volume>: <fpage>99</fpage>–<lpage>111</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32661-1</pub-id><?supplied-pmid 33306989?><pub-id pub-id-type="pmid">33306989</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref062">
      <label>62</label>
      <mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Zeng</surname><given-names>G</given-names></name>, <name><surname>Pan</surname><given-names>H</given-names></name>, <name><surname>Li</surname><given-names>C</given-names></name>, <name><surname>Hu</surname><given-names>Y</given-names></name>, <name><surname>Chu</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.</article-title><source>Lancet Infect Dis.</source><year>2021</year>;<volume>21</volume>: <fpage>181</fpage>–<lpage>192</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30843-4</pub-id><?supplied-pmid 33217362?><pub-id pub-id-type="pmid">33217362</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref063">
      <label>63</label>
      <mixed-citation publication-type="journal"><name><surname>Baden</surname><given-names>LR</given-names></name>, <name><surname>El Sahly</surname><given-names>HM</given-names></name>, <name><surname>Essink</surname><given-names>B</given-names></name>, <name><surname>Kotloff</surname><given-names>K</given-names></name>, <name><surname>Frey</surname><given-names>S</given-names></name>, <name><surname>Novak</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>384</volume>: <fpage>403</fpage>–<lpage>416</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa2035389</pub-id><?supplied-pmid 33378609?><pub-id pub-id-type="pmid">33378609</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref064">
      <label>64</label>
      <mixed-citation publication-type="journal"><name><surname>Shoombuatong</surname><given-names>W</given-names></name>, <name><surname>Schaduangrat</surname><given-names>N</given-names></name>, <name><surname>Nantasenamat</surname><given-names>C</given-names></name>. <article-title>Towards understanding aromatase inhibitory activity via QSAR modeling.</article-title><source>EXCLI J</source>. <year>2018</year>;<volume>17</volume>: <fpage>688</fpage>–<lpage>708</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.17179/excli2018-1417</pub-id><?supplied-pmid 30190660?><pub-id pub-id-type="pmid">30190660</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref065">
      <label>65</label>
      <mixed-citation publication-type="journal"><name><surname>Elsaman</surname><given-names>T</given-names></name>, <name><surname>Mohamed</surname><given-names>MS</given-names></name>, <name><surname>Eltayib</surname><given-names>EM</given-names></name>, <name><surname>Abdel-aziz</surname><given-names>HA</given-names></name>, <name><surname>Abdalla</surname><given-names>AE</given-names></name>, <name><surname>Munir</surname><given-names>MU</given-names></name>, <etal>et al</etal>. <article-title>Isatin derivatives as broad-spectrum antiviral agents: the current landscape</article-title>. <source>Med Chem Res</source>. <year>2022</year>;<volume>31</volume>: <fpage>244</fpage>–<lpage>273</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00044-021-02832-4</pub-id><?supplied-pmid 35039740?><pub-id pub-id-type="pmid">35039740</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref066">
      <label>66</label>
      <mixed-citation publication-type="journal"><name><surname>Hattori</surname><given-names>S ichiro</given-names></name>, <name><surname>Higashi-Kuwata</surname><given-names>N</given-names></name>, <name><surname>Hayashi</surname><given-names>H</given-names></name>, <name><surname>Allu</surname><given-names>SR</given-names></name>, <name><surname>Raghavaiah</surname><given-names>J</given-names></name>, <name><surname>Bulut</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication.</article-title><source>Nat Commun 2021 121</source>. <year>2021</year>;<volume>12</volume>: <fpage>1</fpage>–<lpage>12</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-021-20900-6</pub-id><?supplied-pmid 33510133?><pub-id pub-id-type="pmid">33510133</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref067">
      <label>67</label>
      <mixed-citation publication-type="journal"><name><surname>Weglarz-Tomczak</surname><given-names>E</given-names></name>, <name><surname>Tomczak</surname><given-names>JM</given-names></name>, <name><surname>Talma</surname><given-names>M</given-names></name>, <name><surname>Burda-Grabowska</surname><given-names>M</given-names></name>, <name><surname>Giurg</surname><given-names>M</given-names></name>, <name><surname>Brul</surname><given-names>S</given-names></name>. <article-title>Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2.</article-title><source>Sci Reports 2021 111</source>. <year>2021</year>;<volume>11</volume>: <fpage>1</fpage>–<lpage>10</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-021-83229-6</pub-id><?supplied-pmid 33574416?><pub-id pub-id-type="pmid">33574416</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref068">
      <label>68</label>
      <mixed-citation publication-type="journal"><name><surname>Hengphasatporn</surname><given-names>K</given-names></name>, <name><surname>Wilasluck</surname><given-names>P</given-names></name>, <name><surname>Deetanya</surname><given-names>P</given-names></name>, <name><surname>Wangkanont</surname><given-names>K</given-names></name>, <name><surname>Chavasiri</surname><given-names>W</given-names></name>, <name><surname>Visitchanakun</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Halogenated Baicalein as a Promising Antiviral Agent toward SARS-CoV-2 Main Protease.</article-title><source>J Chem Inf Model.</source><year>2022</year>;<volume>62</volume>: <fpage>1498</fpage>–<lpage>1509</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/acs.jcim.1c01304</pub-id><?supplied-pmid 35245424?><pub-id pub-id-type="pmid">35245424</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref069">
      <label>69</label>
      <mixed-citation publication-type="journal"><name><surname>Glaser</surname><given-names>J</given-names></name>, <name><surname>Sedova</surname><given-names>A</given-names></name>, <name><surname>Galanie</surname><given-names>S</given-names></name>, <name><surname>Kneller</surname><given-names>DW</given-names></name>, <name><surname>Davidson</surname><given-names>RB</given-names></name>, <name><surname>Maradzike</surname><given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Hit Expansion of a Noncovalent SARS-CoV-2 Main Protease Inhibitor.</article-title><source>ACS Pharmacol Transl Sci.</source><year>2022</year>;<volume>5</volume>: <fpage>255</fpage>–<lpage>265</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/acsptsci.2c00026</pub-id><?supplied-pmid 35434531?><pub-id pub-id-type="pmid">35434531</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0287179.ref070">
      <label>70</label>
      <mixed-citation publication-type="journal"><name><surname>Abdallah</surname><given-names>HM</given-names></name>, <name><surname>El-Halawany</surname><given-names>AM</given-names></name>, <name><surname>Sirwi</surname><given-names>A</given-names></name>, <name><surname>El-Araby</surname><given-names>AM</given-names></name>, <name><surname>Mohamed</surname><given-names>GA</given-names></name>, <name><surname>Ibrahim</surname><given-names>SRM</given-names></name>, <etal>et al</etal>. <article-title>Repurposing of Some Natural Product Isolates as SARS-COV-2 Main Protease Inhibitors via In Vitro Cell Free and Cell-Based Antiviral Assessments and Molecular Modeling Approaches</article-title>. <source>Pharm 2021, Vol 14, Page 213.</source><year>2021</year>;<volume>14</volume>: <fpage>213</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/ph14030213</pub-id><?supplied-pmid 33806331?><pub-id pub-id-type="pmid">33806331</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<sub-article article-type="aggregated-review-documents" id="pone.0287179.r001" specific-use="decision-letter">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pone.0287179.r001</article-id>
    <title-group>
      <article-title>Decision Letter 0</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Gallicchio</surname>
          <given-names>Emilio</given-names>
        </name>
        <role>Academic Editor</role>
      </contrib>
    </contrib-group>
    <permissions>
      <copyright-statement>© 2023 Emilio Gallicchio</copyright-statement>
      <copyright-year>2023</copyright-year>
      <copyright-holder>Emilio Gallicchio</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0287179" id="rel-obj001" related-article-type="reviewed-article"/>
    <custom-meta-group>
      <custom-meta>
        <meta-name>Submission Version</meta-name>
        <meta-value>0</meta-value>
      </custom-meta>
    </custom-meta-group>
  </front-stub>
  <body>
    <boxed-text id="pone-0287179-box001" position="float" specific-use="prior_peer_review_unavailable">
      <sec id="sec022">
        <title>Transfer Alert</title>
        <p>This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.</p>
      </sec>
    </boxed-text>
    <p>
      <named-content content-type="letter-date">12 Jan 2023</named-content>
    </p>
    <p><!-- <div> -->PONE-D-22-21799<!-- </div> --><!-- <div> -->Mpropred: A machine learning (ML) driven Web-App for bioactivity prediction of SARS-CoV-2 main protease (Mpro) antagonists<!-- </div> --><!-- <div> -->PLOS ONE</p>
    <p>Dear Dr. Mohiuddin,</p>
    <p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.<!-- </div> --><!-- <div> --> <!-- </div> --><!-- <div> -->Please address the comment of the reviewer, especially the question about the meaning of the fingerprints. Please consider including a figure with a 3D structure of the Mpro receptor site to better convey the structural discussion in the introduction and results. Isabela et al should be probably referenced as Gomes et al. on line 89. Many Mpro inhibitors, including N3 in the structure used for the MD simulations, are covalent inhibitors. It would be beneficial to discuss whether the inhibitors identified by the model are likely covalent inhibitors and which fingerprints recognize such inhibitors.    <!-- </div> --><!-- <div> --> <!-- </div> --><!-- <div> -->Please submit your revised manuscript by Feb 26 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
    <p>Please include the following items when submitting your revised manuscript:<!-- </div> --><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list></p>
    <p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
    <p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link>.</p>
    <p>We look forward to receiving your revised manuscript.</p>
    <p>Kind regards,</p>
    <p>Emilio Gallicchio, Ph.D.</p>
    <p>Academic Editor</p>
    <p>PLOS ONE</p>
    <p>Journal requirements:</p>
    <p>When submitting your revision, we need you to address these additional requirements.</p>
    <p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p>
    <p>
      <ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link>
    </p>
    <p>and <ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link>.</p>
    <p>[Note: HTML markup is below. Please do not edit.]</p>
    <p>Reviewers' comments:</p>
    <p>Reviewer's Responses to Questions</p>
    <p>
      <!-- <font color="black"> -->
      <bold>Comments to the Author</bold>
    </p>
    <p>1. Is the manuscript technically sound, and do the data support the conclusions?</p>
    <p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. <!-- </font> --></p>
    <p>Reviewer #1: Yes</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->2. Has the statistical analysis been performed appropriately and rigorously? <!-- </font> --></p>
    <p>Reviewer #1: Yes</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->3. Have the authors made all data underlying the findings in their manuscript fully available?</p>
    <p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.<!-- </font> --></p>
    <p>Reviewer #1: Yes</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->4. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
    <p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.<!-- </font> --></p>
    <p>Reviewer #1: Yes</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->5. Review Comments to the Author</p>
    <p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)<!-- </font> --></p>
    <p>Reviewer #1: Peer Review of:</p>
    <p>Mpro 1 pred: A machine learning (ML) driven Web-App for bioactivity prediction of SARS-CoV-2 main protease (Mpro) antagonists</p>
    <p>The manuscript, written by Nadim Ferdous and Mahjerin Nasrin Reza et. al discusses about the development of a prediction model to classify inhibitors and non-inhibitors of SARS CoV-2 Main Protease(Mpro) which is a potential drug target to control Coronavirus pandemic that emerged in 2019. The study has its merits and have a great potential to help researchers in the field to identify effective compounds and design specific inhibitors. The authors also developed a web-app to run the model and make it accessible to the research community.</p>
    <p>The authors validated the model by screening existing datasets, and conducting molecule docking, MD simulations and binding free energy estimates. However, the concept underlying the prediction of binding free energies on the select hits , seemed to have some limitation which requires further explanation.</p>
    <p>In line 241 : the authors mentioned “g_mmpbsa” package to compute binding free energies. This was also mentioned in the “Results” section. However, the article cited for “g_mmpbsa” states about computing binding energies of the complex and does not include the entropic terms as stated in the Github page of the tool (<ext-link xlink:href="https://github.com/RashmiKumari/g_mmpbsa" ext-link-type="uri">https://github.com/RashmiKumari/g_mmpbsa</ext-link>).</p>
    <p>The authors also mentioned “binding energy” and “binding free energy” simultaneously to refer to the same quantity that was measured by the “g_mmpbsa” tool.</p>
    <p>Between Line 384 and 387, the authors mentioned that CMNPD16005 is predicted to have the lowest binding free energy of around -296.193 KJ/mol, but in Table 6, it was recorded under the column “Binding energy”. It would be appropriate if the authors use a single term for the quantity measured in this study.</p>
    <p>Table 3 (Docking score) and Table 6 (Binding free energies) are reported with different units (Kcal/mol and KJ/mol respectively). For the ease of reading the article, the authors should use the same unit and conversion, if required, for all data that is tabulated in the study.</p>
    <p>It would be great if the authors explain a little bit more about the difference between binding energy and binding free energies and the type of data that was provided in Table 6. Based on what authors explained about the use of “g_mmpbsa” tool, the data in the last column of Table 6 , is likely to be the interaction energy and not binding free energy that was mentioned in the text.</p>
    <p>For conducting more reliable binding free energy calculations, it will be great if the authors choose a robust method like FEP (Free-Energy Perturbation), or other alchemical approaches and compare the results with the experimental affinities, as the model holds a lot of potential, so, a more robust physics-based prediction approach will be a great addition to this study.</p>
    <p>Line 133 : "…CDK (including extended and graph only version), E-state, PubChem, Klekota–Roth, Substructure and MACCS ": the authors should describe the acronyms in this section, though it seems like these are different fingerprints that are used to describe the structures from different classes. A reference to Table 2 where authors have explained different fingerprints, will be appropriate for the reader to get an idea.</p>
    <p>Few other minor modification and edits may help the readers to understand the manuscript more clearly.</p>
    <p>Line 117 , subheading in Materials and Methods, repeated again in Line 118</p>
    <p>Line 124 : “…with IC50 values that ranged between 1 and 10 were excluded ..” : the authors should mention the concentration units</p>
    <p>Line 135 to 142 : the author mentioned “variables” and “constants” when mentioning about fingerprint descriptors. The authors should explain more about these features as the molecular fingerprinting seems to be a crucial step in the overall design of the model.</p>
    <p>Line 264: The author mentioned “AD” here but did not explain what the acronym means.</p>
    <p>Line 333 : Did the author meant to say “hydrophobic interactions” instead of "hydrophobic bonds" throughout the manuscript?</p>
    <p>In Table 5, units are missing for the IC50 values.</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->6. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
    <p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
    <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.<!-- </font> --></p>
    <p>Reviewer #1: No</p>
    <p>**********</p>
    <p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
    <p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p>
  </body>
</sub-article>
<sub-article article-type="author-comment" id="pone.0287179.r002">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pone.0287179.r002</article-id>
    <title-group>
      <article-title>Author response to Decision Letter 0</article-title>
    </title-group>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0287179" id="rel-obj002" related-article-type="editor-report"/>
    <custom-meta-group>
      <custom-meta>
        <meta-name>Submission Version</meta-name>
        <meta-value>1</meta-value>
      </custom-meta>
    </custom-meta-group>
  </front-stub>
  <body>
    <p>
      <named-content content-type="author-response-date">26 May 2023</named-content>
    </p>
    <p>May 23, 2023</p>
    <p>To </p>
    <p>Editor-in-Chief</p>
    <p>PLOS One</p>
    <p>Re: Resubmission of research article (Submission ID: PONE-D-22-21799)</p>
    <p>Dear Sir,</p>
    <p>Thank you very much for sending us your suggestions and comments. </p>
    <p>We went through the invaluable comments of the honourable editor and tried our best to answer, explain and change the manuscript accordingly. We have addressed the queries each by each in details and listed in the following pages. With the changes made we belief the manuscript is improved substantially. </p>
    <p>We hope that the revised manuscript will be evaluated fairly and considered for publication in your esteemed journal. </p>
    <p>Sincerely yours, </p>
    <p>Dr A. K. M. Mohiuddin</p>
    <p>Professor</p>
    <p>Department of Biotechnology and Genetic Engineering</p>
    <p>Mawlana Bhashani Science and Technology University, Santosh, Tangail-1902, Bangladesh</p>
    <p>E-mail: <email>akmmohiu@yahoo.com</email>
</p>
    <p>Authors Response to honourable Editor Comments</p>
    <p>Editor comments</p>
    <p>In line 241: the authors mentioned “g_mmpbsa” package to compute binding free energies. This was also mentioned in the “Results” section. However, the article cited for “g_mmpbsa” states about computing binding energies of the complex and does not include the entropic terms as stated in the Github page of the tool (<ext-link xlink:href="https://github.com/RashmiKumari/g_mmpbsa" ext-link-type="uri">https://github.com/RashmiKumari/g_mmpbsa</ext-link>).</p>
    <p>The authors also mentioned “binding energy” and “binding free energy” simultaneously to refer to the same quantity that was measured by the “g_mmpbsa” tool.</p>
    <p>Author Response:</p>
    <p>Thank you very much for your suggestions that we feel our manuscript got incredibly improved. We have changed the “binding energy” term to “docking energy” in our revised manuscript. </p>
    <p>Between Line 384 and 387, the authors mentioned that CMNPD16005 is predicted to have the lowest binding free energy of around -296.193 KJ/mol, but in Table 6, it was recorded under the column “Binding energy”. It would be appropriate if the authors use a single term for the quantity measured in this study.</p>
    <p>Author Response:</p>
    <p>Thank you again for your valuable comment. We have changed the title of the last column in Table 6 to “Binding free energy” in our revised manuscript. </p>
    <p>Table 3 (Docking score) and Table 6 (Binding free energies) are reported with different units (Kcal/mol and KJ/mol respectively). For the ease of reading the article, the authors should use the same unit and conversion, if required, for all data that is tabulated in the study.</p>
    <p>Author Response:</p>
    <p>Thank you again for your valuable comment. Binding free energy is the equilibrium constant of complex formation, laws of thermodynamics relate it to the change in Gibbs free energy upon binding: The change in Gibbs free Energy of Binding is equal to - RT times the natural logarithm of the Equilibrium constant, where R is the gas constant and T the absolute temperature. These are experimentally determinable parameters that we predict by calculation. The Docking score is a computational result that is specific for a particular program and energy function, and that in an ideal case allows to predict binding free energy and binding affinity, or to at least rank different complexes according to those parameters. This is why we kept different units for the two different scores.</p>
    <p>It would be great if the authors explain a little bit more about the difference between binding energy and binding free energies and the type of data that was provided in Table 6. Based on what authors explained about the use of “g_mmpbsa” tool, the data in the last column of Table 6, is likely to be the interaction energy and not binding free energy that was mentioned in the text.</p>
    <p>Author Response:</p>
    <p>Thank you again for your valuable comment. The method that the “g_mmpbsa” tool uses, the MM/PBSA method, is widely used in the calculation of receptor-ligand binding free energy. The full name of this method is Molecular Mechanics/Poisson Boltzmann Surface Area. As the name suggests, this method splits the binding free energy into molecular mechanics terms and solvation energies to be calculated separately. The basic principle is to calculate the difference between the binding free energy of two solvated molecules in the bound and unbound states or to compare the free energy of different solvation conformations of the same molecule. We have changed the “binding energy” term to “docking energy” and kept the “binding free energy” term only in case of the g_mmpbsa tool in our revised manuscript.</p>
    <p>For conducting more reliable binding free energy calculations, it will be great if the authors choose a robust method like FEP (Free-Energy Perturbation), or other alchemical approaches and compare the results with the experimental affinities, as the model holds a lot of potential, so, a more robust physics-based prediction approach will be a great addition to this study.</p>
    <p>Author Response:</p>
    <p>Thank you again for your valuable comment. We agree with the authors that addition of the Free-Energy Perturbation method to calculate binding free energy calculations would be a great addition to our study. Unfortunately, due to lack of supercomputing power, we are unable to perform that at this moment.</p>
    <p>Line 133: "…CDK (including extended and graph only version), E-state, PubChem, Klekota–Roth, Substructure and MACCS ": the authors should describe the acronyms in this section, though it seems like these are different fingerprints that are used to describe the structures from different classes. A reference to Table 2 where authors have explained different fingerprints, will be appropriate for the reader to get an idea.</p>
    <p>Author Response:</p>
    <p>Thank you again for your valuable comment. We have added the available acronyms of the fingerprints in Table 2 of our revised manuscript.</p>
    <p>Few other minor modification and edits may help the readers to understand the manuscript more clearly.</p>
    <p>Line 117, subheading in Materials and Methods, repeated again in Line 118</p>
    <p>Author Response:</p>
    <p>Thank you again for your valuable comment. We removed the repeated line in Line 118 in the revised manuscript.</p>
    <p>Line 124: “…with IC50 values that ranged between 1 and 10 were excluded ..” : the authors should mention the concentration units</p>
    <p>Author Response:</p>
    <p>Thank you again for your valuable comment. We added the concentration unit (μM) of the IC50 values in the revised manuscript.</p>
    <p>Line 135 to 142: the author mentioned “variables” and “constants” when mentioning about fingerprint descriptors. The authors should explain more about these features as the molecular fingerprinting seems to be a crucial step in the overall design of the model.</p>
    <p>Author Response:</p>
    <p>Thank you again for your valuable comment. We added the citations of the publications that used the method we followed in selecting the fingerprint descriptors in the revised manuscript</p>
    <p>Line 264: The author mentioned “AD” here but did not explain what the acronym means.</p>
    <p>Author Response:</p>
    <p>Thank you again for your valuable comment. We mentioned the acronym of AD in line 195-196.</p>
    <p>Line 333: Did the author meant to say “hydrophobic interactions” instead of "hydrophobic bonds" throughout the manuscript?</p>
    <p>Author Response:</p>
    <p>Thank you again for your valuable comment. We meant "hydrophobic interactions" instead of "hydrophobic bonds" throughout the manuscript.</p>
    <p>In Table 5, units are missing for the IC50 values.</p>
    <p>Author Response:</p>
    <p>Thank you again for your valuable comment. We added the units for the IC50 values in Table 5 of our revised manuscript.</p>
    <supplementary-material id="pone.0287179.s015" position="float" content-type="local-data">
      <label>Attachment</label>
      <caption>
        <p>Submitted filename: <named-content content-type="submitted-filename">Author Response to reviewers.docx</named-content></p>
      </caption>
      <media xlink:href="pone.0287179.s015.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </body>
</sub-article>
<sub-article article-type="editor-report" id="pone.0287179.r003" specific-use="decision-letter">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pone.0287179.r003</article-id>
    <title-group>
      <article-title>Decision Letter 1</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Gallicchio</surname>
          <given-names>Emilio</given-names>
        </name>
        <role>Academic Editor</role>
      </contrib>
    </contrib-group>
    <permissions>
      <copyright-statement>© 2023 Emilio Gallicchio</copyright-statement>
      <copyright-year>2023</copyright-year>
      <copyright-holder>Emilio Gallicchio</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0287179" id="rel-obj003" related-article-type="reviewed-article"/>
    <custom-meta-group>
      <custom-meta>
        <meta-name>Submission Version</meta-name>
        <meta-value>1</meta-value>
      </custom-meta>
    </custom-meta-group>
  </front-stub>
  <body>
    <p>
      <named-content content-type="letter-date">1 Jun 2023</named-content>
    </p>
    <p>Mpropred: A machine learning (ML) driven Web-App for bioactivity prediction of SARS-CoV-2 main protease (Mpro) antagonists</p>
    <p>PONE-D-22-21799R1</p>
    <p>Dear Dr. Mohiuddin,</p>
    <p>We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p>
    <p>Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p>
    <p>An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <ext-link xlink:href="http://www.editorialmanager.com/pone/" ext-link-type="uri">http://www.editorialmanager.com/pone/</ext-link>, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <email>authorbilling@plos.org</email>.</p>
    <p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email>onepress@plos.org</email>.</p>
    <p>Kind regards,</p>
    <p>Emilio Gallicchio, Ph.D.</p>
    <p>Academic Editor</p>
    <p>PLOS ONE</p>
    <p>Additional Editor Comments (optional):</p>
    <p>Reviewers' comments:</p>
  </body>
</sub-article>
<sub-article article-type="editor-report" id="pone.0287179.r004" specific-use="acceptance-letter">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pone.0287179.r004</article-id>
    <title-group>
      <article-title>Acceptance letter</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Gallicchio</surname>
          <given-names>Emilio</given-names>
        </name>
        <role>Academic Editor</role>
      </contrib>
    </contrib-group>
    <permissions>
      <copyright-statement>© 2023 Emilio Gallicchio</copyright-statement>
      <copyright-year>2023</copyright-year>
      <copyright-holder>Emilio Gallicchio</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0287179" id="rel-obj004" related-article-type="reviewed-article"/>
  </front-stub>
  <body>
    <p>
      <named-content content-type="letter-date">8 Jun 2023</named-content>
    </p>
    <p>PONE-D-22-21799R1 </p>
    <p>M<sup>pro</sup>pred: A machine learning (ML) driven Web-App for bioactivity prediction of SARS-CoV-2 main protease (M<sup>pro</sup>) antagonists </p>
    <p>Dear Dr. Mohiuddin:</p>
    <p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. </p>
    <p>If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <email>onepress@plos.org</email>.</p>
    <p>If we can help with anything else, please email us at <email>plosone@plos.org</email>. </p>
    <p>Thank you for submitting your work to PLOS ONE and supporting open access. </p>
    <p>Kind regards, </p>
    <p>PLOS ONE Editorial Office Staff</p>
    <p>on behalf of</p>
    <p>Dr Emilio Gallicchio </p>
    <p>Academic Editor</p>
    <p>PLOS ONE</p>
  </body>
</sub-article>
